WO2021142435A1 - Combination therapy for treating muscular dystrophy - Google Patents
Combination therapy for treating muscular dystrophy Download PDFInfo
- Publication number
- WO2021142435A1 WO2021142435A1 PCT/US2021/012942 US2021012942W WO2021142435A1 WO 2021142435 A1 WO2021142435 A1 WO 2021142435A1 US 2021012942 W US2021012942 W US 2021012942W WO 2021142435 A1 WO2021142435 A1 WO 2021142435A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- mir
- vector
- aav
- gene
- Prior art date
Links
- 201000006938 muscular dystrophy Diseases 0.000 title claims abstract description 79
- 238000002648 combination therapy Methods 0.000 title description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 221
- 239000004055 small Interfering RNA Substances 0.000 claims abstract description 166
- 239000013598 vector Substances 0.000 claims abstract description 152
- 239000002679 microRNA Substances 0.000 claims abstract description 137
- 108700011259 MicroRNAs Proteins 0.000 claims abstract description 132
- 108091027967 Small hairpin RNA Proteins 0.000 claims abstract description 114
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 99
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 74
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 65
- 230000009368 gene silencing by RNA Effects 0.000 claims abstract description 49
- 108091033409 CRISPR Proteins 0.000 claims abstract description 40
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 20
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 238000010362 genome editing Methods 0.000 claims abstract description 9
- 108091030071 RNAI Proteins 0.000 claims abstract 5
- 239000002924 silencing RNA Substances 0.000 claims abstract 4
- 230000014509 gene expression Effects 0.000 claims description 199
- 108091047189 miR-29c stem-loop Proteins 0.000 claims description 151
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 claims description 151
- 210000004027 cell Anatomy 0.000 claims description 136
- 108010069091 Dystrophin Proteins 0.000 claims description 114
- 239000013603 viral vector Substances 0.000 claims description 106
- 102000001039 Dystrophin Human genes 0.000 claims description 104
- 102000009023 sarcolipin Human genes 0.000 claims description 89
- 108010088766 sarcolipin Proteins 0.000 claims description 89
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 80
- 108091026890 Coding region Proteins 0.000 claims description 75
- 210000003205 muscle Anatomy 0.000 claims description 72
- 108020004999 messenger RNA Proteins 0.000 claims description 66
- 238000013518 transcription Methods 0.000 claims description 52
- 230000035897 transcription Effects 0.000 claims description 52
- 239000013607 AAV vector Substances 0.000 claims description 49
- 102000040430 polynucleotide Human genes 0.000 claims description 49
- 108091033319 polynucleotide Proteins 0.000 claims description 49
- 239000002157 polynucleotide Substances 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 45
- 230000002950 deficient Effects 0.000 claims description 40
- 230000003612 virological effect Effects 0.000 claims description 40
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 35
- 230000035772 mutation Effects 0.000 claims description 32
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 30
- 201000006793 Walker-Warburg syndrome Diseases 0.000 claims description 28
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 27
- -1 IL-Ib Proteins 0.000 claims description 27
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 claims description 26
- 101000616435 Homo sapiens Gamma-sarcoglycan Proteins 0.000 claims description 25
- 208000037141 Congenital muscular dystrophy, Fukuyama type Diseases 0.000 claims description 24
- 201000006813 Fukuyama congenital muscular dystrophy Diseases 0.000 claims description 24
- 239000002773 nucleotide Substances 0.000 claims description 23
- 102000004420 Creatine Kinase Human genes 0.000 claims description 22
- 108010042126 Creatine kinase Proteins 0.000 claims description 22
- 108700024394 Exon Proteins 0.000 claims description 22
- 102100021792 Gamma-sarcoglycan Human genes 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 18
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 16
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 16
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 16
- 201000006948 congenital merosin-deficient muscular dystrophy 1A Diseases 0.000 claims description 15
- 108091028606 miR-1 stem-loop Proteins 0.000 claims description 15
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 claims description 15
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 14
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 14
- 208000033136 Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5 Diseases 0.000 claims description 14
- 108010059343 MM Form Creatine Kinase Proteins 0.000 claims description 13
- 108700026244 Open Reading Frames Proteins 0.000 claims description 13
- 201000009562 autosomal recessive limb-girdle muscular dystrophy type 2C Diseases 0.000 claims description 13
- 210000002744 extracellular matrix Anatomy 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 12
- 208000037150 Dysferlin-related limb-girdle muscular dystrophy R2 Diseases 0.000 claims description 12
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims description 12
- 208000022583 Qualitative or quantitative defects of dysferlin Diseases 0.000 claims description 12
- 201000009563 autosomal recessive limb-girdle muscular dystrophy type 2B Diseases 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims description 11
- 101710082112 Hematopoietic prostaglandin D synthase Proteins 0.000 claims description 11
- 102100039999 Histone deacetylase 2 Human genes 0.000 claims description 11
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 claims description 11
- 101710087566 Ribitol-5-phosphate transferase FKTN Proteins 0.000 claims description 11
- 102000016942 Elastin Human genes 0.000 claims description 10
- 108010014258 Elastin Proteins 0.000 claims description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- 108010056852 Myostatin Proteins 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 10
- 229920002549 elastin Polymers 0.000 claims description 10
- 239000007927 intramuscular injection Substances 0.000 claims description 10
- 238000010255 intramuscular injection Methods 0.000 claims description 10
- 108010085238 Actins Proteins 0.000 claims description 9
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 9
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims description 9
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 9
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 9
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 8
- 102000002689 Toll-like receptor Human genes 0.000 claims description 8
- 108020000411 Toll-like receptor Proteins 0.000 claims description 8
- 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 claims description 8
- 101710178436 Tumor necrosis factor receptor superfamily member 11A Proteins 0.000 claims description 8
- 230000000747 cardiac effect Effects 0.000 claims description 8
- 239000003623 enhancer Substances 0.000 claims description 8
- 108091063796 miR-206 stem-loop Proteins 0.000 claims description 8
- 108091055059 miR-30c stem-loop Proteins 0.000 claims description 8
- 208000022587 qualitative or quantitative defects of dystrophin Diseases 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 238000007910 systemic administration Methods 0.000 claims description 8
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 7
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 7
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 6
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 6
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 6
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims description 6
- 108010084498 Myosin Heavy Chains Proteins 0.000 claims description 6
- 102000004903 Troponin Human genes 0.000 claims description 6
- 108090001027 Troponin Proteins 0.000 claims description 6
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 6
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 6
- 108091079012 miR-133a Proteins 0.000 claims description 6
- 108091024038 miR-133a stem-loop Proteins 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000008488 polyadenylation Effects 0.000 claims description 6
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 5
- 101150091020 FKTN gene Proteins 0.000 claims description 5
- 108020005004 Guide RNA Proteins 0.000 claims description 5
- 101100127663 Homo sapiens LAMA2 gene Proteins 0.000 claims description 5
- 101000972491 Homo sapiens Laminin subunit alpha-2 Proteins 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 101150089565 LAMA2 gene Proteins 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 5
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 5
- 108700015048 receptor decoy activity proteins Proteins 0.000 claims description 5
- 101150086792 CLCN1 gene Proteins 0.000 claims description 4
- 101150083642 DYSF gene Proteins 0.000 claims description 4
- 102000003964 Histone deacetylase Human genes 0.000 claims description 4
- 108090000353 Histone deacetylase Proteins 0.000 claims description 4
- 108091027981 Response element Proteins 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 229960002885 histidine Drugs 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 210000000107 myocyte Anatomy 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 101710177611 DNA polymerase II large subunit Proteins 0.000 claims description 3
- 101710184669 DNA polymerase II small subunit Proteins 0.000 claims description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 101150084750 1 gene Proteins 0.000 claims description 2
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 102100032248 Dysferlin Human genes 0.000 claims 2
- 101001016184 Homo sapiens Dysferlin Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000004472 Myostatin Human genes 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 abstract description 22
- 108091070501 miRNA Proteins 0.000 abstract description 14
- 241000702421 Dependoparvovirus Species 0.000 abstract description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 87
- 101000886098 Homo sapiens Rho guanine nucleotide exchange factor 40 Proteins 0.000 description 61
- 101000836397 Homo sapiens SEC14 domain and spectrin repeat-containing protein 1 Proteins 0.000 description 61
- 102100027289 SEC14 domain and spectrin repeat-containing protein 1 Human genes 0.000 description 61
- 238000004519 manufacturing process Methods 0.000 description 60
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 48
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 44
- 230000008685 targeting Effects 0.000 description 41
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 37
- 230000006870 function Effects 0.000 description 35
- 230000004927 fusion Effects 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 29
- 230000004761 fibrosis Effects 0.000 description 29
- 239000013608 rAAV vector Substances 0.000 description 29
- 206010016654 Fibrosis Diseases 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 23
- 108091033773 MiR-155 Proteins 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 239000002245 particle Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 241000700605 Viruses Species 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 19
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 18
- 210000004413 cardiac myocyte Anatomy 0.000 description 18
- 238000013461 design Methods 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 18
- 102000008186 Collagen Human genes 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 230000009467 reduction Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 238000004806 packaging method and process Methods 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 108090000620 Dysferlin Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 13
- 230000003176 fibrotic effect Effects 0.000 description 13
- 238000003197 gene knockdown Methods 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 102000004168 Dysferlin Human genes 0.000 description 12
- 108700019146 Transgenes Proteins 0.000 description 12
- 230000003828 downregulation Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 108091007431 miR-29 Proteins 0.000 description 12
- 210000000663 muscle cell Anatomy 0.000 description 12
- 230000003827 upregulation Effects 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
- 108091079001 CRISPR RNA Proteins 0.000 description 10
- 108090000565 Capsid Proteins Proteins 0.000 description 10
- 102100023321 Ceruloplasmin Human genes 0.000 description 10
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 10
- 201000001087 Miyoshi muscular dystrophy Diseases 0.000 description 10
- 208000009376 Miyoshi myopathy Diseases 0.000 description 10
- 241000700584 Simplexvirus Species 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 102100021158 Double homeobox protein 4 Human genes 0.000 description 9
- 101710105032 Double homeobox protein 4 Proteins 0.000 description 9
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 9
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 9
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 9
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 9
- 108091036066 Three prime untranslated region Proteins 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 9
- 210000001087 myotubule Anatomy 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 108010069440 Dystrophin-Associated Protein Complex Proteins 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 108010083379 Sarcoglycans Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102100033849 CCHC-type zinc finger nucleic acid binding protein Human genes 0.000 description 7
- 238000010453 CRISPR/Cas method Methods 0.000 description 7
- 101000710837 Homo sapiens CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 239000000074 antisense oligonucleotide Substances 0.000 description 7
- 238000012230 antisense oligonucleotides Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 210000002027 skeletal muscle Anatomy 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 241000701447 unidentified baculovirus Species 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 208000010428 Muscle Weakness Diseases 0.000 description 6
- 206010028372 Muscular weakness Diseases 0.000 description 6
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 6
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102000006308 Sarcoglycans Human genes 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 210000005240 left ventricle Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 108091027963 non-coding RNA Proteins 0.000 description 6
- 102000042567 non-coding RNA Human genes 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 208000031229 Cardiomyopathies Diseases 0.000 description 5
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 206010028289 Muscle atrophy Diseases 0.000 description 5
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 5
- 230000006154 adenylylation Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 108091088477 miR-29a stem-loop Proteins 0.000 description 5
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 5
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 5
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 5
- 238000009126 molecular therapy Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000002578 Dystrophin-Associated Proteins Human genes 0.000 description 4
- 108010093446 Dystrophin-Associated Proteins Proteins 0.000 description 4
- 108010053070 Glutathione Disulfide Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102100030345 Pituitary homeobox 1 Human genes 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 241000125945 Protoparvovirus Species 0.000 description 4
- 102100031774 Ribitol 5-phosphate transferase FKRP Human genes 0.000 description 4
- 101710087595 Ribitol 5-phosphate transferase FKRP Proteins 0.000 description 4
- 101150006192 SGCG gene Proteins 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 4
- 210000002837 heart atrium Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 108091007432 miR-29b Proteins 0.000 description 4
- 238000001964 muscle biopsy Methods 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 101150044789 Cap gene Proteins 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 3
- 101000583156 Homo sapiens Pituitary homeobox 1 Proteins 0.000 description 3
- 101000825933 Homo sapiens Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 208000037161 Laminin subunit alpha 2-related congenital muscular dystrophy Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 208000029578 Muscle disease Diseases 0.000 description 3
- 206010048654 Muscle fibrosis Diseases 0.000 description 3
- 206010061533 Myotonia Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 102100022770 Structural maintenance of chromosomes flexible hinge domain-containing protein 1 Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 101150015424 dmd gene Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000000518 sarcolemma Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 208000034373 type A muscular dystrophy-dystroglycanopathy Diseases 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZVXLKCOOOKREJD-OERAVCCFSA-N 1-[(2R,6S)-6-[[[(2S,6R)-2-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2S,6R)-2-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2S,6R)-2-[[[(2S,6R)-2-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2S,6R)-2-[[[(2S,6R)-2-[[[(2S,6R)-2-[[[(2S,6R)-2-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2R,6S)-2-(2-amino-6-oxo-1H-purin-9-yl)-6-[[[(2R,6S)-2-(4-amino-2-oxopyrimidin-1-yl)-6-[[[(2R,6S)-2-(4-amino-2-oxopyrimidin-1-yl)-6-[[[(2S,6R)-2-[[[(2R,6S)-2-(4-amino-2-oxopyrimidin-1-yl)-6-[[[(2R,6S)-2-(4-amino-2-oxopyrimidin-1-yl)-6-(hydroxymethyl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(4-amino-2-oxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(6-aminopurin-9-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(6-aminopurin-9-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-6-(5-methyl-2,4-dioxopyrimidin-1-yl)morpholin-4-yl]-(dimethylamino)phosphoryl]oxymethyl]-4-[[(2S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)morpholin-2-yl]methoxy-(dimethylamino)phosphoryl]morpholin-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound CN(C)P(=O)(OC[C@@H]1CN(C[C@@H](O1)n1cnc2c(N)ncnc12)P(=O)(OC[C@@H]1CN(C[C@@H](O1)n1cnc2c1nc(N)[nH]c2=O)P(=O)(OC[C@@H]1CN(C[C@@H](O1)n1cnc2c1nc(N)[nH]c2=O)P(=O)(OC[C@@H]1CN(C[C@@H](O1)n1cc(C)c(=O)[nH]c1=O)P(=O)(OC[C@@H]1CN(C[C@@H](O1)n1cnc2c1nc(N)[nH]c2=O)P(=O)(OC[C@@H]1CN(C[C@@H](O1)n1cc(C)c(=O)[nH]c1=O)P(=O)(OC[C@@H]1CN(C[C@@H](O1)n1cc(C)c(=O)[nH]c1=O)P(=O)(OC[C@@H]1CNC[C@@H](O1)n1ccc(N)nc1=O)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N1C[C@@H](COP(=O)(N(C)C)N2C[C@@H](COP(=O)(N(C)C)N3C[C@@H](COP(=O)(N(C)C)N4C[C@@H](COP(=O)(N(C)C)N5C[C@@H](COP(=O)(N(C)C)N6C[C@@H](COP(=O)(N(C)C)N7C[C@@H](COP(=O)(N(C)C)N8C[C@@H](COP(=O)(N(C)C)N9C[C@@H](COP(=O)(N(C)C)N%10C[C@@H](COP(=O)(N(C)C)N%11C[C@@H](COP(=O)(N(C)C)N%12C[C@@H](COP(=O)(N(C)C)N%13C[C@@H](CO)O[C@H](C%13)n%13ccc(N)nc%13=O)O[C@H](C%12)n%12ccc(N)nc%12=O)O[C@H](C%11)n%11cc(C)c(=O)[nH]c%11=O)O[C@H](C%10)n%10ccc(N)nc%10=O)O[C@H](C9)n9ccc(N)nc9=O)O[C@H](C8)n8cnc9c8nc(N)[nH]c9=O)O[C@H](C7)n7cnc8c7nc(N)[nH]c8=O)O[C@H](C6)n6cc(C)c(=O)[nH]c6=O)O[C@H](C5)n5cc(C)c(=O)[nH]c5=O)O[C@H](C4)n4ccc(N)nc4=O)O[C@H](C3)n3cc(C)c(=O)[nH]c3=O)O[C@H](C2)n2cnc3c2nc(N)[nH]c3=O)O[C@H](C1)n1cnc2c(N)ncnc12 ZVXLKCOOOKREJD-OERAVCCFSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101710116319 CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 101150117670 Cnbp gene Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101150054841 DUX4 gene Proteins 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010071885 Dystroglycans Proteins 0.000 description 2
- 102000007623 Dystroglycans Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 102100036721 Insulin receptor Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 102100032832 Integrin alpha-7 Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 102100021970 Myc box-dependent-interacting protein 1 Human genes 0.000 description 2
- 101710146921 Myc box-dependent-interacting protein 1 Proteins 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 102100026531 Prelamin-A/C Human genes 0.000 description 2
- 241000242739 Renilla Species 0.000 description 2
- 101150087983 SLN gene Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 101150084233 ago2 gene Proteins 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 101150062912 cct3 gene Proteins 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000009795 fibrotic process Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 108010024084 integrin alpha7 Proteins 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 229940065638 intron a Drugs 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 108091023685 miR-133 stem-loop Proteins 0.000 description 2
- 108091029162 miR-29 stem-loop Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 206010028320 muscle necrosis Diseases 0.000 description 2
- 230000009756 muscle regeneration Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000009635 nitrosylation Effects 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 208000026526 progressive weakness Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 2
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000010532 sarcoglycanopathy Diseases 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000300529 Adeno-associated virus 13 Species 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 description 1
- 244000234056 Arachis hybrid Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 244000180534 Berberis hybrid Species 0.000 description 1
- 102100031500 Beta-1,4-glucuronyltransferase 1 Human genes 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 102000056162 CELF1 Human genes 0.000 description 1
- 108700015925 CELF1 Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000004918 Cartilage-hair hypoplasia Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100031082 Choline/ethanolamine kinase Human genes 0.000 description 1
- 101710147336 Choline/ethanolamine kinase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000016768 Congenital muscular alpha-dystroglycanopathy with brain and eye anomalies Diseases 0.000 description 1
- 108010002947 Connectin Proteins 0.000 description 1
- 102000004726 Connectin Human genes 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241001136239 Cymbidium hybrid cultivar Species 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102100031515 D-ribitol-5-phosphate cytidylyltransferase Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091007413 Extracellular RNA Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 108091007417 HOX transcript antisense RNA Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000729794 Homo sapiens Beta-1,4-glucuronyltransferase 1 Proteins 0.000 description 1
- 101000994204 Homo sapiens D-ribitol-5-phosphate cytidylyltransferase Proteins 0.000 description 1
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 1
- 101001067880 Homo sapiens Histone H4 Proteins 0.000 description 1
- 101000581326 Homo sapiens Mediator of DNA damage checkpoint protein 1 Proteins 0.000 description 1
- 101000869796 Homo sapiens Microprocessor complex subunit DGCR8 Proteins 0.000 description 1
- 101000874526 Homo sapiens N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 Proteins 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 101001130862 Homo sapiens Oligoribonuclease, mitochondrial Proteins 0.000 description 1
- 101000845685 Homo sapiens Protein Dok-7 Proteins 0.000 description 1
- 101001129345 Homo sapiens Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 Proteins 0.000 description 1
- 101001123963 Homo sapiens Protein O-mannosyl-transferase 1 Proteins 0.000 description 1
- 101001094684 Homo sapiens Protein O-mannosyl-transferase 2 Proteins 0.000 description 1
- 101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 1
- 101001093905 Homo sapiens Ribitol-5-phosphate xylosyltransferase 1 Proteins 0.000 description 1
- 101100256162 Homo sapiens SLN gene Proteins 0.000 description 1
- 101100366030 Homo sapiens SMCHD1 gene Proteins 0.000 description 1
- 101000692225 Homo sapiens Selenocysteine insertion sequence-binding protein 2 Proteins 0.000 description 1
- 101000683839 Homo sapiens Selenoprotein N Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100039903 Integrin alpha-9 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000489569 Mandevilla x amabilis Species 0.000 description 1
- 102100027643 Mediator of DNA damage checkpoint protein 1 Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229940122938 MicroRNA inhibitor Drugs 0.000 description 1
- 241001267494 Microdes Species 0.000 description 1
- 102100032459 Microprocessor complex subunit DGCR8 Human genes 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 108091062140 Mir-223 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 101100107351 Mus musculus Sfn gene Proteins 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 102100031790 Myelin expression factor 2 Human genes 0.000 description 1
- 101710107751 Myelin expression factor 2 Proteins 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 102100030477 Plectin Human genes 0.000 description 1
- 108010054050 Plectin Proteins 0.000 description 1
- 101150107725 Pomk gene Proteins 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100031135 Protein Dok-7 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100031305 Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 Human genes 0.000 description 1
- 102100028655 Protein O-mannose kinase Human genes 0.000 description 1
- 102100028120 Protein O-mannosyl-transferase 1 Human genes 0.000 description 1
- 102100035490 Protein O-mannosyl-transferase 2 Human genes 0.000 description 1
- 102100034207 Protein argonaute-2 Human genes 0.000 description 1
- 208000035955 Proximal myotonic myopathy Diseases 0.000 description 1
- 101710107606 Putative glycosyltransferase Proteins 0.000 description 1
- 208000037328 Qualitative or quantitative defects of sarcoglycan Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100035179 Ribitol-5-phosphate xylosyltransferase 1 Human genes 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 230000006295 S-nitrosylation Effects 0.000 description 1
- 101150023894 SMCHD1 gene Proteins 0.000 description 1
- 102100026077 Selenocysteine insertion sequence-binding protein 2 Human genes 0.000 description 1
- 102100023781 Selenoprotein N Human genes 0.000 description 1
- 108010074686 Selenoproteins Proteins 0.000 description 1
- 102000008114 Selenoproteins Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 108091007415 Small Cajal body-specific RNA Proteins 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010019965 Spectrin Proteins 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 208000037140 Steinert myotonic dystrophy Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- VNJBSPJILLFAIC-BZPMIXESSA-N Tetranor-PGDM Chemical compound O[C@H]1CC(=O)[C@H](CCC(=O)CCCCC(O)=O)[C@H]1CCC(O)=O VNJBSPJILLFAIC-BZPMIXESSA-N 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108010075653 Utrophin Proteins 0.000 description 1
- 102000011856 Utrophin Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108091007416 X-inactive specific transcript Proteins 0.000 description 1
- 108091035715 XIST (gene) Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000025261 autosomal dominant disease Diseases 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 1
- 201000009565 autosomal recessive limb-girdle muscular dystrophy Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 210000001196 cardiac muscle myoblast Anatomy 0.000 description 1
- 229950009744 casimersen Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000013895 congenital muscular dystrophy-dystroglycanopathy A7 Diseases 0.000 description 1
- 208000013898 congenital muscular dystrophy-dystroglycanopathy type A Diseases 0.000 description 1
- 208000014422 congenital muscular dystrophy-dystroglycanopathy type A2 Diseases 0.000 description 1
- 208000014455 congenital muscular dystrophy-dystroglycanopathy type A3 Diseases 0.000 description 1
- 208000014445 congenital muscular dystrophy-dystroglycanopathy type A6 Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229950005470 eteplirsen Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- PHTXVQQRWJXYPP-UHFFFAOYSA-N ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 229950010415 givinostat Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229950000084 golodirsen Drugs 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 102000057878 human DMD Human genes 0.000 description 1
- 102000048177 human SFN Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108010024069 integrin alpha9 Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000008106 junctional epidermolysis bullosa Diseases 0.000 description 1
- 108010008097 laminin alpha 2 Proteins 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 108010091736 luspatercept Proteins 0.000 description 1
- 229950000151 luspatercept Drugs 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 108091035591 miR-23a stem-loop Proteins 0.000 description 1
- 108091025088 miR-29b-2 stem-loop Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 208000011042 muscle-eye-brain disease Diseases 0.000 description 1
- 208000024886 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 Diseases 0.000 description 1
- 201000006951 muscular dystrophy-dystroglycanopathy type B5 Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 101150042523 myod gene Proteins 0.000 description 1
- 201000008709 myotonic dystrophy type 2 Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000038009 orphan disease Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 150000003163 prostaglandin D2 derivatives Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes (mutant genes) produce no functional wild-type proteins needed to form healthy muscle.
- DMD Duchenne type muscular dystrophy
- DAPC dystrophin-associated protein complex
- DMD is caused by mutations in the DMD gene, leading to reductions in DMD mRNA and the absence of dystrophin or functional dystrophin, a 427 kDa sarcolemmal protein associated with the dystrophin-associated protein complex (DAPC) (Hoffman et ah, Cell 51(6): 919-928, 1987).
- the DAPC is composed of multiple proteins at the muscle sarcolemma that form a structural link between the extra-cellular matrix (ECM) and the cytoskeleton via dystrophin, an actin binding protein, and alpha-dystroglycan, a laminin-binding protein. These structural links act to stabilize the muscle cell membrane during contraction, and protect against contraction-induced damage.
- nNOS neuronal nitric oxide synthase
- SERCA sarco/endoplasmic reticulum Ca 2+ ATPase
- the standard of care includes administering corticosteroids (such as prednisone or deflazacort) to stabilize muscle strength and function, prolonging independent ambulation, and delaying scoliosis and cardiomyopathy; bisphosphonates; and denosumab and recombinant parathyroid hormones.
- corticosteroids such as prednisone or deflazacort
- dystrophin function With the advent of gene therapy, research and clinical trials for DMD treatment has focused on gene replacement or other genetic therapies aimed to at least partially restore dystrophin function. These include supplying a functional copy of the dystrophin gene, such as a dystrophin minigene, or repairing a defective dystrophin gene product by exon skipping and nonsense mutation suppression.
- loss of dystrophin leads to the loss of the dystrophin-associated protein complex (DAPC), which in turn leads to the production of nitric oxide (NO) by nNOS, and abnormal N-nitrosylation of HDAC2.
- DAPC dystrophin-associated protein complex
- NO nitric oxide
- HDAC2 abnormally N-nitrosylated HDAC2 dissociates from the chromatin, and releases the inhibition of a cascade of specific microRNAs which in turn lead to a slew of downstream events such as fibrosis and increased oxidative stress.
- DMD Without membrane stabilization from dystrophin or a micro-dystrophin, DMD will manifest uncontrolled cycles of tissue injury and repair, and ultimately replace lost muscle fibers with fibrotic scar tissue through connective tissue proliferation.
- Muscle biopsies taken at the earliest age of diagnosis of DMD reveal prominent connective tissue proliferation.
- Muscle fibrosis is deleterious in multiple ways. It reduces normal transit of endomysial nutrients through connective tissue barriers, reduces the blood flow and deprives muscle of vascular-derived nutritional constituents, and functionally contributes to early loss of ambulation through limb contractures. Over time, treatment challenges multiply as a result of marked fibrosis in muscle. This can be observed in muscle biopsies comparing connective tissue proliferation at successive time points. The process continues to exacerbate leading to loss of ambulation and accelerating out of control, especially in wheelchair-dependent patients.
- fibrotic infiltration is profound in DMD, and is a significant impediment to any potential therapy.
- gene replacement therapy alone is usually hampered by the severity of fibrosis, already present in very young children with DMD.
- Fibrosis is characterized by the excessive deposits of ECM matrix proteins, including collagen and elastin. ECM proteins are primarily produced from cytokines such as TGF that is released by activated fibroblasts responding to stress and inflammation. Although the primary pathological feature of DMD is myofiber degeneration and necrosis, fibrosis as a pathological consequence has equal repercussions. The over-production of fibrotic tissue restricts muscle regeneration and contributes to progressive muscle weakness in the DMD patient.
- MicroRNAs are single- stranded RNAs of ⁇ 22 nucleotides that mediate gene silencing at the post-transcriptional level by pairing with bases within the 3 ’ UTR of mRNA, inhibiting translation or promoting mRNA degradation.
- a seed sequence of 7 bp at the 5’ end of the miRNA targets the miRNA; additional recognition is provided by the remainder of the targeted sequence, as well as its secondary structure.
- MiRNAs play an important role in muscle disease pathology and exhibit expression profiles that are uniquely dependent on the type of muscular dystrophy in question (Eisenberg et al, Proc Natl Acad Sci U.S.A. 104(43):17016- 17021, 2007).
- miR-29 Recently, the down-regulation of miR-29 was shown to contribute to cardiac fibrosis (Cacchiarelli etal. , Cell Metab 12(4):341-351, 2010). Reduced expression of miR-29 was genetically linked with human DMD patient muscles (Eisenberg et al, Proc Natl Acad Sci U.S.A. 104(43): 17016-17021, 2007).
- the miR-29 family consists of three family members expressed from two bicistronic miRNA clusters. MiR-29a is coexpressed with miR-29b (miR-29b-l); miR-29c is co-expressed with a second copy of miR-29b (miR-29b-2).
- the miR-29 family shares a conserved seed sequence, and miR-29a and miR-29b each differ by only one base from miR-29c.
- miR-29 plasmid a cluster of miR-29a and miR-29b-l
- ECM components collagen and elastin
- collagen deposition in muscle sections within 25 days post-treatment
- Adeno-associated virus is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length, including 145 nucleotide inverted terminal repeat (ITRs).
- AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy.
- AAV infection of cells in culture is noncytopathic, and natural infection of humans and other animals is silent and asymptomatic.
- AAV infects many mammalian cells, allowing the possibility of targeting many different tissues in vivo.
- the AAV proviral genome is infectious as cloned DNA in plasmids, which makes construction of recombinant genomes feasible.
- the signals directing AAV replication, genome encapsidation and integration are contained within the ITRs of the AAV genome, some or all of the internal approximately 4.3 kb of the genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA such as a gene cassette containing a promoter, a DNA of interest and a polyadenylation signal.
- the rep and cap proteins may be provided in trans.
- Another significant feature of AAV is that it is an extremely stable and hearty virus. It easily withstands the conditions used to inactivate adenovirus (56° to 65°C for several hours), making cold preservation of AAV less critical. AAV may even be lyophilized. Finally, AAV-infected cells are not resistant to superinfection.
- AAV-based viral vectors range from 10 11 to 10 14 genomic particles (vector genomes; vg) per patient dependent on therapeutic area.
- current scale-up approaches fall short of supplying the required number of doses to allow later Phase (e.g ., Phases II/III) trails to progress, thus retarding the development of gene therapy products.
- Phases II/III Phases II/III
- muscular dystrophies may benefit from treatments simultaneously targeting different disease-causing pathways.
- methods of reducing such secondary cascade symptoms e.g ., fibrosis
- Such combination therapy must also overcome the significant clinical and commercialization challenge of producing sufficient quantities of gene therapy vectors to deliver both therapeutic components to the target tissue, particularly in the setting of systematic delivery of gene therapy vectors.
- the invention described herein provides a viral vector for gene therapy, comprising a polynucleotide sequence that simultaneously encodes a first polypeptide or a first RNA (“a first transcription and/or expression unit or cassette”), and a second polypeptide or a second RNA (“a second transcription and/or expression unit or cassette”) expressed from a so-called “divergent cassette” in relation to the first transcription and/or expression cassette, which confers separate and independent control for the expression of each of first and second polypeptide and/or RNA, with minimal or no transcriptional interference between different transcription and/or expression units or casettes.
- the two transcription and/or expression units or cassettes are each under the control of its owe independent control elements or promoters.
- the two independent control elements or propmoters operate in opposite directions, such as each transcribing towards (as opposed to away from) its nearest terminal repeat sequences (such as the ITR sequences in an AAV vector).
- the invention is partly based on the surprising discovery that the one or more coding sequence(s) can be inserted into certain positions, such as into a so-called “divergent cassette” (see below) situated between the control element or promoter for the gene of interest (GOI) and the nearest ITR, while both the functional protein (such as the dystrophin microgene or minigene product) and one or more coding sequences can be expressed inside the infected target cells (e.g., muscle cells) without significant reduction in expression compared to similar vector constructs encompassing only the functional protein (such as the dystrophin minigene product) or only the one or more coding sequences.
- a so-called “divergent cassette” situated between the control element or promoter for the gene of interest (GOI) and the nearest ITR
- both the functional protein such as the dystrophin microgene or minigene product
- one or more coding sequences can be expressed inside the infected target cells (e.g., muscle cells) without significant reduction in expression compared to similar vector constructs
- the expression of the one or more coding sequences from the divergent cassette is greatly increased compared to inserting the same coding sequences into the other parts of the viral vector, such as into the heterologous intron or 3’-UTR of the GOI.
- transcription and/or expression unit or cassette includes at a minimum a control element, a coding sequence, and a transcription termination sequence.
- the coding sequence in each transcription and/or expression unit or cassette can independently encode any of a protein, a polypeptide, an mRNA, a non-coding RNA (such as an shRNA, miRNA, siRNA, or a precursor thereof), an antisense sequence, a guide sequence for a gene editing enzyme, or a miRNA inhibitor, etc.
- the coding sequence is operably linked to and under the control of a control element which includes a promoter, and optionally one or more enhancers or other control elements, for initiating or affecting transcription by an RNA polymerase (including Pol II or Pol III), such that whatever that is encoded by the coding sequence can be transcribed.
- a control element which includes a promoter, and optionally one or more enhancers or other control elements, for initiating or affecting transcription by an RNA polymerase (including Pol II or Pol III), such that whatever that is encoded by the coding sequence can be transcribed.
- the coding sequence is also operably linked to a downstream transcription termination sequence (such as the T6 transcripiton termination sequence) so that transcription can be terminated as desired.
- constructs with two or more transcriptional units and/or cassettes operating in opposite / divergent / multiple directions are referred to as “divergent constructs.”
- viral vectors of the invention such as an AAV-based viral vector or a lentivirus-based viral vector having such arrangements of two transcription and/or expression units or cassettes, or divergent constructs in viral plasmid vector backbone, are referred to as “divergent vectors.”
- the vector of the invention may simultaneously encode a first therapeutic agent (e.g ., a protein) expressed from the first transcripition cassette, and a second therapeutic agent (e.g., an RNA) expressed from the divergent cassette.
- a first therapeutic agent e.g ., a protein
- a second therapeutic agent e.g., an RNA
- first and second (divergent) expression units and/or cassettes are relative, such that any of the two GOI’s can be expressed from either expression units and/or cassettes.
- a microdystrophin coding sequence can be expressed from the first or the second (divergent) expression cassette.
- any of the shRNA, siRNA, miRNA, etc. can also be expressed from the first or the second (divergent) expression cassette.
- both expression units / cassettes ean be used to express proteins or non-protein products described herein (such as miRNA or precursors thereof).
- either the first or the second RNA, or both may be a non-coding RNA that does not produce a protein or polypeptide.
- non-coding RNA can be microRNA (miR), shRNA (short hairpin RNA), piRNA, snoRNA, snRNA, exRNA, scaRNA, long ncRNAs such as Xist and HOTAIR, anti-sense RNA, or precursor thereof, preferably with therapeutic value, e.g., those associated with diseases such as cancer, autisum, Alzheimer's disease, Cartilage-hair hypoplasia, hearing loss, and Prader-Willi syndrome, particularly various types of muscular dystrophies (MDs), including DMD/BMD.
- MDs muscular dystrophies
- Such non-coding RNA can also be the single or multiple guide RNA(s) of a CRISPR/Cas9 protein, or a CRISPR RNA (crRNA) of a CRISPR/Casl2a(formerly Cpfl) protien.
- crRNA CRISPR RNA
- the two transcription units / cassettes may be used to express products (protein, peptide, RNA etc.) that are either biologically unrelated, or are somehow related in terms of biological function.
- products protein, peptide, RNA etc.
- one of the coded / expressed products may replace the function of a defective gene product in a disease or condition, while the other coded / expressed product may act on a separate biological pathway and thus the two products are delivered and result in desirably additive or synergistic biological and therapeutic effects.
- one of the coded / expressed products may be a functional version of a dystrophin (such as pDys) that supplements the lost dystrophin function, while the other coded / expressed product may antagonize a side effect associated with the loss of dystrophin function, such as fibrosis.
- a dystrophin such as pDys
- the invention provides a recombinant viral vector comprising: a) a first transcripiton / expression unit encoding a first functional gene or protein of interest (GOI), and b) a second transcripiton / expression unit encoding a seoend functional gene or protein of interest (GOI), wherein the first transcripiton / expression unit and the second transcripiton / expression unit are independently under the control of their own transcription control element / promoter that directs transcription in opposite / divergent directions, preferably each towards the nearest terminal repeat sequences (e.g., ITR of AAV).
- a first transcripiton / expression unit encoding a first functional gene or protein of interest (GOI)
- a second transcripiton / expression unit encoding a seoend functional gene or protein of interest (GOI)
- the first transcripiton / expression unit and the second transcripiton / expression unit are independently under the control of their own transcription control element / promoter that directs transcription in opposite
- the invention provides a recombinant viral vector comprising: a) a polynucleotide encoding a functional gene or protein of interest (GOI), such as one effective to treat a muscular dystrophy, wherein said polynucleotide comprises a 3’-UTR coding region, and is immediately 3 ’ to a heterologous intron sequence that enhances expression of the functional protein encoded by the polunucleotide; b) a first control element (e.g ., a muscle- specific control element) operably linked to and drives the expression of the polynucleotide; and, c) one or more coding sequences (1) inserted between the first control element and the nearest viral terminal sequence (e.g., ITR in AAV) and operably linked to a second control element, and (2) optionally further inserted in the intron sequence or in the 3’-UTR coding region; wherein said one or more coding sequences independently encode: a protein, a polypeptid
- the recombinant viral vector is a recombinant AAV (adeno associated viral) vector or a recombinant lentiviral vector.
- the invention provides a recombinant AAV (rAAV) vector comprising: a) a polynucleotide encoding a functional protein effective to treat a muscular dystrophy, wherein said polynucleotide comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the functional protein encoded by the polunucleotide; b) a muscle-specific control element operably linked to and drives the expression of the polynucleotide; and, c) one or more coding sequences inserted between the muscle-specific control element and the nearest AAV ITR and operably linked to a second control element, and (2) optionally further inserted in the intron sequence or in the 3’-UTR coding region; wherein said one or more coding sequences independently encode: an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a microRNA (miRNA), and/or a miRNA
- the invention described herein provides a viral vector, such as a recombinant AAV vector, that comprises: a) a dystrophin microgene or minigene encoding a functional micro-dystrophin protein (e.g., microD5), wherein said dystrophin microgene or minigene comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the dystrophin microgene or minigene; b) a muscle- specific control element operably linked to and drives the expression of the dystrophin microgene or minigene; and, c) one or more ( e.g ., 1, 2, 3, 4, or 5) coding sequence(s) inserted between the muscle-specific control element and the nearest AAV ITR and operably linked to a second control element, and (2) optionally further inserted in the intron sequence or in the 3’- UTR coding region; wherein said one or more coding sequence(s) independently encode(s
- the second control element in the divergent cassette
- the second control element is a promoter or portion of a promoter that transcribes the one or more coding sequences.
- the second control element is a pol II promoter that transcribes the one or more coding sequences inserted between the first control element and the nearest viral terminal sequence, optionally in a direction opposite to the transcription initiated by the first control element.
- the second control element (in the divergent cassette) is a pol III promoter.
- first and seond control elements are both the same promoter. In other embodiments, the first and second control elements are different promoters.
- the functional dystrophin protein is microD5, and/or the muscle- specific control element / promoter is CK promoter.
- the recombinant viral vector is a recombinant AAV (adeno associated viral) vector.
- the one or more coding sequences are inserted into the divergent cassette. In certain embodiments, the one or more coding sequences are further inserted into the 3’-UTR coding region, or after the polyadenylation (poly A) signal sequence (e.g., AATAAA).
- poly A polyadenylation
- expression of the functional GOI is substantially unaffected in the presence of the one or more coding sequences (e.g., as compared to otherwise identical control constructs without said one or more coding sequences).
- the polynucleotide in the recombinant AAV (rAAV) vector: a) the polynucleotide is a dystrophin minigene encoding a functional 5-spectrin-like repeat dystrophin protein (e.g., microD5; as described in US 10,479,821, incorporated herein by reference); and/or, b) the muscle-specific control element is a CK promoter operably linked to and drives the expression of the dystrophin minigene.
- a functional 5-spectrin-like repeat dystrophin protein e.g., microD5; as described in US 10,479,821, incorporated herein by reference
- the muscle-specific control element is a CK promoter operably linked to and drives the expression of the dystrophin minigene.
- the one or more coding sequences comprise an exon-skipping antisense sequence that induces skipping of an exon of a defective dystrophin, such as skipping any one of exons 45-55 of dystrophin, or exon 44, 45, 51, and/or 53 of dystrophin.
- the microRNA is miR-1, miR-133a, miR-29c, miR-30c, and/or miR-206.
- the miR-29c optionally has a modified flanking backbone sequence that enhances the processing of the guide strand of miR-29c designed for a target sequence.
- the modified flanking backbone sequence can be from or based on other miR sequences, such as miR-30, -101, -155, or -451.
- expression of the microRNA in a host cell is up-regulated by at least about 1.5-100 fold (e.g ., about 2-80 fold, about 1.5-10 fold, about 15-70 fold, about 50-70 fold, about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or about 80 fold) compared to endogenous expression of the microRNA in the host cell.
- 1.5-100 fold e.g ., about 2-80 fold, about 1.5-10 fold, about 15-70 fold, about 50-70 fold, about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or about 80 fold
- the RNAi sequence is an shRNA against sarcolipin (shSLN).
- the one or more coding sequences encode one or more identical or different shRNAs against sarcolipin (shSLN).
- the shRNA reduces sarcolipin mRNA and/or sarcolipin protein expression by at least about 50%.
- the GOI is CRISPR/Cas9, and the guide sequence is the sgRNA; or wherein the GOI is CRISPR/Casl2a, and the guide sequende is the crRNA.
- the RNAi sequence (siRNA, shRNA, miRNA), the antisense sequence, said CRISPR/Cas9 sgRNA, said CRISPR/Casl2a crRNA and/or the microRNA antagonizes the function of one or more target genes, such as an inflammatory gene, an activator of NF-KB signaling pathway (e.g., TNF-a, IL-1, IL-Ib, IL-6, Receptor activator of NF-KB (RANK), and Toll-like receptors (TLRs)), NF-KB, a downstream inflammatory cytokine induced by NF-KB, a histone deacetylase (e.g., HDAC2), TGF-b, connective tissue growth factor (CTGF), collagens, elastin, a structural component of the extracellular matrix, Glucose-6- phosphate dehydrogenase (G6PD), myostatin, phosphodiesterase-5 (PED-5) or
- the recombinant AAV (rAAV) vector a) the polynucleotide encodes a functional fukutin (FKTN) protein; and/or, b) the one or more coding sequences encode an exon-skipping antisense sequence that restores correct exon 10 splicing in a defective FKTN gene in a Fukuyama congenital muscular dystrophy (FCMD) patient.
- FKTN functional fukutin
- FCMD Fukuyama congenital muscular dystrophy
- the polynucleotide encodes a functional LAMA2 protein; and/or, b) the one or more coding sequences encode an exon-skipping antisense sequence that restores expression of the C-terminal G-domain (exons 45-64), particularly G4 and G5 of a defective LAMA2 gene in a Merosin- deficient congenital muscular dystrophy type 1 A (MDC1A) patient.
- rAAV recombinant AAV
- the polynucleotide encodes a functional LAMA2 protein
- the one or more coding sequences encode an exon-skipping antisense sequence that restores expression of the C-terminal G-domain (exons 45-64), particularly G4 and G5 of a defective LAMA2 gene in a Merosin- deficient congenital muscular dystrophy type 1 A (MDC1A) patient.
- MDC1A Merosin- deficient congenital muscular dystrophy type 1 A
- the recombinant AAV (rAAV) vector a) the polynucleotide encodes a functional DMPK protein, or a CLCN1 gene; and/or, b) the RNAi sequence (siRNA, shRNA, miRNA), the antisense sequence, or the microRNA (miRNA) targets expanded repeats of mutant transcripts in a defective DMPK gene, or encodes an exon-skipping antisense sequence leading to the skipping of exon 7A in CLCN1 gene in a DM1 patient.
- rAAV recombinant AAV
- the polynucleotide encodes a functional DYSF protein; and/or, b) one or more coding sequences encode an exon-skipping antisense sequence leading to the skipping of exon 32 in a defective DYSF gene in a dysferlinopathy (LGMD2B or MM) patient.
- rAAV recombinant AAV
- the polynucleotide encodes a functional SGCG protein; and/or, b) one or more coding sequences encode an exon-skipping antisense sequence leading to the skipping of exons 4-7 in a defective LGMD2C gene (e.g, one with the A-521T SGCG mutation) in a LGMD2C patient.
- a defective LGMD2C gene e.g, one with the A-521T SGCG mutation
- the heterologous intron coding sequence is SEQ ID NO: 1.
- the one or more coding sequences are inserted in the intron sequence.
- expression of the functional protein is not negatively affected by the insertion of said one or more coding sequences.
- the vector is of the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV 11, AAV 12, or AAV 13.
- the vector is a derivative of a known serotype.
- the derivative may exhibit a desired tissue specificity or tropism, a desired immunogenic profile (e.g., not subject to attack by a subject patient’s immune system), or other desirable properties for a pharmaceutical composition or gene therapy for various indications.
- the first control element (or the promoter in the divergent cassette) is a promoter or portion of a promoter that transcribes in a tissue specific manner the one or more coding GOI sequences.
- the tissue specific specific control element is a muscle-specific control element.
- the muscle-specific control element is human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor mef, muscle creatine kinase (MCK), truncated MCK (tMCK), myosin heavy chain (MHC), C5-12, murine creatine kinase enhancer element, skeletal fast-twitch troponin c gene element, slow-twitch cardiac troponin c gene element, slow-twitch troponin i gene element, hypoxia-inducible nuclear factors, steroid-inducible element, or glucocorticoid response element (gre).
- the muscle-specific control element comprises the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO: 11 of W02017/181015 (incorporated herein by reference).
- compositions comprising any of the vector, e.g., the recombinant viral (AAV) vector of the invention.
- AAV recombinant viral
- the composition is a pharmaceutical composition further comprising a therapeutically compatible carrier, diluent, or excipient.
- the therapeutically acceptable carrier, diluent, or excipient is a sterile aqueous solution comprising 10 mM L-histidine at pH 6.0, 150 mM sodium chloride, and 1 mM magnesium chloride.
- the composition is in a dosage form of about 10 mL of aqueous solution having at least 1.6 x 10 13 vector genomes.
- the composition has a potency of at least 2 x 10 12 vector genomes per milliliter.
- Another aspect of the invention provides a method of producing the subject composition, comprising producing the vector, e.g., the recombinant AAV vector in a cell and lysing the cell to obtain the vector.
- the vector is an AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV 11, AAV 12, or AAV 13 vector.
- Another aspect of the invention provides a method of treating a muscular dystrophy or dystrophinopathy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of any one of the recombinant vector, e.g., the recombinant AAV vector of the invention, or any one of the composition of the invention.
- the recombinant vector e.g, the recombinant AAV vector or the composition is administered by intramuscular injection, intravenous injection, parental administration or systemic administration.
- the muscular dystrophy is Duchenne muscular dystrophy or Becker muscular dystrophy.
- the muscular dystrophy is Duchenne muscular dystrophy
- FCMD Fukuyama congenital muscular dystrophy
- FCMD Fukuyama congenital muscular dystrophy
- FCMD dysferlinopathy
- myotonic dystrophy myotonic dystrophy
- merosin-deficient congenital muscular dystrophy type 1A facioscapulohumeral muscular dystrophy
- FSHD facioscapulohumeral muscular dystrophy
- CMD congenital muscular dystrophy
- LGMDR5 or LGMD2C limb-girdle muscular dystrophy
- kits for preventing or treating DMD or related / associated diseases in a subject comprising: one or more vector, e.g., the recombinant AAV as described herein, or a composition as described herein; instructions for use (written, printed, electronic / optical storage media, or online); and/or packaging.
- a kit also includes a known MD (e.g., DMD) therapeutic for combination therapy.
- FIG. 1 shows schematic drawings (not to scale) showing a representative and non- limiting embodiment of the subject recombinant viral (e.g., lentiviral or AAV) vector encompassing a gene of interest (GOI), such as a microdystrophin, minidystrophin or dystrophin minigene as described below (e.g., the 5-spectrin-like-repeat microD5 dystrophin protein described below, or a version of a functional DMD gene (micro dystrophin or labeled as “pDys” in the figure)) and one or more additional coding sequences for non-protein coding RNA (ncRNA) such as shRNA, between the two ITR sequences.
- ncRNA non-protein coding RNA
- shRNA non-protein coding RNA
- Transcript can be inserted anywhere in the vector where “Transcript” is indicated, e.g., in the region between the promoter for the GOI (labeled in the figure as the exemplary muscle specific promoter CK8) and the nearest ITR sequence; in the intron before the GOI; in the 3’-UTR region; or after the polyA signal sequence.
- the additional ncRNA (e.g., shRNA) coding sequences can be the same or different.
- fusion transcripts have been described in more detail in International Patent Application No. PCT/US2019/065718, filed on December 11, 2019 (incorporated herein by reference).
- the initial transcription from the GOI promoter will result in a fusion transcript or a pre-processed mRNA encompassing the GOI and the additionally coded sequences, which, upon further processing, will be sepatrated as the GOI transcript and and the additional coded sequences.
- the so-called “divergent / independent” transcripts of the invention are transcribed from its own, independent promoter, and are described in further details below.
- FIG. 2 shows the relative miR-29c expression level changes (in folds over the control vector expressing pDys only) in human iPS-derived cardiomyocytes, for the various recombinant viral (e.g., AAV) vectors encoding miR-29c, either as the sole coding sequence in the viral vector (the “Solo” constructs), as part of the fusion constructs described in PCT/US2019/065718, filed on December 11, 2019 (the “Fusion” constructs), or as part of the divergent constructs of the present disclosure (the “Divergent” constructs).
- AAV recombinant viral vectors encoding miR-29c
- FIG. 3 shows relative expression levels of miR-29c in differentiated C2C12 myotube or primary mouse cardiomyocytes for the various recombinant AAV vectors encoding miR-29c, either as the sole coding sequence in the viral vector (the “Solo” constructs), or as part of the divergent constructs of the present disclosure (the “Divergent” constructs).
- FIG. 4 shows about 90% knock-down of mouse SLN luciferase construct levels measured via firefly activity normalized to control renilla construct activity via multiple shSLN-pDys divergent construct of the present disclosure. As comparison, results from using solo constructs were also shown. The last two samples are commercial negative and positive shRNA controls for mSLN knock-down.
- FIG. 5 shows relative expression levels of siSLN (processed siRNA product from the transcribed shSLN) in differentiated C2C12 myotubes or mouse cardiomyocytes for the various recombinant AAV vectors encoding shSLN, either as the sole coding sequence in the viral vector (“Solo”), or as part of the divergent construct of the present disclosure (“Divergent”).
- FIG. 6 shows up to -90-95% human SLN mRNA knock-down in human iPS-derived cardiomyocytes by several subject divergent constructs encoding shhSLN.
- FIG. 7 shows up to -90% mouse SLN mRNA knock-down in primary mouse cardiomyocytes by several subject solo and divergent constructs encoding shmSLN.
- FIG. 8 shows normalized pDys mRNA levels of several Hum-shSLN-pDys divergent constructs in human iPS-derived cardiomyocytes.
- FIG. 9 is an image of denaturing agarose gel, suggesting largely intact AAV genomes in the solo, fusion, and divergent constructs with miR-29c or shSLN coding sequence.
- FIG. 10 shows that the ratio of all three AAV9 capsid proteins VP1-VP3 remains the same across AAV9-based solo, fusion, and divergent vectors.
- FIG. 11 shows up to 6-fold miR-29c up-regulation in left gastrocnemius (top panel), up to 5.8-fold miR-29c up-regulation in diaphragm (lower left panel), and up to 7.5-fold miR-29c up- regulation in left ventricle (lower right panel), using a miR-29c-pDys divergent construct of the invention in AAV9 vector.
- FIG. 12 shows elevated plasma levels of miR-29c in mice infected by the solo or divergent vectors.
- FIG. 13 shows no reduction of pDys expression at RNA (left panel) and protein (right panel) level in left gastrocnemius with miR-29c up-regulating divergent AAV9 vector.
- FIG. 14 shows up to 75% mSLN mRNA down-regulation in the diaphragm (top panel), up to 95% mSLN mRNA down-regulation in the left atrium (lower left panel), and up to 80% mSLN mRNA down- regulation in the left gast (lower right panel), via AAV9-mediated expression of shSLN-pDys divergent construct relative to pDys-only AAV9.
- FIG. 15 shows similar levels of pDys RNA/protein expression in diaphragm via an shmSLN-pDys divergent construct of AAV9. Similar results were also obtained for atrium (data not shown).
- FIG. 16 shows similar levels of pDys protein expression and mSLN mRNA knock down in tongue, via an shmSLN-pDys divergent construct of AAV9.
- FIG. 17 shows that miR-29c solo and miR-29c-pDys divergent constructs of AAV9 reduce serum CK levels. Mir-29c and pDys co-expression may cause further reductions in serum CK levels.
- FIG. 18 shows serum CK levels in shmSLN solo and divergent constructs of AAV9.
- FIG. 19 shows that miR-29c solo and miR-29c-pDys divergent constructs of AAV9 reduce serum TIMP1 levels.
- FIG. 20 shows largely similar biodistribution of miR-29c or shSLN vectors in gastrocnemius from several miR-29c-pDys divergent vectors of AAV9, or shmSLN-pDys divergent vectors of AAV9.
- FIG. 21 shows generally lower titers of AAV9 vectors in liver for miR-29c-pDys and shmSLN-pDys divergent constructs vs. the pDys solo construct.
- FIG. 22 shows that plasma ALT levels were comparable in animals infected by miR-29c- expressing divergent vectors, suggesting that liver damage was not a likely casue for observed lower liver titer in certain infected animals.
- FIG. 23 shows added benefit of the divergent constructs of the invention over pDys construct alone in diaphragm, based on their effects on two fibrotic marker genes.
- the present invention is partly directed to gene therapy methods to treat a patient that not only compensate defects in dystrophin and its function by providing a replacement, functional dystrophin minigene, but also directly target one or more secondary cascade genes using one or more additional coding sequences in the same gene therapy vector, thus achieving combination therapy in one compact vector for systematic delivery.
- the present invention is not limited to treating DMD.
- the invention is applicable for treating other muscular dystrophies in which a gene is defective.
- the recombinant AAV (rAAV) vector of the invention can provide a functional protein and/or one or more coding sequences (such as non-coding RNAs, e.g., RNAi sequence, antisense RNA, miRNA) to treat the muscular dystrophy, wherein the functional protein either provides a wild-type substitute for the defective gene product in the muscular dystrophy, or provides a non-wild-type substitute that is nevertheless effective to treat the muscular dystrophy (e.g., the 5-spectrin-like microD5 dystrophin minigene product).
- a functional protein such as non-coding RNAs, e.g., RNAi sequence, antisense RNA, miRNA
- the invention provides a recombinant viral vector, e.g., a recombinant lentiviral or AAV (rAAV) vector comprising: a) a polynucleotide encoding a functional gene or protein of interest (GOI), such as one effective to treat the muscular dystrophy in a patient / subject / individual in need of treatment, wherein said polynucleotide comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the functional protein encoded by the polynucleotide, wherein the corresponding wild-type of the functional protein is defective in a muscular dystrophy, or wherein the functional protein, though not wild-type, is nevertheless effective to treat the muscular dystrophy; b) a first control element (e.g., a muscle-specific control element) operably linked to and drives the expression of the polynucleotide; and, c) one or more coding sequences (1)
- the recombinant viral vector is a recombinant AAV (adeno associated viral) vector.
- the invention described herein can also be used as a viral vector for simultaneously delivering / expressing two or more components of an enzyme-based gene editing system, e.g., such as a target sequence-specific (engineered) nuclease that can create DNA double stranded break (DSB) at a target genomic site / target genomic sequence, and a donor or template sequence that matches the (wild-type or desired) target genome sequence.
- an enzyme-based gene editing system e.g., such as a target sequence-specific (engineered) nuclease that can create DNA double stranded break (DSB) at a target genomic site / target genomic sequence, and a donor or template sequence that matches the (wild-type or desired) target genome sequence.
- Such a system makes it possible to utilize the endogenous homologous recombination (HR) processes within the target cell to edit out a defective / undesired target genomic sequence, and replace it with a wild-type or otherwise desired sequence at the desired target genomic location.
- HR homologous recombination
- the recombinant viral vector is a recombinant AAV (adeno associated viral) vector.
- the target sequence-specific (engineered) nuclease may include meganucleases (such as those in the LAGLIDADG family) and variants thereof that recognize unique target genomic sequences; Zinc Finger Nucleases (ZFNs); Transcription Activator-Like Effector Nucleases (TALENs); and CRISPR/Cas gene editing enzymes.
- meganucleases such as those in the LAGLIDADG family
- ZFNs Zinc Finger Nucleases
- TALENs Transcription Activator-Like Effector Nucleases
- CRISPR/Cas gene editing enzymes CRISPR/Cas gene editing enzymes.
- the subject vector can simultaneously deliver, other than or in addition to the donor sequence, one or more gene editing guide sequence(s) having a desired sequence(s) for targeting one or more target sequence(s), and a compatible editing enzyme that can be encoded by the viral vector as the GOI.
- a viral delivery system can be used to substitute the undesired sequence occurring in the cell, tissue, or organism for the desired sequence.
- CRISPR/Cas enzyme system is CRISPR/Cas9 or CRISPR/Cas 12a (formerly Cpfl), and one or more required guide sequences (e.g ., single guide RNA or sgRNA for Cas9, or crRNA for Casl2a) to a target cell.
- Cas9 includes the wild-type Cas9 and functional variants thereof.
- Several Cas9 variants are about the same size as the micro Dystrophin gene, and can be the functional GOI encoded by the viral vector of the invention.
- Casl2a is even smaller than Cas9 and can also be encoded as the GOT
- the Cas genes encoded by the viral constructs may or may not have UTR and/or intron elements.
- the GOI is CRISPR/Cas9
- the guide sequence is an sgRNA (single guide RNA); or wherein the GOI is CRISPR/Casl2a, and the guide sequence is a crRNA.
- the invention provides a recombinant lentiviral vector for use in ex vivo or in vivo gene therapy.
- ex vivo gene therapy cultured host cells are transfected in vitro using a subject viral vector to express the gene of interest, and then transplanted into the body.
- In vivo gene therapy is a direct method of inserting the genetic material into the targeted tissue, and transduction takes place within the patient's own cells.
- the lentiviral vector of the invention may comprise: a) a polynucleotide encoding a functional gene or protein (GOI) effective to treat the muscular dystrophy in a patient / subject / individual in need of treatment, wherein said polynucleotide comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the functional protein encoded by the polynucleotide, wherein the corresponding wild-type of the functional protein is defective in a muscular dystrophy, or wherein the functional protein, though not wild-type, is nevertheless effective to treat the muscular dystrophy; b) a first control element (e.g., a muscle-specific control element) operably linked to and drives the expression of the polynucleotide; and, c) one or more coding sequences (1) inserted between the first control element and the nearest viral terminal sequence (e.g., ITR in AAV) and operably linked to a second control element, and (2) optional
- fusion may have different meanings, including fusion proteins, fusion RNA transcripts in which more than one encoded sequence may be present (such as the coding sequence for the GOI and the coding sequence for one or more RNAi agents etc inserted into / embedded in the 3-UTR region or intron sequences of the GOI, and fusion constructs in which the viral vectors contain coding sequences for the GOI and the one or more RNAi agents, etc.
- the term “divergent” refers to the fact that there are at least two transcription cassettes or units in the viral construct / vector, such that one (under the control of the first control element or first promoter) is responsible for the transcription of one (first) GOI (protein, polypeptide, RNA, etc) in the first transcription cassette / unit, while the other GOI (under the control of the second control element or second promoter) is responsible for the transcription of other encoded sequences other than the first GOI, such as the ncRNA or another protein- coding sequence, wherein the other / second transcripiton unit largely operates separately and independently from the one for the first GOI transcription.
- the second transcrioption cassettes / units may be situated between the promoter for the first transcription unit for the first GOI, and the nearest viral vector terminal sequence (such as the nearest ITR in the AAV vector).
- the second transcription unit transcribes in the opposite direction compared to the transcription direction of the first transcription units.
- the second control element in the divergent cassette
- the second control element is a promoter or portion of a promoter that transcribes the one or more coding sequences.
- the second control element is a pol II promoter that transcribes the one or more coding sequences inserted between the first control element and the nearest viral terminal sequence, optionally in a direction opposite to the transcription initiated by the first control element.
- the second control element (in the divergent cassette) is a pol III promoter.
- first and seond control elements are both the same promoter. In other embodiments, the first and second control elements are different promoters.
- the one or more coding sequences are further inserted in the 3’- UTR coding region, or after the polyadenylation (poly A) signal sequence (e.g ., AATAAA).
- poly A polyadenylation
- expression of the functional GOI is up- or down-regulated due to the presence of the one or more coding sequences (e.g., as compared to otherwise identical control constructs without inserted said one or more coding sequences).
- expression of the functional GOI is substantially unaffected in the presence of the one or more coding sequences (e.g., as compared to otherwise identical control constructs without inserted said one or more coding sequences).
- MD muscle dystrophy
- DMD Duchenne muscular dystrophy
- BMD Becker muscular dystrophy
- CMD congenital muscular dystrophy
- FCMD Fukuyama congenital muscular dystrophy
- MDCIA Merosin-deficient congenital muscular dystrophy type 1 A
- LGMD2B and Miyoshi myopathy myotonic dystrophy
- LGMD2C limb-girdle muscular dystrophy
- FSHD Facioscapulohumeral
- a subject is used interchangeably to include a mammalian (e.g., human) subject to be treated, diagnosed, and/or to obtain a biological sample from in the subject methods.
- the subject is affected or likely to be affected with DMD and the other related diseases described herein, and in some embodiments, DMD and associated cardiomyopathy and dystrophic cardiomyopathy.
- a subject is a human child or adolescent (e.g ., no more than 18 years old, 15 years old, 12 years old, 10 years old, 8 years old, 5 years old, 3 years old, 1 year old, 6 months old, 3 months old, 1 month old, etc.).
- the child or adolescent is male.
- a subject is a human adult (e.g., >18 years old), such as a male adult.
- the full-length dystrophin gene is 2.6 mb and encodes 79 exons.
- the 11.5-kb coding sequence translates into a 427-kD protein.
- Dystrophin can be divided into four major domains, including the N-terminal domain, rod domain, cysteine- rich domain, and C-terminal domain.
- the rod domain can be further divided into 24 spectrin-like repeats and four hinges.
- a functional “dystrophin minigene” or “dystrophin microgene” has less than 24 spectrin- like repeats and one or more hinge region/s compatible with gene therapy delivery vectors (adenoviral and lentiviral) and have been described in US7001761, US6869777, US8501920, US7892824, US10479821, and US10166272 (all incorporated herein by reference).
- the muscular dystrophy is DMD or BMD
- the polynucleotide in the recombinant AAV (rAAV) vector: a) the polynucleotide is a dystrophin minigene encoding a functional 5- spectrin-like repeat dystrophin protein (such as the microD5 dystrophin protein as described in US 10,479,821, incorporated herein by reference); and/or, b) the muscle-specific control element is a CK promoter operably linked to and drives the expression of the dystrophin minigene.
- rAAV recombinant AAV
- microD5 refers to a specific engineered 5 -repeat microdystrophin protein that contains, from N- to C-terminus, the N-terminal actin binding domain, Hinge region 1 (HI), spectrin-like repeats Rl, R16, R17, R23, and R24, Hinge region 4 (H4), and the C-terminal dystroglycan binding domain of the human full-length dystrophin protein.
- Hinge region 1 HI
- spectrin-like repeats Rl, R16, R17, R23, and R24 Hinge region 4
- H4 Hinge region 4
- the protein sequence of this 5- repeat microdystrophin and the related dystrophin minigene are described in US10,479,821 & WO2016/115543 (incorporated herein by reference).
- the dystrophin minigene encoding a functional dystrophin protein different from microD5 with respect to, for example, the specific spectrin-like repeats, and/or the number of spectrin-like repeats (e.g., comprising a minimum of 4, 5, or 6 spectrin-like repeats of the human dystrophin, preferably including 1, 2, or 3 most N- and/or most C-terminal repeats).
- One or more spectrin-like repeats of the human dystrophin may also be substituted by spectrin-like repeats from utrophin or spectrin.
- the dystrophin minigene is smaller than the 5 kb packaging limit of AAV viral vectors, preferably no more than 4.9 kb,
- the dystrophin minigene encodes a micro-dystrophin protein that is, e.g., at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or 99% sequence identity to microD5, wherein the protein retains micro-dystrophin activity.
- a micro-dystrophin protein that is, e.g., at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or 99% sequence identity to microD5, wherein the protein retains micro-
- the micro-dystrophin is encoded by a nucleotide sequence that has at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%,
- polynucleotide sequence encoding the microD micro-dystrophin.
- the polynucleotide is optionally codon optimized for expression in a mammal, such as in a human.
- the nucleotide sequence hybridizes under stringent conditions to the nucleic acid sequence encoding the microD5 micro-dystrophin, or compliments thereof, and encodes a functional micro-dystrophin protein.
- stringent is used to refer to conditions that are commonly understood in the art as stringent.
- Hybridization stringency is principally determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide.
- Examples of stringent conditions for hybridization and washing are 0.015 M sodium chloride, 0.0015 M sodium citrate at 65-68°C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at 42°C. See Sambrook el ah, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, N.Y. 1989).
- More stringent conditions may also be used, however, the rate of hybridization will be affected.
- additional exemplary stringent hybridization conditions include washing in 6* SSC 0.05% sodium pyrophosphate at 37°C (for 14-base oligoes), 48°C (for 17-base oligos), 55°C (for 20- base oligos), and 60°C (for 23-base oligos).
- agents may be included in the hybridization and washing buffers for the purpose of reducing non-specific and/or background hybridization.
- agents include 0.1% bovine serum albumin, 0.1% polyvinyl -pyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecylsulfate, NaDodS04, (SDS), ficoll, Denhardf s solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, although other suitable agents can also be used.
- concentration and types of these additives can be changed without substantially affecting the stringency of the hybridization conditions.
- Hybridization experiments are usually carried out at pH 6.8-7.4, however, at typical ionic strength conditions, the rate of hybridization is nearly independent of pH. See Anderson el al. , Nucleic Acid Hybridisation: A Practical Approach, Ch. 4, IRL Press Limited (Oxford, England). Hybridization conditions can be adjusted by one skilled in the art in order to accommodate these variables and allow DNAs of different sequence relatedness to form hybrids.
- Additional dystrophin minigene sequences can be found in, for example,
- the nucleotide sequence encoding any dystrophin minigene such as microD5 can be any one based on the disclosed protein sequence.
- the nucleotide sequence is codon optimized for expression in human.
- micro-dystrophin protein provides stability to the muscle membrane during muscle contraction, e.g., micro-dystrophin acts as a shock absorber during muscle contraction.
- At least one of the one or more coding sequences target one of the secondary cascade genes in DMD.
- At least one of the one or more coding sequences encodes a microRNA, such as miR-1, miR-133a, miR-29 particularly miR29c, miR-30c, and/or miR-206.
- miR-29c directly reduce the three primary components of connective tissue (e.g., collagen 1, collagen 3 and fibronectin) to reduce fibrosis.
- said microRNA such as miR-1, miR-133a, miR-29 particularly miR29c, miR-30c, and/or miR-206, has a modified flanking backbone sequence that enhances the processing of the guide strand designed for a target sequence.
- the modified flanking backbone sequence can be from or based on miR-30, -101, -155, or -451.
- Fibrosis refers to the excessive or unregulated deposition of extracellular matrix (ECM) components and abnormal repair processes in tissues upon injury including skeletal muscle, cardiac muscle, liver, lung, kidney, and pancreas.
- ECM extracellular matrix
- the ECM components that are deposited include fibronectin and collagen, e.g., collagen 1, collagen 2 or collagen 3.
- miR-29 refers to one of miR-29a, -29b, or -29c. In certain embodiments, miR-29 refers to miR-29c.
- miR29 (such as miR-29a, miR-29b, or miR-29c) binds to the 3 ’ UTR of the collagen and fibronectin genes to down-regulate expression of these target genes.
- At least one of the one or more coding sequences encodes an RNAi sequence, such as an shRNA against sarcolipin (shSLN).
- the one or more coding sequences may encode identical or different shRNAs against sarcolipin (shSLN).
- the shRNA reduces sarcolipin mRNA and/or sarcolipin protein expression by at least about 50%.
- sarcolipin As used herein, “sarcolipin (SLN),” “sarcolipin protein,” “SLN protein,” “sarcolipin polypeptide” and “SLN polypeptide” are used interchangeably to include an expression product of a SLN gene, such as the native human SLN protein having the amino acid sequence of (MGINTRELLLNLTIVLITVTLMWLLVRSYGY) (SEQ ID NO: 5), accession number NP 003054.1. The term preferably refers to the human SLN.
- the term may also be used to refer to a variant SLN protein that differs from SEQ ID NO: 5 by 1 amino acid, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, or 8 amino acids, optionally the differences are within residues 2-5, 10, 14, 17, 20, and 30, preferably 2-5 and 30.
- the term may also be used to refer to a variant SLN protein that are identical to SEQ ID NO: 5 at residues 6-29, or differ in residues 6-29 by up to 1 , 2, or 3 conservative substitutions such as L- I and/or I- V.
- the variant SLN has a G30Q substitution.
- the variants displays a functional activity of a native SLN protein, which may include: phosphorylation, dephosphorylation, nitrosylation and/or ubiquitination of SLN, or binding to a SERCA and/or reduce the rate of calcium import by SERCA into the sarcoendoplasmic reticulum through, for example, uncoupling of Ca 2+ transport from ATP hydrolysis, or its role in energy metabolism and regulation of weight gain.
- SLN gene As used herein, “SLN gene,” “SLN polynucleotide,” and “SLN nucleic acid” are used interchangeably to include a native human SLN-encoding nucleic acid sequence, e.g., the native human SLN gene (RefSeq Accession: NM_003063.2), a nucleic acid having sequences from which a SLN cDNA can be transcribed; and/or allelic variants and homologs of the foregoing, such as a polynucleotide encoding any of the variant SLN described herein.
- the terms encompass double-stranded DNA, single-stranded DNA, and RNA.
- the one or more additional coding sequences of the subject vector may be targeting any other genes associated with one of the secondary cascade events resulting from the loss of dystrophin gene, such as inflammatory gene, an activator of NF-KB signaling pathway (e.g., TNF-a, IL-1, IL-Ib, IL-6, Receptor activator of NF-KB (RANK), and Toll-like receptors (TLRs)), NF-KB, a downstream inflammatory cytokine induced by NF-KB, a histone deacetylase (e.g., HDAC2), TGF-b, connective tissue growth factor (CTGF), ollagens, elastin, a structural component of the extracellular matrix, Glucose-6-phosphate dehydrogenase (G6PD), myostatin, phosphodiesterase-5 (PED-5) or ACE, VEGF decoy-receptor type 1 (VEGFR-l or Flt-1), and hema
- the design of the subject recombinant vectors can simultaneously target one or more (e.g., 1, 2, 3, 4, 5) such secondary cascade genes or pathways, such as SLN, microRNA, etc.
- one of the additional coding sequence of the subject vector may be an RNAi sequence (siRNA, shRNA, miRNA) or an antisense sequence designed to down-regulate SLN expression, hence at least partially alleviate the secondary defect of abnormal elevation of intracellular Ca 2+ in dystrophy muscle by increasing the reuptake of calcium by SERCA.
- RNAi sequence siRNA, shRNA, miRNA
- antisense sequence designed to down-regulate SLN expression, hence at least partially alleviate the secondary defect of abnormal elevation of intracellular Ca 2+ in dystrophy muscle by increasing the reuptake of calcium by SERCA.
- At least one of the one or more coding sequences may be an exon skipping antisense sequence that induces skipping of an exon of a defective endogenous dystrophin, such as any one of exons 45-55 of dystrophin, or exon 44, 45, 51, and/or 53 of dystrophin, thus further enhancing the therapeutic effect of the dystrophin minigene (e.g., microD5).
- a defective endogenous dystrophin such as any one of exons 45-55 of dystrophin, or exon 44, 45, 51, and/or 53 of dystrophin
- an “exon skipping” or “splice-switching” antisense oligonucleotide (AON) is a type of antisense sequence that is RNase-H-resistant, and acts to modulate pre- mRNA splicing and correct splicing defects in the pre-mRNA.
- AONs are usually used to block specific splicing signals and induce specific skipping of certain exons. This leads to the correction of the reading frame of a mutated transcript, such that it can be translated into an internally deleted but partially functional protein.
- the invention provides a recombinant AAV (rAAV) vector encoding both a dystrophin minigene coding sequence (such as microD5 / SGT-001), and one or more additional sequences for targeting one or more additional target genes involved in a secondary cascade resulting from loss of dystrophin function.
- a dystrophin minigene coding sequence such as microD5 / SGT-001
- additional sequences for targeting one or more additional target genes involved in a secondary cascade resulting from loss of dystrophin function.
- Such construct comprises both a dystrophin minigene, and one or more additional coding sequences inserted between the first control element or promoter of the dystrophin minigene and the nearest viral terminal sequence (e.g., ITR in AAV) and operably linked to a second control element, and (2) optionally further inserted into heterologous intron 5’ to the dystrophin minigene or 3’-UTR region of the dystrophin minigene.
- the invention provides a recombinant AAV (rAAV) vector comprising: a) a dystrophin minigene encoding a functional micro-dystrophin protein, wherein said dystrophin minigene comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the dystrophin minigene; b) a muscle- specific control element operably linked to and drives the expression of the dystrophin minigene; and, c) one or more (e.g., 1, 2, 3, 4, or 5) coding sequence(s) inserted between the muscle- specific control element and the nearest AAV ITR sequence and operably linked to a second control element, and (2) optionally further inserted into the intron sequence or in the 3’-UTR coding region; wherein said one or more coding sequence(s) independently encode(s): an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a microRNA (mi)
- the rAAV vector may comprise a polynucleotide sequence expressing miR- 29 (e.g., miR-29c), such as a nucleotide sequence comprising the miR-29c target guide strand ( ACCGATTT C AAAT GGT GCT AGA, SEQ ID NO: 3 of W02017/181015 or , incorporated herein by reference), the miR-29c guide strand (TCTAGCACCATTTGAAATCGGTTA, SEQ ID NO: 4 of W02017/181015, incorporated herein by reference) and the natural miR-30 back bone and stem loop (GTGAAGCCACAGATG, SEQ ID NO: 5 of W02017/181015, incorporated herein by reference).
- miR-29c e.g., miR-29c
- An exemplary polynucleotide sequence comprising the miR-29c cDNA in a miR-30 backbone is set out as SEQ ID NO: 2 and FIG. 1 of W02017/181015 (incorporated herein by reference).
- the microRNA-29 coding sequence encodes miR-29c.
- miR-29c optionally has a modified flanking backbone sequence that enhances the processing of the guide strand of miR-29c designed for a target sequence.
- the modified flanking backbone sequence can be from or based on that of miR-30 (miR-30E), -101, -155, or -451.
- the microRNA is miR-1, miR-133a, miR-30c, and/or miR-206.
- expression of said microRNA in a host cell is up-regulated by at least about 1.5-15 fold (e.g ., about 2-10 fold, about 1.4-2.8 fold, about 2-5 fold, about 5-10 fold, about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or about 15 fold) compared to endogenous expression of said microRNA in said host cell.
- 1.5-15 fold e.g ., about 2-10 fold, about 1.4-2.8 fold, about 2-5 fold, about 5-10 fold, about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or about 15 fold
- the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of sarcobpin (SEN).
- the vector of the invention encodes an shRNA that antagonizes the function of sarcobpin (shSLN).
- shSLN sequences include those disclosed in FIGs. 9 and 10 of PCT/US2019/065718, filed on December 11, 2019 (e.g., the underlined sequences in FIG. 9, and the highlighted sequences in FIG. 10). Additional exemplary shSFN sequences include SEQ ID NOs: 7-11 disclosed in WO2018/136880 (incorporated herein by reference).
- the invention is also partly directed to gene therapy vectors, e.g., lentiviral or AAV expressing the one or more coding sequence(s), and the dystrophin minigene, as well as methods of delivering the same to the muscle to reduce and/or prevent a secondary cascade symptom while restoring dystrophin function.
- gene therapy vectors e.g., lentiviral or AAV expressing the one or more coding sequence(s), and the dystrophin minigene
- the muscular dystrophy is a congenital muscular dystrophy (CMD) associated with a known genetic defect, such as the fukutin gene or the FKRP (fukutin related protein) gene.
- CMD congenital muscular dystrophy
- FKRP fukutin related protein gene
- FCMD Fukuyama congenital muscular dystrophy
- CMD Congenital Muscular Dystrophy
- the methods and rAAV of the invention can be used to treat CMD, especially CMD with known genetic defect in genes such as titin (CMD with cardiomyopathy); SEPN1 (CMD with desmin inclusions, or CMD with (early) spinal rigidity); integrin-alpha 7 (CMD with integrin alpha 7 mutations); integrin-alpha 9 (CMD with joint hyperlaxity); plectin (CMD with familial junctional epidermolysis bullosa); fukutin (Fukuyama CMD or MDDGA4); fukutin-related protein (FKRP) (CMD with muscle hypertrophy or MDCIC); FARGE (MDCID); DOK7 (CMD with myasthenic syndrome); lamin A/C (CMD with spinal rigidity and lamin A/C abnormality); SBP2 (CMD with spinal rigidity and selenoprotein deficiency); choline kinase beta (CMD with structural abnormalities of mitochondria); laminin
- the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding any of the wild-type genes defective in the CMD (such as the ones listed herein above), or a functional equivalent thereof, to treat the CMD in a subject in need thereof.
- the one or more additional coding sequences may encode an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, or a microRNA (miRNA) that eliminates or modifies the mutant CMD gene, or a secondary cascade gene up-regulated due to the loss of the wild-type gene function.
- FCMD Fukuyama congenital muscular dystrophy
- the one or more additional coding sequences may encode an exon-skipping antisense oligonucleotide to restore correct exon 10 splicing in the defective FKTN gene in the patient.
- the congenital muscular dystrophy is Merosin-deficient congenital muscular dystrophy type 1A (MDCl A) caused by mutations in the 65-exon FAMA2 gene.
- MDCl A Merosin-deficient congenital muscular dystrophy type 1A
- the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding a functional FAMA2 protein.
- the one or more additional coding sequences may encode an exon-skipping antisense sequence leading to the restored expression of the C-terminal G-domain (exons 45-64), particularly G4 and G5 of LAMA2 that are most important for mediating interaction with a-dystroglycan.
- exon 4 of the mutant LAMA2 gene may be skipped to treat MDC1 A.
- the muscular dystrophy is myotonic dystrophy (DM), such as DM1 or DM2.
- DM myotonic dystrophy
- the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding a functional Dystrophia Myotonica Protein Kinase (DMPK) protein defective in DM1, or a functional CCHC-type zinc finger, nucleic acid binding protein gene (CNBP) protein in DM2.
- the one or more additional coding sequences may encode an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, or a microRNA (miRNA) that can be used to target expanded repeats of mutant transcripts in the DMPK gene or the CNBP gene for RNase- mediated degradation.
- the one or more additional coding sequences may also encode an exon skipping antisense sequence leading to the skipping of exon 7A in CLCN1 gene in a DM1 patient.
- the muscular dystrophy is Dysferlinopathy caused by mutations in the dysferlin (DYSF) gene, including limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM).
- DYSF dysferlin
- LGMD2B limb-girdle muscular dystrophy type 2B
- MM Miyoshi myopathy
- the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding a functional DYSF protein defective in LGMD2B or MM.
- the one or more additional coding sequences may encode an exon-skipping antisense sequence leading to the skipping of exon 32 in a defective DYSF gene in a dysferlinopathy patient.
- the muscular dystrophy is limb-girdle muscular dystrophy (LGMD) caused by mutations in any of the four sarcoglycans genes, namely a (LGMD2D), b (LGMD2E), g (LGMD2C) and d (LGMD2F) gene, particularly the g sarcoglycan (LGMD2C) encoded by the SGCG gene.
- LGMD2D limb-girdle muscular dystrophy
- LGMD2E limb-girdle muscular dystrophy
- LGMD2C g sarcoglycan
- LGMD2F d gene
- the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding a functional sarcoglycan protein defective in a LGMD, such as the SGCG gene defective in LGMD2C.
- the one or more additional coding sequences may encode an exon skipping antisense sequence leading to the skipping of exons 4-7 in a defective LGMD2C gene, such as one with the A-521T SGCG mutation.
- the muscular dystrophy is Facioscapulohumeral muscular dystrophy (FSHD) caused by mutations in the DUX4 gene.
- FSHD Facioscapulohumeral muscular dystrophy
- the one or more additional coding sequences may encode an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, or a microRNA (miRNA) that reduces the expression of DUX4 or a downstream target such as PITX1.
- the one or more additional coding sequences encode an exon skipping antisense sequence that targets 3’-UTR of DUX4 to reduce its expression. This is because the DUX4 coding sequence is entirely located in the gene first exon, and exon skipping that targets elements in the mRNA 3 ’ UTR can either disrupt the permissive polyadenylation or interfere with intron 1 or 2 splicing, hence destroying a functional DUX4 mRNA.
- Facioscapulohumeral muscular dystrophy is an inherited autosomal dominant disorder characterized clinically by progressive muscle degeneration. It is the third most common muscular dystrophy after Duchenne muscular dystrophy (DMD) and myotonic dystrophy.
- FSHD is genetically characterized by a pathogenic contraction of a subset of macrosatellite repeats on chromosome 4, leading to aberrant expression of the double homeobox protein 4 (DUX4) gene.
- FSHDl is the most common form that occurs in over 95% of all FSHD patients. Genetic analysis links FSHD 1 to the genetic contraction of macrosatellite D4Z4 repeat array on chromosome 4. FSHD2, on the other hand, has a normal number of D4Z4 repeats but instead involves a heterozygous mutation in the SMCHD1 gene on chromosome 18p, a chromatin modifier. Patients with FSHDl and FSHD2 share similar clinical presentations.
- FSHD myostatin inhibitor luspatercept
- ATYR1940 anti-inflammatory biologies
- the basis for anti-inflammatory biologies is to suppress inflammation commonly seen in muscle pathology of FSHD patients in order to slow phenotype progression.
- one or more coding sequences may encode an RNAi reagent or antisense RNA against myostatin or an inflammatory pathway gene.
- RNAi reagent such as small interfering RNA (siRNA) and small hairpin RNA (shRNA), or microRNA (miRNA), or antisense oligonucleotides
- shRNA small interfering RNA
- miRNA microRNA
- antisense oligonucleotides can be used to knockdown expression of the myopathic DUX4 gene and its downstream molecules including paired-like homeodomain transcription factor 1 (PITX1).
- PITX1 paired-like homeodomain transcription factor 1
- in vitro studies have demonstrated success in the suppression of DUX4 mRNA expression by administering antisense oligoes into primary skeletal muscle cells of FSHD patients, and by using miRNA against DUX4 delivered to a DUX4 mouse model using AAV vector.
- success in the suppression of PITX1 expression has already been demonstrated systemically in vivo.
- the one or more additional coding sequences can encode the same sequence (e.g ., siRNA, shRNA, miRNA, or antisense), and thus the copy number of the additional coding sequence may be regulated or fine tuned for dosing consideration.
- the one or more additional coding sequences can encode different sequences, either targeting different targets, or targeting the same target.
- one additional coding sequence is an antisense against a target
- another additional coding sequence is an shRNA against the same target.
- two additional coding sequences are both shRNAs but they target different regions of the same target.
- expression of the functional protein is not negatively affected by the insertion of the one or more coding sequence(s).
- intronless transgenes While express perfectly in tissue culture cells in vitro , fail to express the same transgene in vivo (e.g., in transgenic mice harboring the transgene), while inserting certain heterologous intron sequences between the promoter and the (intronless) coding sequence of the transgene greatly enhances transgene expression in vivo.
- Palmiter etal. Proc. Natl. Acad. Sci. U.S.A. 88:478-482, 1991, incorporated herein by reference
- heterologous introns selected from: the natural first intron of rGH, intron A of the rat insulin II (rlns-II) gene, intron B of the IibO gene, and the SV40 small t intron.
- the heterologous intron in the subject lentiviral or rAAV vector is selected from the group consisting of: the natural first intron of rGH, intron A of the rat insulin II (rlns-II) gene, intron B of the IibO gene, the SV40 small t intron, and the hybrid intron of Choi.
- the heterologous intron sequence is SEQ ID NO: 1:
- the one or more additional coding sequences are all inserted into the heterologous intron sequence (SEQ ID NO: 1), or all inserted into the 3’-UTR region, or are inserted into both regions.
- the microRNA-29c coding sequence can be inserted into the intron coding sequence as in SEQ ID NO: 2 GTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGATCTC TTACACAGGCTGACCGATTTCTCCTGGTGTTCAGAGTCTGTTTTTGTCTAGCACCATTTGAAAT CGGTTATGATGTAGGGGGAAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGAC ATCCACTTTGCCTTTCTCTCCACAG.
- the lentiviral or rAAV further comprises two lentiviral or AAV LTR/ITR sequences flanking the polynucleotide (such as the dystrophin minigene) and the additional coding sequence(s).
- the GOI encoded by the lentiviral or rAAV vectors of the invention may be operably linked to a muscle-specific control element.
- the muscle-specific control element can be: human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor MEF, muscle creatine kinase (MCK), tMCK (truncated MCK), myosin heavy chain (MHC), C5-12 (synthetic promoter), murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, slow-twitch troponin I gene element, hypozia-inducible nuclear factors, steroid-inducible element, or glucocorticoid response element (GRE).
- GRE glucocorticoid response element
- muscle-specific control element is 5’ to the heterologous intron sequence, which is 5’ to the dystrophin minigene, which comprises a 3’-UTR region including a translation stop codon (such as TAG), a polyA adenylation signal (such as AATAAA), and an mRNA cleavage site (such as CA).
- a translation stop codon such as TAG
- a polyA adenylation signal such as AATAAA
- CA mRNA cleavage site
- the muscle-specific control element comprises the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO: 11 of W02017/181015.
- the rAAV vectors of the invention can be operably linked to the muscle-specific control element comprising the MCK enhancer nucleotide sequence (see SEQ ID NO: 10 of W02017/181015, incorporated herein by reference) and/or the MCK promoter sequence (see SEQ ID NO: 11 of W02017/181015, incorporated herein by reference).
- the rAAV further comprises a promoter operably linked to and is capable of driving the transcription of the dystrophin minigene and the additional coding sequence.
- An exemplary promoter is the CMV promoter.
- the rAAV further comprises a poly-A adenylation sequence for inserting a polyA sequence into a transcribed mRNA.
- the rAAV vectors of the invention are of the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV 12 or AAV13.
- Another aspect of the invention provides a method of producing a viral vector, e.g., rAAV vector of the invention, comprising culturing a cell that has been transfected with any viral vector, e.g., rAAV vector of the invention and recovering the virus, e.g, rAAV particles from the supernatant of the transfected cells.
- a viral vector e.g., rAAV vector of the invention
- viral particles comprising any of the viral vector, e.g., recombinant AAV vectors of the invention.
- Another aspect of the invention provides methods of producing a functional protein either defective in a muscular dystrophy, or effective to treat the muscular dystrophy (such as a micro dystrophin protein), and one or more additional coding sequence(s), comprising infecting a host cell with a subject recombinant AAV vector co-expressing the functional protein (e.g., micro dystrophin) of the invention and the coding sequence product (e.g., RNAi, siRNA, shRNA, miRNA, antisense, microRNA or inhibitor thereof) in the host cell.
- the coding sequence product e.g., RNAi, siRNA, shRNA, miRNA, antisense, microRNA or inhibitor thereof
- Another aspect of the invention provides methods of treating a muscular dystrophy (such as DMD or BMD) or dystrophinopathy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a viral vector, e.g., recombinant AAV vector of the invention, or a composition of the invention.
- a viral vector e.g., recombinant AAV vector of the invention, or a composition of the invention.
- the invention contemplates administering any of the viral vector, e.g., AAV vectors of the invention to patients diagnosed with dystrophinopathy or muscular dystrophy, such as DMD or BMD or any other MD, particularly defective dystrophin-associated muscular dystrophy, preferably before one or more secondary cascade symptoms such as fibrosis is observed in the subject, or before the muscle force has been reduced in the subject, or before the muscle mass has been reduced in the subject.
- AAV vectors of the invention to patients diagnosed with dystrophinopathy or muscular dystrophy, such as DMD or BMD or any other MD, particularly defective dystrophin-associated muscular dystrophy, preferably before one or more secondary cascade symptoms such as fibrosis is observed in the subject, or before the muscle force has been reduced in the subject, or before the muscle mass has been reduced in the subject.
- the invention also contemplates administering any of the viral vector, e.g., rAAV of the invention to a subject suffering from dystrophinopathy or muscular dystrophy, such as DMD or BMD or any other MD, particularly dystrophin-associated muscular dystrophy, who already has developed one or more secondary cascade symptoms such as fibrosis, in order to prevent or slow down further disease progression in these subjects.
- dystrophinopathy or muscular dystrophy such as DMD or BMD or any other MD, particularly dystrophin-associated muscular dystrophy, who already has developed one or more secondary cascade symptoms such as fibrosis
- Another aspect of the invention provides recombinant viral vector, e.g., AAV vectors comprising a nucleotide sequence encoding a functional protein either defective in a muscular dystrophy, or effective to treat the muscular dystrophy (e.g, a micro-dystrophin protein) and the one or more additional coding sequences.
- AAV vectors comprising a nucleotide sequence encoding a functional protein either defective in a muscular dystrophy, or effective to treat the muscular dystrophy (e.g, a micro-dystrophin protein) and the one or more additional coding sequences.
- the invention provides for a rAAV comprising a nucleotide sequence having at least 85%, 90%, 95%, 97%, or 99% identity to the nucleotide sequence that encodes a functional micro-dystrophin protein such as microD5.
- the viral vector e.g., rAAV vector may comprise a muscle-specific promoter, such as the MCK promoter, a heterologous intron sequence effective to enhance the expression of the dystrophin gene, the coding sequence for the micro-dystrophin gene, polyA adenylation signal sequence, the ITR/LTR repeats flanking these sequences.
- the viral vector, e.g., rAAV vector may optionally further comprises ampicillin resistance and plasmid backbone sequences or pBR322 origin or replication for amplification in a bacteria host.
- the recombinant AAV vectors of the invention are AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV 11 , AAV 12 or AAV 13.
- the rAAV vector can be administered by intramuscular injection or intravenous injection.
- the viral vector e.g., rAAV vector or composition is administered systemically.
- the viral vector e.g., rAAV vector or composition is parentally administration by injection, infusion or implantation.
- compositions such as a pharmaceutical composition, comprising any of the viral vector, e.g., rAAV vectors of the invention.
- the composition is a pharmaceutical composition, which may further comprise a therapeutically compatible carrier or excipient.
- the invention provides for composition comprising any of the viral vector, e.g., rAAV vectors co-expressing the subject functional protein (e.g., micro dystrophin) and said one or more additional coding sequences for treating a subject suffering from dystrophinopathy or a muscular dystrophy, such as DMD or Becker Muscular dystrophy.
- the viral vector e.g., rAAV vectors co-expressing the subject functional protein (e.g., micro dystrophin) and said one or more additional coding sequences for treating a subject suffering from dystrophinopathy or a muscular dystrophy, such as DMD or Becker Muscular dystrophy.
- compositions (e.g., pharmaceutical compositions) of the invention can be formulated for intramuscular injection or intravenous injection.
- the composition of the invention can also be formulated for systemic administration, such as parentally administration by injection, infusion or implantation.
- any of the compositions are formulated for administration to a subject suffering from dystrophinopathy or a muscular dystrophy, such as DMD, Becker muscular dystrophy or any other dystrophin associated muscular dystrophy.
- the invention provides for use of any of the viral vector, e.g., rAAV vectors of the invention co-expressing a subject functional protein (e.g., a micro dystrophin) and said one or more additional coding sequences for preparation of a medicament for reducing the subject suffering from dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy or any other dystrophin associated muscular dystrophy.
- a subject functional protein e.g., a micro dystrophin
- additional coding sequences for preparation of a medicament for reducing the subject suffering from dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy or any other dystrophin associated muscular dystrophy.
- the invention contemplates use of the any of the viral vector, e.g., AAV vectors of the invention for the preparation of a medicament for administration to a patient diagnosed with DMD before one or more secondary cascade symptoms such as fibrosis is observed in the subject.
- AAV vectors of the invention for the preparation of a medicament for administration to a patient diagnosed with DMD before one or more secondary cascade symptoms such as fibrosis is observed in the subject.
- the invention also contemplates use of any of the viral vector, e.g., AAV vectors of the invention for the preparation of a medicament for administering any of the viral vector, e.g., rAAV of the invention to a subject suffering from muscular dystrophy who already has developed a secondary cascade symptom such as fibrosis, in order to prevent or delay disease progression in these subjects.
- AAV vectors of the invention for the preparation of a medicament for administering any of the viral vector, e.g., rAAV of the invention to a subject suffering from muscular dystrophy who already has developed a secondary cascade symptom such as fibrosis, in order to prevent or delay disease progression in these subjects.
- the invention also provides for use of the viral vector, e.g., rAAV vectors of the invention co-expressing a subject functional protein such as a micro-dystrophin, and said one or more additional coding sequences for the preparation of a medicament for treatment of a muscular dystrophy, such as DMD / BMD.
- a subject functional protein such as a micro-dystrophin
- the medicament can be formulated for intramuscular injection.
- any of the medicaments may be prepared for administration to a subject suffering from muscular dystrophy such as DMD or any other dystrophin associated muscular dystrophy.
- the present invention also provides for gene therapy vectors, e.g., rAAV vectors that co express a subject functional protein (e.g., a micro-dystrophin) and said one or more additional coding sequences in a muscular dystrophy patient.
- a subject functional protein e.g., a micro-dystrophin
- AAV is a standard abbreviation for adeno-associated virus.
- Adeno-associated virus is a single-stranded DNA parvovirus that grows only in cells in which certain functions are provided by a co-infecting helper virus.
- General information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228, and Berns, 1990, Virology, pp. 1743- 1764, Raven Press, (New York) (incorporated herein by reference).
- the degree of relatedness is further suggested by heteroduplex analysis which reveals extensive cross-hybridization between serotypes along the length of the genome; and the presence of analogous self-annealing segments at the termini that correspond to “inverted terminal repeat sequences” (ITRs).
- ITRs inverted terminal repeat sequences
- AAV vector refers to a vector comprising one or more polynucleotides of interest (or transgenes) that are flanked by AAV terminal repeat sequences (ITRs).
- ITRs AAV terminal repeat sequences
- AAV virion or “AAV viral particle” or “AAV vector particle” refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. If the particle comprises a heterologous polynucleotide (i.e., a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell), it is typically referred to as an “AAV vector particle” or simply an “AAV vector.” Thus, production of AAV vector particle necessarily includes production of AAV vector, as such a vector is contained within an AAV vector particle.
- a heterologous polynucleotide i.e., a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell
- Recombinant AAV genomes of the invention comprise nucleic acid molecule of the invention and one or more AAV ITRs flanking a nucleic acid molecule.
- AAV serotype 2 AAV2
- AAV-2 AAV2
- Srivastava etal J Virol 45:555-564 (1983) as corrected by Ruffing etal, J Gen Virol 75:3385-3392 (1994). Both incorporated herein by reference.
- AAV-1 is provided in GenBank Accession No. NC_002077 (incorporated herein by reference);
- the complete genome of AAV-3 is provided in GenBank Accession No. NC 001829 (incorporated herein by reference);
- the complete genome of AAV-4 is provided in GenBank Accession No.
- NC_001829 (incorporated herein by reference); the AAV-5 genome is provided in GenBank Accession No. AF085716 (incorporated herein by reference); the complete genome of AAV-6 is provided in GenBank Accession No. NC_001862 (incorporated herein by reference); at least portions of AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 (incorporated herein by reference) and AX753249 (incorporated herein by reference), respectively (see also U.S. Patent Nos. 7,282,199 and 7,790,449 relating to AAV-8); the AAV-9 genome is provided in Gao et ah, J. Virol 78:6381-6388 (2004), incorporated herein by reference; the AAV-10 genome is provided in Mol.
- the AAVrh74 serotype is described in Rodino-Klapac et ah, J. Trans. Med. 5:45 (2007), incorporated herein by reference.
- AAV DNA in the rAAV genomes may be from any AAV serotype for which a recombinant virus can be derived including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV- 9, AAV-10, AAV-11, AAV-12, AAV-13, RhlO, Rh74, and AAV-2i8.
- rAAV variants for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014).
- the nucleotide sequences of the genomes of various AAV serotypes are known in the art.
- AAV1, AAV6, AAV8 or AAVrh.74 may be used to promote skeletal muscle specific expression.
- the AAV serotype of the subject AAV vector is AAV9.
- V.s-acting sequences directing viral DNA replication (rep), encapsidation/packaging and host cell chromosome integration are contained within the ITRs.
- Three AAV promoters (named p5, pi 9, and p40 for their relative map locations) drive the expression of the two AAV internal open reading frames encoding rep and cap genes.
- the two rep promoters (p5 and pi 9), coupled with the differential splicing of the single AAV intron (e.g., at AAV2 nucleotides 2107 and 2227), result in the production of four rep proteins (rep 78, rep 68, rep 52, and rep 40) from the rep gene.
- Rep proteins possess multiple enzymatic properties that are ultimately responsible for replicating the viral genome.
- the cap gene is expressed from the p40 promoter and it encodes the three capsid proteins VP1, VP2, and VP3. Alternative splicing and non-consensus translational start sites are responsible for the production of the three related capsid proteins.
- a single consensus polyadenylation site is located at map position 95 of the AAV genome.
- the life cycle and genetics of AAV are reviewed in Muzyczka, Current Topics in Microbiology and Immunology 158:97-129 (1992).
- DNA plasmids of the invention comprise rAAV genomes of the invention.
- the DNA plasmids are transferred to cells permissible for infection with a helper virus of AAV (e.g., adenovirus, El-deleted adenovirus or herpes virus) for assembly of the rAAV genome into infectious viral particles.
- helper virus of AAV e.g., adenovirus, El-deleted adenovirus or herpes virus
- rAAV Production of rAAV requires that the following components are present within a single cell (denoted herein as a packaging cell): a rAAV genome, AAV rep and cap genes separate from (i.e., not in) the rAAV genome, and helper virus functions.
- the AAV rep and cap genes may be from any AAV serotype for which recombinant virus can be derived and may be from a different AAV serotype than the rAAV genome ITRs, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV- 7, AAVrh.74, AAV-8, AAV-9, AAV- 10, AAV-11, AAV- 12 and AAV-13.
- a method of generating a packaging cell is to create a cell line that stably expresses all the necessary components for AAV particle production.
- a plasmid (or multiple plasmids) comprising a rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell.
- AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al, Proc. Natl. Acad. Sci. U.S.A.
- Suitable methods employ adenovirus or baculovirus rather than plasmids to introduce rAAV genomes and/or rep and cap genes into packaging cells.
- the foregoing documents are hereby incorporated by reference in their entirety herein, with particular emphasis on those sections of the documents relating to rAAV production.
- the AAV vectors of the invention are produced according to the method described in Adamson-Small et al. (Molecular Therapy - Methods & Clinical Development (2016) 3, 16031; doi:10.1038/mtm.2016.31, incorporated herein by reference), a scalable method for the production of high-titer and high quality adeno-associated type 9 vectors using the HSV platform. It is a complete herpes simplex virus (HSV)-based production and purification process capable of generating greater than 1 xlO 14 rAAV9 vector genomes per 10- layer CellSTACK of HEK 293 producer cells, or greater than 1 10 5 vector genome per cell, in a final, fully purified product.
- HSV herpes simplex virus
- rAAV vectors produced by this method demonstrated improved biological characteristics when compared to transfection-based production, including increased infectivity as shown by higher transducing unit-to-vector genome ratios and decreased total capsid protein amounts, shown by lower empty-to-full ratios.
- This method can also be readily adapted to large- scale good laboratory practice (GLP) and good manufacturing practice (GMP) production of rAAV9 vectors to enable preclinical and clinical studies and provide a platform to build on toward late-phases and commercial production.
- GLP large- scale good laboratory practice
- GMP good manufacturing practice
- AAV9 was used in the study, this method is likely extendable to other serotypes and should bridge the gap between preclinical research, early phase clinical studies, and large-scale, worldwide development of gene therapy based-drugs for genetic diseases and disorders.
- packaging cells that produce infectious rAAV.
- packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line).
- packaging cells are cells that are not transformed cancer cells, such as low passage 293 cells (human fetal kidney cells transformed with El of adenovirus), MRC-5 cells (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).
- Recombinant AAV i.e., infectious encapsidated rAAV particles
- Recombinant AAV i.e., infectious encapsidated rAAV particles
- the genomes of both rAAV lack AAV rep and cap DNA, that is, there is no AAV rep or cap DNA between the ITRs of the genomes.
- Examples of rAAV that may be constructed to comprise the nucleic acid molecules of the invention are set out in International Patent Application No. PCT/US2012/047999 (WO 2013/016352) incorporated by reference herein in its entirety.
- the rAAV may be purified by methods standard in the art such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper virus are known in the art and include methods disclosed in, for example, Clark etal, Hum.
- the recombinant vector of the invention also comprises one or more additional coding sequences for targeting gene(s) in one of the secondary complications / secondary cascades associated with or resulting from loss of dystrophin.
- the vector of the invention encodes an exon-skipping antisense sequence that can correct specific dystrophin gene mutations.
- the exon-skipping antisense sequence induces skipping of specific exons during pre-messenger RNA (pre-mRNA) splicing of a defective dystrophin gene in the subject, resulting in restoration of the reading frame and partial production of an internally truncated protein, similar to the dystrophin protein expression seen in Becker muscular dystrophy.
- pre-mRNA pre-messenger RNA
- the exon-skipping antisense sequence skips or splices out a frame-disrupting exon (mutated exon) and/or a neighboring exon to restore the correct transcriptional reading frame, and to produce a shorter but functional dystrophin protein.
- the exon-skipping antisense sequence induces single exon skipping. In certain embodiments, the exon-skipping antisense sequence induces multiple exon skipping, such as skipping of one or more of, or all of exons 45-55 (i.e., native exons 44 is joined directly to exon 56). For example, 11 antisense sequences may be used together to skip all 11 exons including exons 45-55. A cocktail of 10 AONs was used in the mdx52 mouse model (with deletion of exon 52) to induce skipping of exon 45-51 and 53-55, thus restoring functional dystrophin expression.
- the exon-skipping antisense sequence induces skipping of exon 51 in a dystrophin pre-mRNA.
- Successful skipping of exon 51 can in theory treat about 14% of all DMD patients.
- the exon-skipping antisense sequence targets an exonic splice enhancer (ESE) site in exon 51 of dystrophin gene, thus causing a skip of exon 51 and producing a truncated but partially functional dystrophin protein.
- ESE exonic splice enhancer
- the exon-skipping antisense sequence induces skipping of one or more of exons 44, 45, and 53.
- the exon-skipping antisense sequence targets the same target sequence as that of casimersen (exon 45), NS-065/NCNP-01 or golodirsen (exon 53), or eteplirsen or Exondys 51 (exon 51).
- the exon-skipping antisense sequence targets a cryptic splicing donor and/or acceptor site in the mutated FCMD/FKTN gene in a Fukuyama congenital muscular dystrophy (FCMD) patient to restore correct exon 10 splicing.
- FCMD Fukuyama congenital muscular dystrophy
- FCMD Fukuyama congenital muscular dystrophy
- FKTN The gene responsible for FCMD (FCMD, also known as FKTN) encodes the protein fukutin, which is a putative glycosyltransferase and glycosylates a-dystroglycan, a member of the dystrophin-associated glycoprotein complex (DAGC).
- DAGC dystrophin-associated glycoprotein complex
- FCMD The pathogenesis of FCMD is caused by an ancestral insertion of SINE-VNTR-Alu(SVA) retrotransposon into the 3 ’ -untranslated region (UTR) of the fukutin gene, leading to the activation of a new, cryptic splice donor in exon 10, and a new, cryptic splice acceptor in the SVA insertion site, thus inducing aberrant mRNA splicing between the cryptic donor and acceptor sites.
- UTR -untranslated region
- FCMD patient cells and model mice in vivo it has been shown that a cocktail of three vivo- PMOs targeting the cryptic splice modulating regions prevented pathogenic SVA exon trapping and restored normal FKTN protein levels and O-glycosylation of a-dystroglycan.
- the antisense sequence targets a pathological expansion of 3- or 4-nucleotide repeats, such as a CTC triplet repeat in the 3 ’-UTR region of the DMPK gene in DM1 patients, or a CCTG repeat in the first intron of the CNBP gene in DM2 patients.
- a pathological expansion of 3- or 4-nucleotide repeats such as a CTC triplet repeat in the 3 ’-UTR region of the DMPK gene in DM1 patients, or a CCTG repeat in the first intron of the CNBP gene in DM2 patients.
- Myotonic dystrophy is the most common form of muscular dystrophy in adulthood. It is an autosomal dominant disease that can be categorized into myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2).
- DM1 is caused by a pathological expansion of CTC triplet in 3’-UTR region of the Dystrophia Myotonica Protein Kinase (DMPK) gene
- DM2 is caused by a pathological expansion of CCTG tract in the first intron of the CCHC-type zinc finger, nucleic acid binding protein gene (CNBP).
- CNBP nucleic acid binding protein gene
- RNA disrupts the function of alternative splicing regulators such as Muscleblind-like (MBNL) protein and CUG-binding protein 1 (CUGBP1), by sequestering and depleting the former within the nuclear RNA foci, and increasing the expression and phosphorylation of the latter in DM1.
- Alterations in the function of MBNL and CUGBP1 proteins lead to aberrant splicing in pre-mRNAs of target genes, namely insulin receptor (INSR), the muscle chloride channel (CLCN1), bridging integrator-1 (BIN1), and dystrophin (DMD), which are respectively associated with insulin resistance, myotonia, muscle weakness, and dystrophic muscle processes (all typical symptoms of myotonic dystrophy).
- ILR insulin receptor
- CLCN1 muscle chloride channel
- BIN1 bridging integrator-1
- DMD dystrophin
- an expanded CUG repeat in the DMPK gene sequesters MBNLl protein and causes aberrant splicing in several downstream genes, thereby causing DM1 phenotype.
- antisense oligonucleotides can be used to target such expanded repeats of mutant transcripts for RNase- mediated degradation, thereby restoring splicing of downstream genes.
- a 2’-0- methoxyethyl gapmer AON has been used to target the degradation of expanded CUG by RNase H in mutant RNA transcripts, resulting in a reduction of mutant mRNA transcripts and restored protein expression.
- the exon-skipping antisense sequence leads to skipping of exon 7A in CLCN 1 gene in a DM1 patient.
- DM1 can also be treated by correcting aberrant splicing of chloride channel 1 (CLCN1), as this gene causes myotonia in DM1 patients.
- CLCN1 chloride channel 1
- PMOs phosphorodiamidate morpholino oligomer
- the exon-skipping antisense sequence targets exons 17, 32, 35, 36, and/or 42 of the DYSF gene, preferably exon 32 and/or 36, for exon skipping in a dysferlinopathy (e.g., LGMD2B or MM) patient with a DYSF mutation.
- Dysferlinopathy is an umbrella term that encompasses muscular dystrophies caused by mutations in the dysferlin (DYSF) gene.
- Dysferlin gene encodes a sarcolemmal protein required for repairing muscle membrane damage. It consists of calcium-dependent C2 lipid binding domains and a vital transmembrane domain.
- LGMD2B limb- girdle muscular dystrophy type 2B
- MM Miyoshi myopathy
- Dysferlinopathies can be treated by exon skipping using antisense oligonucleotides, partly due to the observed mild phenotype in a patient with only 10% wild- type level expression of a truncated mutant DYSF protein.
- the patient harbored one null allele and a DYSF branch point mutation on the other allele in intron 31.
- a natural in-frame skipping of exon 32 resulted in a truncated dysferlin protein expressed at about 10% that of the wild type levels, which was sufficient to partially complement the null mutation.
- the patient exhibited mild symptoms, and was ambulant at age 70.
- the exon-skipping antisense sequence targets exon 4 of the LAMA2 gene, for exon skipping in a merosin-deficient congenital muscular dystrophy type 1 A (MDCIA) patient with a LAMA2 mutation.
- exon skipping results in restored expression of the C-terminal G-domain (exons 45-64), particularly G4 and G5 that are most important for mediating interaction with a-dystroglycan.
- Merosin-deficient congenital muscular dystrophy type 1A is caused by mutations in the 65 -exon LAMA2 gene that results in a complete or partial deficiency in laminin-a2 chain expression.
- Laminin-a2 chain, together with betal (b ⁇ ), and gammal (g ⁇ ) chains, are parts of the heterotrimeric laminin isoform known as Laminin-211 or merosin, which is expressed particularly in the basement membranes of skeletal muscles, including the neuromuscular junction and Schwann cells (peripheral nerves).
- Laminin-a2 interacts with the dystrophin-dystroglycan complex (DGC), mediating cell signaling, adhesion, and tissue integrity in skeletal muscles and peripheral nerves.
- DGC dystrophin-dystroglycan complex
- laminin-a2 causes milder MDC1A, while complete absence of laminin-a2 causes severe MDC1A.
- the C-terminal G-domain (exons 45-64), particularly G4 and G5, are most important for mediating interaction with a-dystroglycan. Mutations eliminating G4 and G5 is associated with severe phenotypes even in the presence of partial truncated laminin-a2 expression.
- the exon-skipping antisense sequence induces skipping of exons 4-7 of the most common A-521T mutation in the LGMD2C / SGCG gene, and restoration of the reading frame to generate an internally truncated SGCG protein, for treating a limb-girdle muscular dystrophy type 2C patient with a A-521T SGCG mutation.
- exon skipping results in restored expression of the internally truncated SGCG protein that retains the intracellular, transmembrane, and extreme carboxy -terminus of the wild-type SGCG protein.
- Dystrophin-associated protein is a complex in the muscle cell membrane, the transmembrane components of which link the cytoskeleton to the extracellular matrix in adult muscle fibers, and are essential for the preservation of the integrity of the muscle cell membrane.
- the sarcoglycan subcomplex within the DGC is composed of 4 single-pass transmembrane subunits: a-, b-, g-, and d-sarcoglycan.
- the a to d-sarcoglycans gene namely a (LGMD2D), b (LGMD2E), g (LGMD2C) and d (LGMD2F), are expressed predominantly (b) or exclusively (a, g and d) in striated muscle.
- a mutation in any of the four sarcoglycan genes may lead to a secondary deficiency of the other sarcoglycan proteins, presumably due to destabilization of the sarcoglycan complex, leading to sarcoglycanopathies - autosomal recessive limb girdle muscular dystrophies (LGMDs).
- LGMDs autosomal recessive limb girdle muscular dystrophies
- the disease-causing mutations in the a to d genes cause disruptions within the dystrophin-associated protein (DAP) complex in the muscle cell membrane.
- DAP dystrophin-associated protein
- LGMD2C g sarcoglycan
- SCARMD Severe childhood autosomal recessive muscular dystrophy
- Mutations in the g-sarcoglycan gene were first described in the Maghreb countries of North Africa, where g- sarcoglycanopathy has a higher than usual incidence.
- D-521T One of the most common mutation in LGMD 2C patients, D-521T, is a deletion of a thymine from a string of 5 thymines at nucleotide bases 521-525 in exon 6 of the g-sarcoglycan gene. This mutation shifts the reading frame and results in the absence of g-sarcoglycan protein and secondary reduction of b- and d-sarcoglycans, thus causing a severe phenotype. The mutation occurs both in the Maghreb population and in other countries.
- the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of sarcolipin (SLN).
- the vector of the invention encodes an shRNA that antagonizes the function of sarcolipin (shSLN).
- Exemplary shSLN sequences include those disclosed in FIGs. 9 and 10 of PCT/US2019/065718, filed on December 11, 2019 (e.g ., the underlined sequences in FIG. 9, and the highlighted sequences in FIG. 10). Additional exemplary shSFN sequences include SEQ ID NOs: 7-11 disclosed in WO2018/136880 (incorporated herein by reference).
- the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of one or more target genes, such as an inflammatory gene.
- the IKB kinase / nuclear factor-kappa B (NF-kB) signaling is persistently elevated in immune cells and regenerative muscle fibers in both animal models and patients with DMD.
- activators of NF-KB such as TNF-a and IL-1 and IL-6 are upregulated in DMD muscles.
- inhibiting the NF-KB signaling cascade components, such as NF-KB itself, its upstream activators and the downstream inflammatory cytokines are beneficial for treating the subject patients in conjunction with replacing / repairing a defective dystrophin gene.
- the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of one or more inflammatory genes, such as NF-KB, TNF-a, IL-1 (IL-1 b), IL-6, Receptor activator of NF- KB (RANK), and Toll-like receptors (TLRs).
- RNAi sequence such as NF-KB, TNF-a, IL-1 (IL-1 b), IL-6, Receptor activator of NF- KB (RANK), and Toll-like receptors (TLRs).
- the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of a histone deacetylase, such as HDAC2.
- a histone deacetylase such as HDAC2.
- HDAC2 histone deacetylase 2
- DMD the absence of dystrophin at the sarcolemma delocalizes and downregulates nitric oxide synthase (nNOS), which alters S-nitrosylation of HDAC2 and its chromatin association.
- nNOS nitric oxide synthase
- the activity of HDAC2 resulted to be specifically increased.
- rescue of nNOS expression in mdx animals ameliorated the dystrophic phenotype.
- deacetylase inhibitors conferred a strong morphofunctional benefit to dystrophic muscle fibers.
- givinostat a histone deacetylase inhibitor, is under evaluation as potential disease-modifying treatment for DMD.
- Data indicates that, in both murine and human dystrophic cells, the absence of dystrophin correlates with HDAC2 binding to a specific subset of miRNAs (see below), while upon dystrophin rescue HDAC2 is released from these promoters.
- the vector of the invention encodes an antisense sequence, an RNAi sequence (siRNA, shRNA, miRNA etc.), or a microRNA, that antagonizes the function of TGF-b, or connective tissue growth factor (CTGF).
- RNAi sequence siRNA, shRNA, miRNA etc.
- CGF connective tissue growth factor
- Elevated levels of TGF-b in muscular dystrophies stimulate fibrosis and impair muscle regeneration by blocking the activation of satellite cells.
- Anti-fibrotic agents have been tested in murine models of muscular dystrophy, including losartan, an angiotensin II-type 1 receptor blocker that reduces the expression of TGF- b.
- FIT-100 halofuginone
- FG-3019 a fully human monoclonal antibody that interferes with the action of connective tissue growth factor, a central mediator in the pathogenesis of fibrosis, has been evaluated in an open-label phase 2 trial in patients with idiopathic pulmonary fibrosis (IPF).
- IPF idiopathic pulmonary fibrosis
- the vector of the invention encodes a microRNA (miR), such as miR-1, miR-29c, miR-30c, miR-133, and/or miR-206.
- miR microRNA
- the differential HDAC2 nitrosylation state in Duchenne versus wild-type conditions deregulates the expression of a specific subset of microRNA genes.
- circuitries controlled by the identified microRNAs such as the one linking miR-1 to the G6PD enzyme and the redox state of cell, or miR-29 to extracellular proteins and the fibrotic process, explain some of the DMD pathogenetic traits.
- the mdx model when dystrophin synthesis was restored via exon skipping, the levels of miR-1, miR-133a, miR-29c, miR-30c, and miR-206 increased, while miR-23a expression did not change.
- the vector of the invention encodes a microRNA inhibitor, which inhibits the function of a microRNA upregulated in DMD or its related diseases.
- a microRNA inhibitor which inhibits the function of a microRNA upregulated in DMD or its related diseases.
- the inflammatory miR-223 expression level is upregulated in mdx mice muscles, and is downregulated in exon-skipping-treated mice. Its decrease is consistent with the observed amelioration of the inflammatory state of the muscle, due to dystrophin rescue by exon-skipping.
- miR-29 The mdx animals undergo extensive fibrotic degeneration, and miR-29 has been shown to target mRNAs of crucial factors involved in fibrotic degeneration, such as collagens, elastin, and structural components of the extracellular matrix. In mdx mice, miR-29 is poorly expressed, and the mRNAs for collagen (COL1A1) and elastin (ELN) were upregulated. Thus expression of miR-29c alleviates fibrotic degeneration in DMD patients, partly through downregulating collagen and elastin expression, and pathological extracellular matrix modification associated with collagen and elastin expression.
- the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of G6PD (Glucose- e-phosphate dehydrogenase).
- G6PD Glucose- e-phosphate dehydrogenase
- G6PD Glucose- e-phosphate dehydrogenase
- G6PD a cytosolic enzyme in the pentose phosphate pathway that supplies reducing energy to cells by maintaining the level of NADPH, which in turn ensures high ratio between reduced and oxidized glutathione (GSH/GSSG), GSH being the major antioxidant molecule that protects cells against oxidative damage.
- G6PD mRNA is deregulated in mdx muscles.
- the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of myostatin.
- Myostatin is a negative regulator of muscle mass. Inhibition or blockade of endogenous myostatin compensates for the severe muscle wasting common in many types of muscular dystrophies including DMD.
- a myostatin blocking antibody, MYO-029 is in clinical trial for adult subjects with BMD and other dystrophies. Other clinical trials using myostatin inhibitors such as follistatin and PF-06252616 (NCT02310764) and BMS-986089 have also been conducted.
- the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of phosphodiesterase-5 (PED-5) or ACE, or VEGF decoy-receptor type 1 (VEGFR-l or Flt-1).
- the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of hematopoietic prostaglandin D synthase (HPGDS).
- HPGDS hematopoietic prostaglandin D synthase
- Prostaglandin D2 (PGD2) is produced by various inflammatory cells, and hematopoietic PGD synthase (HPGDS) is shown to be expressed in necrotic muscle of DMD patients.
- the administration of an HPGDS inhibitor decreased the urinary excretion of tetranor-PGDM, a urinary metabolite of PGD2, and suppressed myonecrosis in a mdx mouse model of DMD.
- TAS-205 a novel HPGDS inhibitor, has been evaluated for DMD treatment in clinical trial.
- RNA interference In RNA interference (RNAi), short RNA molecules are created that are complimentary and bind to endogenous target mRNA. Such binding leads to functional inactivation of the target mRNA, including degradation of the target mRNA.
- RNAi pathway is found in many eukaryotes, including plants and animals, and is initiated in the cytoplasm by the enzyme Dicer, which cleaves long double-stranded RNA (dsRNA) or small hairpin RNAs (shRNA) molecules into short double-stranded fragments of ⁇ 21 nucleotide siRNAs. Each siRNA is then unwound into two single-stranded RNAs (ssRNAs), the passenger strand and the guide strand. The passenger strand is degraded and the guide strand is incorporated into the RNA-induced silencing complex (RISC).
- Dicer cleaves long double-stranded RNA
- shRNA small hairpin RNAs
- miRNA miRNA
- MicroRNAs are genomically encoded non-coding RNAs that help regulate gene expression, particularly during development. Mature miRNAs are structurally similar to siRNAs, but they must first undergo extensive post-transcriptional modification before reaching maturity. An miRNA is expressed from a much longer RNA-coding gene as a primary transcript known as a pri-miRNA, which is then processed in the cell nucleus to a 70-nucleotide stem-loop structure called pre-miRNA, by the microprocessor complex consisting of an RNase III enzyme Drosha and a dsRNA-binding protein DGCR8.
- a primary transcript known as a pri-miRNA
- the dsRNA portion Upon transporting this pre-miRNA into the cytosol, its dsRNA portion is bound and cleaved by Dicer to produce the mature miRNA molecule, which two strands can be separated into a passenger strand and a guide strand.
- the miRNA guide strand like the siRNA guide strand, can be integrated into the same RISC complex.
- the two dsRNA pathways both require processing of a precursor molecule (pri-miRNA, pre-miRNA, and dsRNA or shRNA) with a backbone sequence in order to generate the mature functional guide strand for miRNA or siRNA, and both pathways eventually converge at the RISC complex.
- a precursor molecule pri-miRNA, pre-miRNA, and dsRNA or shRNA
- siRNAs After integration into the RISC, siRNAs base-pair to their target mRNA and cleave it, thereby preventing it from being used as a translation template. Differently from siRNA, however, a miRNA-loaded RISC complex scans cytoplasmic mRNAs for potential complementarity. Instead of destructive cleavage (by Ago2), miRNAs target the 3’-UTR regions of mRNAs where they typically bind with imperfect complementarity, thus blocking the access of ribosomes for translation. siRNAs differ from miRNAs in that miRNAs, especially those in animals, typically have incomplete base pairing to a target and inhibit the translation of many different mRNAs with similar sequences. In contrast, siRNAs typically base-pair perfectly and induce mRNA cleavage only in a single, specific target.
- siRNA and shRNA have been used in RNAi applications.
- siRNA is typically a double-stranded RNA molecules, 20-25 nucleotides in length.
- siRNA inhibits the target mRNA transiently until they are also degraded within the cell.
- shRNA is typically ⁇ 80 base pairs in length, that include a region of internal hybridization that creates a hairpin structure.
- shRNA molecules are processed within the cell to form siRNA, which in turn knock down gene expression.
- One benefit of shRNA is that they can be incorporated into plasmid vectors and integrated into genomic DNA for longer-term or stable expression, and thus longer knockdown of the target mRNA.
- shRNAs design is commercially available.
- Cellecta offers RNAi screening service against any target gene (e.g ., all 19,276 protein-encoding human genes) using the Human Genome-Wide shRNA Library or Mouse DECIPHER shRNA Library (which targets about 10,000 mouse genes).
- ThermoFisher Scientific provides Silencer Select siRNA (classic 21- mers) from Ambion, which, according to the manufacturer, incorporates the latest improvements in siRNA design, off-target effect prediction algorithms, and chemistry.
- ThermoFisher Scientific also provides Ambion® Pre-miRTM miRNA Precursor Molecules that are small, chemically modified double-stranded RNA molecules designed to mimic endogenous mature miRNAs.
- Use of such Pre-miR miRNA Precursors enable miRNA functional analysis by up-regulation of miRNA activity, and can be used in miRNA target site identification and validation, screening for miRNAs that regulate the expression of a target gene, and screening for miRNAs that affect a function of the target gene (such as SLN) or a cellular process.
- ThermoFisher Scientific further provides Ambion® Anti-miRTM miRNA Inhibitors, which are chemically modified, single stranded nucleic acids designed to specifically bind to and inhibit endogenous microRNA (miRNA) molecules.
- miRNA microRNA
- Antisense sequence design is also commercially available from a number of commercial and public sources, such as IDT (Integrated DNA Technologies) and GenLink. Design considerations may include oligo length, secondary / tertiary structure in the target mRNA, protein-binding sites on target mRNA, presence of CG motifs in either the target mRNA or the antisense oligo, formation of tetraplexes in antisense oligo, and the presence of antisense activity-increasing or -decreasing motifs.
- Exon skipping antisense oligo design is known in the art. See, for example, Camilla Bernardini (ed.), Duchenne Muscular Dystrophy: Methods and Protocols, Methods in Molecular Biology, vol. 1687, DOI 10.1007/978-l-4939-7374-3_10, Chapter 10 by Shimo etai, published by Springer Science+Business Media LLC, 2018), which discuss in detail the design of effective exon-skipping oligonucleotides, taking into consideration factors such as the selection of target sites, the length of the oligoes, the oligo chemistry, and the melting temperature versus the RNA strand, etc.
- DMD Digienne muscular dystrophy
- LAMA2 merosine-deficient CMD
- DYSF disferlinopathy
- FKTN Factor for oxidative stress
- DMPK myotonic dystrophy
- SGCG SGCG
- protein / gene sequences and mutations thereof in the affected disease genes are publically available from NCBI and the Leiden muscular dystrophy pages online.
- Potential target sites for efficient exon skipping can be obtained by using the human splicing finder website at www dot umd dot be slash HSF. Secondary structure of the target mRNA can be evaluated using, e.g., the mfod web server at the Albany dot edu website.
- the length of the oligoes normally can be 8-30 mer.
- Oligo GC content calculation is available at OligoCalc website at the Northwestern University server. Search for any off-target sequences can be done using the GGGenome website.
- Melting temperature of the oligoes can be estimated by LNA oligo prediction tool or OligoAnalyzer 3.1 software at sg dot idtdna dot com.
- RNAi RNAi Enhanced Guide Strand Generation for RNAi (miR, siRNA, & shRNA)
- the coding sequence encodes an RNAi reagent, such as miR, siRNA, or shRNA.
- the wild-type backbone sequence from which a mature miR or a mature siRNA is generated can be modified to enhance guide strand generation and minimize / eliminate passenger strand production. Since both strands of a mature miR / siRNA / shRNA (after cleavage) can in theory be incorporated into the RISC complex and become guide strand for RNAi, it is advantageous to selectively enhance the utilization of the designed guide strand and minimize the utilization of the largely complementary passenger strand in the RISK complex, in order to reduce or minimize, e.g., off- target effect (e.g., due to the cleavage of unintended target sequences when the passenger strand is loaded into the RISC.
- off- target effect e.g., due to the cleavage of unintended target sequences when the passenger strand is loaded into the RISC.
- One approach that can be used to achieve this goal is through using a hybrid construct in which the designed mature miR / siRNA / shRNA sequences comprising the desired guide strand are embedded inside the backbone sequences of other miR sequences which favor the generation of the guide strand and disfavor the production of the passenger strand.
- the adopted design strategy includes engineering flanking backbone sequences, loop sequences, and passenger strand nucleotide sequences, in order to preserve the 2D and 3D structure of the natural backbone sequence.
- 2D/3D structure of the natural backbone sequence refers largely to the distances between stem loop and the flanking backbone polynucleotide sequences, the structure of the central stem, the location and/or sizes of the bulges, the presence and localization of any internal loops and mismatches within the stem, etc.
- Certain exemplary 2D structure maps for selected miR-30E, miR-101, and miR-451 backbone sequence-based miR-29c hybrid constructs are provided below as illustration.
- 29c-M30E hybrid sequences were generated based on the desired mature miR-29c sequence, and the engineered / optimized miR-30 backbone sequence described in Fellmann et al.
- This 29c-M30E sequence (see FIG. 29 of PCT/US2019/065718, filed on December 11, 2019 for its predicted 2D structure) has been incorporated into the following subject viral vectors used in the examples below: pDys-29c-M30E-i2, EF1 A-29c- M30E, U6-29c-M30E.
- the following 5’->3’ sequence of 29c-M30E is a continuous sequence artificially separated to different lines to illustrate the different segments of the continuous sequence.
- the middle line represents the passenger strand sequence, the double underlined loop sequence, and the mature miR-29c guide sequence.
- the passenger and guide sequences can be reverse complement of each other and can snap back and form a stem-loop structure with the intervening loop sequence.
- perfect reverse complement sequences are not necessary. There can be internal bulges, etc., and therefore the two strands are not necessarily 100% complementary to each other in some cases (see the guide and passenger strands in the last sequence of this subsection).
- the top line and the bottom line represent the M30E flanking backbone sequence optimized to ensure enhanced production of the guide sequence and to minimize the production of the passenger strand.
- siRNA targeting human SLN is embedded in the same M30E backbone sequence in miR-30E-hSLN-cl (compare the top and bottom rows of the sequences immediately above and below this paragraph, and the double underlined loop sequence). But the guide and passenger strands are different.
- This so-called cl-M30E sequence has been incorporated into the following subject viral vectors used in the examples below: cl-M30E-i2, cl-M30E-3UTR, and cl-M30E-pa.
- a similarly designed second siRNA also targeting human SLN is embedded in the same M30E backbone sequence in miR-30E-hSLN-c2 (compare the top and bottom rows of the sequences immediately above and below this paragraph, and the double underlined loop sequence). But the guide and passenger strands are different.
- This so-called c2-M30E sequence has been incorporated into the following subject viral vectors used in the examples below: c2- M30E-12, C2-M30E-3UTR, and c2-M30E-pa.
- M30N modified miR-29c using the natural miR-30 backbone sequence
- M30N modified miR-30 backbone sequence
- This M3 ON backbone sequence similarly enhanced the production of the guide strand, though to a lesser extent than the M30E backbone sequence in the experimental system tested (data not shown).
- a different miR-29c hybrid (29c-101, see FIG. 30 of PCT/US2019/065718, filed on December 11, 2019 for its predicted 2D structure) using the miR-101 backbone sequence is illustrated below using the same naming convention herein.
- the top row and the last two rows represent the backbone sequences of miR-101, while the 2nd row is the mature miR-29c with the passenger strand, loop sequence, and guide strand.
- This 29c-101 sequence has been incorporated into the following subject viral vectors used in the examples below: pDys-29c-101- i2, pDys-29c-3UTR-101.
- a different miR-29c hybrid (29c-155) using the miR-155 backbone sequence is illustrated below using the same naming convention herein.
- the top row and the bottom row represent the flanking backbone sequences of miR-155, while the 2nd row is the mature miR-29c with the guide strand, loop sequence, and passenger strand.
- This 29c-155 sequence has been incorporated into the following subject viral vector used in the examples below: EF1 A- 29c- 155
- Another miR-29c hybrid also using the miR-155 backbone sequence is illustrated below using the same naming convention herein.
- the top row and the bottom row represent the flanking backbone sequences of miR-155 (identical to that in the sequence immediately above), while the 2nd row is the mature miR-29c with the guide strand, loop sequence, and passenger strand.
- the loop sequence here is 19 nt, instead of the 17 nt loop in the sequence above.
- This 29c-19nt sequence has been incorporated into the following subject viral vector used in the examples below: EFlA-29c-19nt, 29c-19nt-pDys-pA, 29c-19nt-pDys- 3UTR.
- a shSLN in the miR-155 backbone sequence is illustrated below using the same naming convention herein.
- the top row and the bottom row represent the flanking backbone sequences of miR-155, while the 2nd row is the mature shRNA targeting mouse SLN (shmSLN) with the guide strand, loop sequence (19 nt), and passenger strand.
- shmSLN-v2 sequence has been incorporated into the following subject viral vector used in the examples below: EF1 A- mSLN, Fusion-vl, pDys-shmSFN-vl .
- a shSFN in the miR-155 backbone sequence is illustrated below using the same naming convention herein.
- the top row and the bottom row represent the flanking backbone sequences of miR-155
- the 2nd row is another mature shRNA targeting mouse SFN (shmSFN) with the guide strand, loop sequence (19 nt), and passenger strand.
- shmSFN mature shRNA targeting mouse SFN
- loop sequence (19 nt) the guide strand
- passenger strand Compared to the similar / related shmSFN sequence above, the presence of the extra dinucleotide base pairs TT:AA (or strictly speaking, UU at the 3’ end of the siRNA) have been associated with increased potency of the produced guide strand siRNA.
- This shmSFN-v2 sequence has been incorporated into the following subject viral vector used in the examples below: EF1 A-mSFN-v2, Fusion-v2, pDys-shmSLN-v2.
- shSFN in the miR-155 backbone sequence is illustrated below using the same naming convention herein.
- the top row and the bottom row represent the flanking backbone sequences of miR-155, while the 2nd row is the mature shRNA targeting human SFN with the guide strand, loop sequence (19 nt), and passenger strand.
- This cl -ml 55 sequence has been incorporated into the following subject viral vector used in the examples below: cl-ml55- pa, cl-ml55-i2, cl-ml55-3UTR
- shSLN in the miR-155 backbone sequence is illustrated below using the same naming convention herein.
- the top row and the bottom row represent the flanking backbone sequences of miR-155, while the 2nd row is the mature shRNA targeting human SLN with a different guide strand, loop sequence (19 nt), and passenger strand.
- This c2-ml55 sequence has been incorporated into the following subject viral vector used in the examples below: c2-ml55-pa, c2-ml55-i2, c2-ml55-3UTR.
- a miR-29c hybrid (29c-451, see FIG. 31 of PCT/US2019/065718, filed on December 11, 2019 for its predicted 2D structure) using the miR-451 backbone sequence is illustrated below using the same naming convention herein.
- the top 2 rows and the bottom 2 rows represent the flanking backbone sequences of miR-451
- the 3rd row is the mature miR-29c with the guide strand, loop sequence, and passenger strand.
- nucleotides in the first row of the continuous sequence below are the first 5 nucleotides after the transcription start site in the U6 promoter, and the T6 transcription termination sequence preceeds the sequence used for cloning in the last row of the continuous sequence below.
- a shSLN driven by the U6 promoter is illustrated below (U6-shmSLN-vl).
- the 2nd row is the mature shSLN with the passenger strand, loop sequence, and guide strand. This has been used in the U6-shmSLN-vl vector in the examples.
- a shSLN driven by the U6 promoter is illustrated below (U6-mSLN-v4).
- the 2nd row is the mature shSLN with the passenger strand, loop sequence, and guide strand. This has been used in the U6-mSLN-v4 vector in the examples.
- miR29c coding sequences and SLN-targeting shRNA coding sequences, as expressed from the divergent expression cassette within the subject viral vectors, are described herein below.
- a miR-29c driven by the U6 promoter in the divergent expression cassette is depicted just 5’ to the T6 transcription stop site.
- a miR-29c driven by the U6 promoter in the divergent expression cassette is depicted just 5’ to the T6 transcription stop site.
- a miR-29c driven by the U6 promoter in the divergent expression cassette is depicted just 5’ to the T6 transcription stop site.
- a miR-29c driven by the U6 promoter in the divergent expression cassette is depicted just 5’ to the T6 transcription stop site.
- the miR-29c uses the miR-155 backbone sequences, with the top row and the bottom row sequences represent the flanking backbone sequences of miR-155, while the 2nd row sequence, from 5’ to 3’, includes the mature miR-29c with the guide strand sequence, loop sequence (double underlined), and the passenger strand sequence.
- shhSLN shRNA targeting human SLN
- combo combination constructs encoding both a GOI (e.g., a pDys coding sequence) and an shRNA targeting human SLN in the divergent expression cassette. See FIG. 6.
- compositions comprising rAAV of the present invention.
- Compositions of the invention comprise rAAV and a pharmaceutically acceptable carrier.
- the compositions may also comprise other ingredients such as diluents and adjuvants.
- Acceptable carriers, diluents and adjuvants are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming
- Titers of rAAV to be administered in methods of the invention will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art.
- Titers of rAAV may range from about 1 x 10 6 , about 1 x 10 7 , about 1 x 10 8 , about 1 x 10 9 , about 1 x 10 10 , about lxlO 11 , about 1 xlO 12 , aboutlxlO 13 , to about lxlO 14 or more DNase resistant particles (DRP) per ml. Dosages may also be expressed in units of viral genomes (vg).
- the in vivo methods comprise the step of administering an effective dose, or effective multiple doses, of a composition comprising a rAAV of the invention to an animal (including a human being) in need thereof. If the dose is administered prior to development of a disorder/disease, the administration is prophylactic. If the dose is administered after the development of a disorder/disease, the administration is therapeutic.
- an effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with the disorder/disease state being treated, that slows or prevents progression to a disorder/disease state, that slows or prevents progression of a disorder/disease state, that diminishes the extent of disease, that results in remission (partial or total) of disease, and/or that prolongs survival.
- An example of a disease contemplated for prevention or treatment with methods of the invention is PMD or other disease characterized by defects in myelin production, degeneration, regeneration, or function.
- effective amounts and therapeutically effective amounts may be initially estimated based on results from in vitro assays and/or animal model studies.
- a dose may be formulated in animal models to achieve a circulating concentration range that includes the IC50 as determined in cell culture. Such information may be used to more accurately determine useful doses in subjects of interest.
- compositions may be by routes standard in the art including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal.
- routes standard in the art including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal.
- Route(s) of administration and serotype(s) of AAV components of the rAAV (in particular, the AAV ITRs and capsid protein) of the invention may be chosen and/or matched by those skilled in the art taking into account the infection and/or disease state being treated and the target cells/tissue(s) that are to express the one or more coding sequences and/or micro-dystrophin.
- the formulations described herein may be administered by, without limitation, injection, infusion, perfusion, inhalation, lavage, and/or ingestion.
- Routes of administration may include, but are not limited to, intravenous, intradermal, intraarterial, intraperitoneal, intralesional, intracranial, intraarticular, intraprostatic, intrapleural, intratracheal, intranasal, intravitreal, intravaginal, intrarectal, topically, intratumoral, intramuscular, intravesicular, intrapericardial, intraumbilical, intraocularal, mucosal, oral, subcutaneous, and/or subconjunctival.
- systemic administration is administration into the circulatory system so that the entire body is affected.
- Systemic administration includes enteral administration such as absorption through the gastrointestinal tract and parental administration through injection, infusion or implantation.
- rAAV of the present invention may be accomplished by using any physical method that will transport the rAAV recombinant vector into the target tissue of an animal, such as the skeletal muscles.
- Administration according to the invention includes, but is not limited to, injection into muscle, the bloodstream and/or directly into the liver. Simply re-suspending a rAAV in phosphate buffered saline has been demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known restrictions on the carriers or other components that can be co-administered with the rAAV (although compositions that degrade DNA should be avoided in the normal manner with rAAV).
- Capsid proteins of a rAAV may be modified so that the rAAV is targeted to a particular target tissue of interest such as muscle. See, for example, WO 02/053703, the disclosure of which is incorporated by reference herein.
- compositions can be prepared as injectable formulations or as topical formulations to be delivered to the muscles by transdermal transport.
- Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the invention.
- the rAAV can be used with any pharmaceutically acceptable carrier for ease of administration and handling.
- the dose of rAAV to be administered in methods disclosed herein will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art.
- the actual dose amount administered to a particular subject may also be determined by a physician, a veterinarian, or a researcher, taking into account parameters such as, but not limited to, physical and physiological factors including body weight, severity of condition, type of disease, previous or concurrent therapeutic interventions, idiopathy of the subject, and/or route of administration.
- Titers of each rAAV administered may range from about 1 x 10 6 , about 1 x 10 7 , about lxlO 8 , about lxlO 9 , about lxlO 10 , about lxlO 11 , about l xlO 12 , aboutlxlO 13 , about lxlO 14 , or to about lxlO 15 or more DNase resistant particles (DRP) per ml.
- DNase resistant particles DNase resistant particles
- Dosages may also be expressed in units of viral genomes (vg) (i.e., Ixl0 7 vg, lxl0 8 vg, lxl0 9 vg, l xl0 10 vg, l xlO n vg, l xl0 12 vg, 1 xlO 13 vg, 1 xlO 14 vg, 1 xlO 15 vg, respectively). Dosages may also be expressed in units of viral genomes (vg) per kilogram (kg) of bodyweight (i.e., lxlO 10 vg/kg, lxlO 11 vg/kg, lxlO 12 vg/kg,
- Exemplary doses may range from about l xlO 10 to about l xlO 15 vector genomes (vg)/kilogram of body weight.
- doses may comprise l xlO 10 vg/kg of body weight, l xlO 11 vg/kg of body weight, lxlO 12 vg/kg of body weight, l xlO 13 vg/kg of body weight, l xlO 14 vg/kg of body weight, or 1 x 10 15 vg/kg of body weight.
- Doses may comprise lxlO 10 vg/kg/day, l xlO 11 vg/kg/day, l xlO 12 vg/kg/day, l xlO 13 vg/kg/day, lxlO 14 vg/kg/day, or lxlO 15 vg/kg/day. Doses may range from 0.1 mg/kg/day to 5 mg/kg/day or from 0.5 mg/kg/day to 1 mg/kg/day or from 0.1 mg/kg/day to 5 pg/kg/day or from 0.5 mg/kg/day to 1 pg/kg/day.
- a dose may comprise 1 pg/kg/day, 5 pg/kg/day, 10 pg/kg/day, 50 pg/kg/day, 100 pg/kg/day, 200 pg/kg/day, 350 pg/kg/day, 500 pg/kg/day, 1 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day, 50 mg/kg/day, 100 mg/kg/day, 200 mg/kg/day, 350 mg/kg/day, 500 mg/kg/day, or 1000 mg/kg/day.
- Therapeutically effective amounts may be achieved by administering single or multiple doses during the course of a treatment regimen (i.e., days, weeks, months, etc.).
- the pharmaceutical composition is in a dosage form of 10 mL of aqueous solution having at least 1.6xl0 13 vector genomes. In some embodiments, the dosage has a potency of at least 2xl0 12 vector genomes per milliliter. In some embodiments, the dosage comprises a sterile aqueous solution comprising 10 mM L- histidine at pH 6.0, 150 mM sodium chloride, and 1 mM magnesium chloride.
- the pharmaceutical composition is in a dosage form of 10 mL of a sterile aqueous solution comprising 10 mM L- histidine at pH 6.0, 150 mM sodium chloride, and 1 mM magnesium chloride; and having at least 1.6x10 13 vector genomes.
- the pharmaceutical composition may be a dosage comprising between l xlO 10 and l xlO 15 vector genomes in 10 mL aqueous solution; between l xlO 11 and lxlO 14 vector genomes in 10 mL aqueous solution; between l xlO 12 and 2xl0 13 vector genomes in 10 mL aqueous solution; or greater than or equal to about 1.6x10 13 vector genomes in 10 mL aqueous solution.
- the aqueous solution is a sterile aqueous solution comprises about 10 mM L-histidine pH 6.0, with 150 mM sodium chloride, and 1 mM magnesium chloride.
- the dosage has a potency of greater than about lxlO 11 vector genomes per milliliter (vg/mL), greater than about V I 0 12 vg/mL, greater than about 2/ 10 12 vg/mL, greater than about 3/ 10 12 vg/mL, or greater than about 4/ 10 12 vg/mL.
- At least one AAV vector is provided as part of a pharmaceutical composition.
- the pharmaceutical composition may comprise, for example, at least 0.1% w/v of the AAV vector.
- the pharmaceutical composition may comprise between 2% to 75% of compound per weight of the pharmaceutical composition, or between 25% to 60% of compound per weight of the pharmaceutical composition.
- the dosage is in a kit.
- the kit may further include directions for use of the dosage.
- solutions in an adjuvant such as sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions.
- aqueous solutions can be buffered, if desired, and the liquid diluent first rendered isotonic with saline or glucose.
- Solutions of rAAV as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxpropylcellulose.
- a dispersion of rAAV can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.
- formulations may be made as aqueous solutions, such as in buffers including, but not limited to, Hanks' solution, Ringer's solution, and/or physiological saline.
- the solutions may contain formulatory agents such as suspending, stabilizing, and/or dispersing agents.
- the formulation may be in lyophilized and/or powder form for constitution with a suitable vehicle control (e.g., sterile pyrogen-free water) before use.
- Any formulation disclosed herein may advantageously comprise any other pharmaceutically acceptable carrier or carriers which comprise those that do not produce significantly adverse, allergic, or other untoward reactions that may outweigh the benefit of administration, whether for research, prophylactic, and/or therapeutic treatments.
- Exemplary pharmaceutically acceptable carriers and formulations are disclosed in Remington's Pharmaceutical Sciences, 18th Ed., Mack Printing Company, 1990, which is incorporated by reference herein for its teachings regarding the same.
- formulations may be prepared to meet sterility, pyrogenicity, general safety, and purity standards as required by the United States FDA’s Division of Biological Standards and Quality Control and/or other relevant U.S. and foreign regulatory agencies.
- Exemplary, generally used pharmaceutically acceptable carriers may comprise, but are not limited to, bulking agents or fillers, solvents or co-solvents, dispersion media, coatings, surfactants, antioxidants (e.g ., ascorbic acid, methionine, and vitamin E), preservatives, isotonic agents, absorption delaying agents, salts, stabilizers, buffering agents, chelating agents (e.g., EDTA), gels, binders, disintegration agents, and/or lubricants.
- bulking agents or fillers solvents or co-solvents
- dispersion media coatings
- surfactants e.g ., ascorbic acid, methionine, and vitamin E
- antioxidants e.g ., ascorbic acid, methionine, and vitamin E
- preservatives e.g., ascorbic acid, methionine, and vitamin E
- isotonic agents e.g., absorption delaying agents, salts, stabilizers
- Exemplary buffering agents may comprise, but are not limited to, citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers, and/or trimethylamine salts.
- Exemplary preservatives may comprise, but are not limited to, phenol, benzyl alcohol, meta-cresol, methylparaben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkyl parabens (such as methyl or propyl paraben), catechol, resorcinol, cyclohexanol, and/or 3-pentanol.
- Exemplary isotonic agents may comprise polyhydric sugar alcohols comprising, but not limited to, trihydric or higher sugar alcohols, (e.g., glycerin, erythritol, arabitol, xylitol, sorbitol, and/or mannitol).
- polyhydric sugar alcohols comprising, but not limited to, trihydric or higher sugar alcohols, (e.g., glycerin, erythritol, arabitol, xylitol, sorbitol, and/or mannitol).
- Exemplary stabilizers may comprise, but are not limited to, organic sugars, polyhydric sugar alcohols, polyethylene glycol, sulfur- containing reducing agents, amino acids, low molecular weight polypeptides, proteins, immunoglobulins, hydrophilic polymers, and/or polysaccharides.
- Formulations may also be depot preparations.
- such long-acting formulations may be administered by, without limitation, implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection.
- compounds may be formulated with suitable polymeric and/or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g ., as a sparingly soluble salt).
- the AAV vectors may be delivered using sustained-release systems, such as semipermeable matrices of solid polymers comprising the AAV vector.
- sustained-release systems such as semipermeable matrices of solid polymers comprising the AAV vector.
- sustained-release materials have been established and are well known by those of ordinary skill in the art.
- Sustained-release capsules may, depending on their chemical nature, release the vector following administration for a few weeks up to over 100 days.
- the pharmaceutical carriers, diluents or excipients suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating actions of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating rAAV in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization.
- dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and the freeze drying technique that yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile- filtered solution thereof.
- Transduction with rAAV may also be carried out in vitro.
- desired target muscle cells are removed from the subject, transduced with rAAV and reintroduced into the subject.
- syngeneic or xenogeneic muscle cells can be used where those cells will not generate an inappropriate immune response in the subject.
- cells can be transduced in vitro by combining rAAV with muscle cells, e.g., in appropriate media, and screening for those cells harboring the DNA of interest using conventional techniques such as Southern blots and/or PCR, or by using selectable markers.
- Transduced cells can then be formulated into pharmaceutical compositions, and the composition introduced into the subject by various techniques, such as by intramuscular, intravenous, subcutaneous and intraperitoneal injection, or by injection into smooth and cardiac muscle, using e.g., a catheter.
- Transduction of cells with rAAV of the invention results in sustained co-expression of said one or more additional coding sequences and micro-dystrophin.
- the present invention thus provides methods of administering/delivering rAAV which co-expresses said one or more additional coding sequences and micro-dystrophin to an animal, preferably a human being.
- transducing tissues including, but not limited to, tissues such as muscle, organs such as liver and brain, and glands such as salivary glands
- Transduction may be carried out with gene cassettes comprising tissue specific control elements.
- tissue specific control elements including, but not limited to, those derived from the actin and myosin gene families, such as from the myoD gene family (See Weintraub et al., Science 251 :761-766, 1991), the myocyte- specific enhancer binding factor MEF-2 (Cserjesi and Olson, Mol Cell Biol 11 : 4854-4862,
- control elements derived from the human skeletal actin gene (Muscat et al., Mol Cell Biol 7:4089-4099, 1987), the cardiac actin gene, muscle creatine kinase sequence elements (Johnson et al., Mol Cell Biol 9:3393-3399, 1989), and the murine creatine kinase enhancer (mCK) element, control elements derived from the skeletal fast-twitch troponin C gene, slow-twitch cardiac troponin C gene and the slow-twitch troponin I gene: hypoxia-inducible nuclear factors (Semenza et al., Proc Natl Acad Sci U.S.A.
- steroid-inducible elements and promoters including the glucocorticoid response element (GRE) (See Mader and White, Proc. Natl. Acad. Sci. U.S.A. 90:5603-5607, 1993), and other control elements.
- GRE glucocorticoid response element
- Muscle tissue is an attractive target for in vivo DNA delivery, because it is not a vital organ and is easy to access.
- the invention contemplates sustained co-expression of miRNAs and micro-dystrophin from transduced myofibers.
- muscle cell or “muscle tissue” is meant a cell or group of cells derived from muscle of any kind (for example, skeletal muscle and smooth muscle, e.g., from the digestive tract, urinary bladder, blood vessels or cardiac tissue). Such muscle cells may be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes and cardiomy oblasts.
- transduction is used to refer to the administration/delivery of the one or more additional coding sequences and the coding region of the micro-dystrophin to a recipient cell either in vivo or in vitro, via a replication-deficient rAAV of the invention resulting in co expression of the one or more additional coding sequences and micro-dystrophin by the recipient cell.
- the invention provides methods of administering an effective dose (or doses, administered essentially simultaneously or doses given at intervals) of rAAV that encode said one or more additional coding sequences and micro-dystrophin to a patient in need thereof.
- Genes encoding the necessary replication (rep) and structural (cap) proteins of AAV vectors have been deleted from AAV vectors to allow insertion of the sequences to be delivered between the remaining terminal repeat sequences.
- rep necessary replication
- cap structural proteins
- the genes encoding the rep and cap proteins need to be delivered to infected cells.
- the genes encoding the rep and cap proteins need to be present in the cells used for production.
- AAV vectors suitable for the methods of the invention can be produced using any of the art-recognized methods.
- Penaud-Budloo et al. Molecular Therapy: Methods & Clinical Development Vol. 8, pages 166-180, 2018
- Penaud-Budloo et al. provided a review of the most commonly used upstream methods to produce rAAVs. Each methods described therein are incorporated herein by reference.
- the AAV vector is produced using transient transfection of a packaging cell line such as HEK293 cells.
- a packaging cell line such as HEK293 cells.
- HEK293 cells are simultaneously transfected by a vector plasmid (containing the gene of interest, such as the subject polynucleotide encoding both the dystrophin minigene and the one or more additional coding sequences), and one or two helper plasmids, using calcium phosphate or polyethylenimine (PEI), a cationic polymer.
- PEI polyethylenimine
- helper plasmid(s) allow the expression of the four Rep proteins, the three AAV structural proteins VP1, VP2, and VP3, the AAP, and the adenoviral auxiliary functions E2A,
- the additional adenoviral E1A/E1B co-factors necessary for rAAV replication are ex-pressed in HEK293 producer cells.
- Rep-cap and adenoviral helper sequences are either cloned on two separate plasmids or combined on one plasmid, hence both a triple plasmid system and a two plasmid system for transfection are possible.
- the triple plasmid protocol lends versatility with a cap gene that can easily be switched from one serotype to another.
- the plasmids are usually produced by conventional techniques in E. coli using bacterial origin and anti-biotic-resistance gene or by minicircle technology.
- Transient transfection in adherent HEK293 cells has been used for large-scale manufacturing of rAAV vectors. Recently, HEK293 cells have also been adapted to suspension conditions to be economically viable in the long term.
- HEK293 lines are usually propagated in DMEM completed with L-glutamine, 5%-10% of fetal bovine serum (FBS), and 1% penicillin-streptomycin, except for suspension HEK293 cells that are maintained in serum-free suspension FI 7, Expi293, or other manufacturer-specific media.
- FBS fetal bovine serum
- penicillin-streptomycin 1% penicillin-streptomycin, except for suspension HEK293 cells that are maintained in serum-free suspension FI 7, Expi293, or other manufacturer-specific media.
- the percentage of FBS can be reduced during AAV production in order to limit contamination by animal-derived components.
- the rAAV vectors are recovered 48-72 hr after plasmid transfection from the cell pellet and/or supernatant, depending on the serotype.
- the baculovirus- Sf9 platform has been established as a GMP-compatible and scalable alternative AAV production method in mammalian cells. It can generate up to 2x10 5 vector genomes (vg) per cell in crude harvests.
- the dual-baculovirus-Sf9 production system has many advantages over other production platforms regarding these safety issues: (1) the use of serum-free media; (2) despite the discovery of adventitious virus transcripts in Sf cell lines, most of the viruses infecting insects do not replicate actively in mammalian cells; and (3) no helper virus is required for rAAV production in insect cells besides baculovirus.
- stable Sf9 insect cell lines expressing Rep and Cap proteins are used, thus requiring the infection of only one recombinant baculovirus for the production of infectious rAAV vectors at high yield.
- HSV is a helper virus for replication of AAV in permissive cells.
- the HSV can serve both as a helper and as a shuttle to deliver the necessary AAV functions that support AAV genome replication and packaging to the producing cells.
- AAV production based on co-infection with rHSV can efficiently generate a large amount of rAAV.
- the method is further advantageous in that it creates rAAV stocks with apparently increased quality as measured by an improved viral potency.
- cells typically the hamster BHK21 cell line or the HEK293 and derivatives
- rHSV- AAV the gene of interest bracketed by AAV ITR
- rHSVrepcap the gene of interest bracketed by AAV rep and cap ORFs of the desired serotype
- HSV serves as a helper virus for AAV infection.
- AAV growth is accomplished using non-replicating mutants of HSV with ICP27 deleted.
- Certain methods for producing recombinant AAV viral particles in a mammalian cell have been known in the art and improved over the past decade.
- U.S. Application Publication No. 20070202587 describes recombinant AAV production in mammalian cells based on co-infection of the cells with two or more replication-defective recombinant HSV vectors.
- Mammalian Stable Cell Lines rAAV vectors can also be efficiently and scalably produced using stable mammalian producer cells stably expressing rep and cap genes. Such cells can be infected by wild-type Ad5 helper virus (which is genetically stable and can be easily produced at high titers) to induce high- level expression of rep and cap. Infectious rAAV vectors can be generated upon infection of these packaging cells lines with wild-type Ad type 5, and providing the rAAV genome by either plasmid transfection or after infection with a recombinant Ad/AAV hybrid virus.
- Ad5 helper virus which is genetically stable and can be easily produced at high titers
- Ad can be replaced by HSV-1 as the helper virus.
- Suitable stable mammalian producer cells may include HeLa-derived producer cell lines, A549 cells, or HEK293 cells.
- a preferred HeLa cell line is HeLaS3 cells, a suspension adapted HeLa subclone.
- the methods herein described can be used to manufacture the subject AAV vectors in animal components-free medium, preferably at 250-L scale, or 2,000-L commercial scale.
- the divergent viral vectors of the invention are capable of expressing not only the functional gene or protein of interest (GOI) but also one or more coding sequences for certain RNAi, antisense, sgRNA, miRNA or inhibitors thereof.
- a representative, non-limiting configuration of the recombinant viral vector of the invention is illustrated in FIG. 1.
- the recombinant viral vector of the invention may be a divergent AAV vector, such as AAV9 vector, designed to express a version of a functional dystrophin gene, such as any one of the pDys gene described herein above.
- the same divergent vector also expresses one or more additional coding sequence(s) from an independent / divergent transcription unit situated between the GOI promoter and the nearest ITR sequence (see FIG.
- At least one of such one or more additional coding sequence(s) is/are transcribed from an independent / divergent promoter different from the GOI promoter (such as the muscle specific CK8 promoter).
- the direction of transcription in the divergent transcription unit can be opposite to that of the GOI promoter.
- the design of the subject divergent vector permits independent and separate control of the GOI transcripiton unit and the divergent transcription unit, thus providing more flexibility and control in expression of the separate transcription units.
- the backbone sequence of the miR-29c coding sequence can be modified such that the surrounding sequences for the mature miR-29c sequence are obtained from other miRNA, such as that for miR-30, -101, -155, or -451 (see above). It has been found that replacing the native surrounding sequences of miR-29c by those from miR-30, -101, -155, or -451 can enhance the production of the one strand (i.e., the guide strand) of miR-29c designed to target the miR-29c target sequence (i.e., reduce the production of its complement passenger strand that is not useful for targeting the miR-29c target sequence).
- miR-29c “solo” expression constructs were generated on the same vector background. These miR-29c solo expressing constructs do not express pDys gene, but may instead express a reporter gene such as EGFP or GFP.
- one such solo vector may express the miR-29c coding sequence inserted into the intron sequence upstream of an EGFP coding sequence, all from an EF1 A promoter.
- the backbone sequences of the miR-29c coding sequence may be modified by that of miR-30, - 101, -155, or -451.
- Another such solo vector may express an shRNA, such as shSLN that targets / down- regulates the expression of SLN.
- Expression of the shRNA may be driven by the U6 promoter that can be used by RNA Pol III, which produces strong transcription of short RNA transcripts.
- the shRNA coding sequence can be inserted into the intron in the U6 transcription cassette, before a coding sequence for GFP.
- fusion vectors as described in International Patent Application No. PCT/US2019/065718, filed on December 11, 2019 were also included in this experiment.
- the five solo constructs, five fusion constructs, three divergent constructs, and a couple of control pDys expressing constructs were transfected to human iPS-derived cardiomyocytes according to standard procedure. Mature miR-29c levels were measured via Taqman stem-loop QPCR.
- the five solo constructs tested include U6- or EF1 A- driven miR-29c expression cassettes designed in miR-30 (EFlA-29c-M30E and U6-29c-M30E) and miR-155 (EF1 A-29c-19nt and EF1 A-29c-l 55) backbones.
- the five fusion constructs tested include miR- 29c expression cassettes designed in miR-101 (pDys-29c-101-i2 & pDys-29c-3UTR- 101 ), miR- 30 (pDys-29c-M30E-i2), and miR-155 (29c- 19nt-pDys-3UTR & 29c-19nt-pDys-pa) backbones, inserted into intronic (i2), 3’UTR (3UTR) and after pA (pa) site locations relative to the pDys expression cassette.
- the three divergent constructs (Divergent-29c-vl, -v2, and -v5) all expressed miR-29c from the divergent expression cassette driven by a Pol III (U6) promoter.
- 29c-19nt-pDys-3UTR a modified miR29c in miR-155 backbone, inserted into the 3’- UTR region of the pDys expression cassette (before the polyA adenylation signal sequence).
- 29c-19nt-pDys-pA the same modified miR29c coding sequence in miR-155 backbone, inserted after the polyA adenylation signal sequence of the pDys expression cassette.
- pDys-29c-M30E-i2 a modified miR29c coding sequence in miR-30E backbone, inserted into the intron region of the pDys expression cassette.
- pDys-29c-101-i2 a modified miR29c coding sequence in miR-101 backbone, inserted into the intron region of the pDys expression cassette.
- pDys-29c-3UTR- 101 a modified miR29c coding sequence in miR-101 backbone, inserted into the 3’-UTR region of the pDys expression cassette.
- the solo constructs expressing miR-29c generally over-expressed miR-29c in the infected human iPS-derived cardiomyocytes by a factor of 6-73 fold, compared to the same control vector that expresses only pDys.
- EF1 A-29c-M30E a modified miR29c coding sequence in the miR-30E backbone, driven by the EF1 A promoter.
- U6-29c-M30E a modified miR29c coding sequence in miR-30E backbone, driven by the Pol III U6 promoter.
- U6-29c-vl a miR29c coding sequence driven by the Pol III U6 promoter.
- EFlA-29c-19nt a modified miR29c coding sequence in miR-155 backbone, driven by the EF1A promoter.
- EFlA-29c-155 another modified miR29c coding sequence in miR-155 backbone, driven by the EF1 A promoter.
- the three divergent constructs all expressed high to very high levels of miR-29c transcripts, with the v2 construct approaching that of the highest fusion construct pDys-29c- M30E-i2, while the vl and v5 divergent constructs both approaching the highest solo constructs (50-70-fold). See FIG. 2.
- a few selected divergent recombinant viral vectors in AAV9 viral particles were also used to infect differentiated C2C12 myotube and primary mouse cardiomyocytes, and expression of miR-29c was confirmed in these cells as well. See FIG. 3, with results being expressed as relative miR-29c expression after normalization against controls expressing only pDys.
- pDys control AAV9 vector encoding only the pDys (GOI).
- EF1 A-mSLN a solo construct expressing only shRNA targeting mouse SLN (mSLN). Transcription of the shRNA coding sequence is driven by the EF1 A promoter.
- EF1 A-mSLN V2
- EF1 A-mSLN V2
- mSLN-shRNA control a commercial positive control shRNA targeting mouse SLN.
- scramble a commercial negative control shRNA with scambled sequence of the positive control shRNA.
- the subject divergent constructs consistently achieved >90% mSLN knock down in a dual luciferase based assay, with the results being expressed as the ratio of RLU (relative luciferase unit) from the firefly luciferase to RLU from the renilla liciferase.
- RLU relative luciferase unit
- FIG. 5 shows relative expression levels of siSLN (processed siRNA product from the transcribed shSLN) in differentiated C2C12 myotubes or mouse primary cardiomyocytes for the various recombinant AAV9 vectors encoding shmSLN, either as the sole coding sequence in the viral vector (“Solo”), or as part of the divergent construct of the present disclosure (“Divergent”).
- siRNA production was quantified via a custom Taqman stem-loop QPCR system.
- the relative siSLN expression levels of the solo and divergent constructs were normalized against the level in the pDys control group, although apparent high fold changes may not be informative due to the near absent or very minimal siSLN-like RNA production in the control group.
- the solo construct expressed about 1000-fold higher level of siSLN from the strong U6 Pol III promoter, as compared to the control group. Meanwhile, the tested divergent construct reached similarly high (if not higher) level of siSLN compared the solo constructs.
- the negative controls include: two constructs (pDysl and pDys2) expressing pDys alone (which had no effect on the expression level of SLN mRNA); a construct expressing GFP under the muscle-specific promoter CK8 (CK8-GFP) (which GFP also had no effect on SLN mRNA expression); and “sigma scramble” - a construct expressing a scrambled sequence of a hSLN-targeting shSLN (which expectedly had no effect on SLN mRNA expression).
- the positive control is “sigma shrna,” which is a commercially available shRNA plasmid from Sigma that encodes an hSLN-targeting shSLN that down-regulates about 80% of the hSLN mRNA.
- the combo-cl-vl construct is a divergent construct that co-expresses pDys and shRNA targeting hSLN. Up to 90% of the hSLN mRNA was knocked down upon infecting the human iPS-derived cardiomyocytes with this construct. The same was also observed for three other combo constructs, combo-cl-v2, combo-c2-vl, and combo-c2-v2.
- the two tested fusion constructs one in M30E backbone and inserted into the intron of the pDys expression cassette, and one in miR-101 backbone and inserted into the 3’-UTR region of the pDys expression cassette, led to 1.4-2.8-fold miR-29c up-regulation in left gastrocnemius (see FIG. 20 A of PCT/US2019/065718), diaphragm (see FIG. 20B of PCT/US2019/065718), and left ventricle (see FIG. 20C of PCT/US2019/065718).
- the miR-29c-pDys fusion AAV9 constructs were administered at 5E13 vg/kg dose.
- the solo U6 promoter-driven miR-29c construct in AAV9 produced 2-11 fold up-regulation at 5E13 vg/kg dose, and 6-16-fold at 1E14 vg/kg dose.
- miR-29c up-regulation by the fusion AAV9 constructs did not result in reduction of pDys production in gastrocnemius (see FIG. 21 of PCT/US2019/065718), diaphragm (data not shown) and left ventricle (data not shown).
- the fusion AAV9 constructs showed similar pDys expression, at both RNA and protein levels, as that of the control pDys- only AAV9 constructs.
- Solo constructs expressing only miR-29c do not produce pDys, therefore showed absent pDys levels.
- miR-29c up-regulation by the divergent AAV9 constructs also did not result in reduction of pDys production in the left gastrocnemius (FIG. 13, left panel for RNA, right panel for protein), diaphragm (data not shown) and left ventricle (data not shown).
- the divergent AAV9 constructs showed similar pDys expression, at both RNA and protein levels, as that of the control pDys-only AAV9 constructs.
- Solo constructs expressing only miR-29c do not produce pDys, therefore showed negligible pDys levels.
- mSLN mRNA down- regulation by one divergent AAV9 construct also did not result in reduction of pDys production, at both RNA and protein levels, in diaphragm (FIG. 15, left panel for RNA, right panel for protein), tongue (FIG. 16, left panel), and atrium (data not shown), as compared to that of the control AAV9 expressing only pDys, except that the Divergent- shmSLN-v2 construct reduced pDys expression in the left gastrocnemius by 60-70%.
- Solo construct expressing only shmSLN did not produce pDys, thus showing absent pDys levels.
- Dystrophin provides structural stability to the muscle cell membrane, and increased permeability of the sarcolemma leads to the release of creatine kinase (CK) from muscle fibers.
- creatine kinase (CK) levels are a hallmark of muscle damage.
- CK levels are significantly increased above the normal range (e.g ., 10-100 times the normal level since birth).
- serum CK levels are considered as a general measure of muscle health in the mdx mouse model.
- the data in this experiment shows that miR-29c solo (administered at the high dose of 1E14 vg/kg) and miR-29c-pDys divergent (administered at 5E13 vg/kg dose) constructs of AAV9 both reduced serum CK levels in the mdx mouse model, to the similar extent compared to the pDys control, therefore suggesting a therapeutic benefit of expressing miR-29c in DMD patients.
- FIG. 17 shows that expression of pDys alone caused significant drop in serum CK level.
- expressing miR-29c alone also led to significant decrease of serum CK level, especially when a higher viral dose (of miR-29c-expressing solo constructs) was used.
- tissue inhibitors of metalloproteinase- 1 has been proposed as a serum biomarker for monitoring disease progression and/or treatment effects in Duchenne muscular dystrophy (DMD) patients, since serum levels of TIMP-1 were significantly higher in DMD patients compared to healthy controls.
- ⁇ MR1 is also a serum marker for muscle health in the mdx mouse model.
- FIG. 25 of PCT/US2019/065718, right panel shows that expression of pDys alone caused significant drop in serum TIMP1 level.
- Co-expressing pDys and shRNA against mSLN with the tested fusion construct also led to similarly significant drop in serum ⁇ MR1 levels. Meanwhile, expressing shRNA against mSLN alone did not lead to decrease of serum TIMP1 level.
- biodistribution of the divergent viral vectors was compared to that of the solo viral vector expressing only pDys. It was found that biodistribution for most viral vectors used were largely similar in gastrocnemius, regardless of whether the divergent construct expresses miR-29c or shmSLN. See FIG. 20. One of the divergent vector encoding shmSLN, however, appeared to be lower compared to that of the pDys solo construct.
- liver levels of the divergent viral vectors were compared to that of the solo viral vector expressing only pDys. It was found that viral titers of most viral vectors used were somewhat lower in liver, regardless of whether the divergent construct expresses miR-29c or shSLN. See FIG. 21. The only exception seems to be the DIV- 29c-v5 vector expresing miR-29c, which apparently had the same (if not higher) viral titer compared to that of the pDys solo construct.
- liver damage was the cause for the apparent lower titer in the liver
- plasma ALT levels were assessed for the verious groups infected by the divergent vectors.
- the results in FIG. 22 showed that liver damage is unlikely to be the cause of lower titer in liver, because the two divergent constructs having lower viral titers in the liver, DIV-29c- vl and -v2, both had plasma ALT levels comparable, if not lower than that of the PBS control.
- the subject viral vectors e.g., rAAV viral vectors can be used to deliver CRISPR/Cas9 or CRISPR/Cas 12a (or other engineered or modified Cas enzymes or homologous thereof) into a target cell, together with one or more sgRNA (for Cas9), or one or more crRNA (for Cas 12a), for simultaneous knock down of target genes in the target cell.
- the target cell tropism can be controlled in part by the tropism of the viral particles in which the CRISPR/Cas and sgRNA/crRNA-encoding sequences resides.
- the GOI in the subject viral vector can be the coding sequence for CRISPR/Cas9 or CRISPR/Casl2a.
- the one or more sgRNA or crRNA that can be loaded onto Cas9 or Cast 2a, respectively, can be expressed from the divergent expression cassette, the intron, the 3’-UTR, and/or elsewhere in the expression cassette of Cas9 / Casl2a.
- the target cell Upon infecting the target cell with the subject viral vectors, e.g., AAV vectors, Cas proteins and sgRNA/crRNA are co-expressed inside the target cell to mediate gene editing.
- the subject viral vectors e.g., AAV vectors, Cas proteins and sgRNA/crRNA are co-expressed inside the target cell to mediate gene editing.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention described herein provides gene therapy vectors, such as adeno-associated virus (AAV) vectors, that co-express a functional protein (such as a miniaturized human micro-dystrophin gene product) and one or more additional coding sequences for an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a guide sequence for a gene editing enzyme (such as an sgRNA for CRISPR/Cas9, or a crRNA for CRISPR/Casl2a), and/or a microRNA, from a divergent vector, and methods of using such vectors to treat subjects suffering from a muscular dystrophy such as DMD / BMD.
Description
Combination Therapy for Treating Muscular Dystrophy
REFERENCE TO RELATED APPLICATION
This application claims priority to U.S. Provisional Patent Application No. 62/959,256, filed on January 10, 2020, the entire contents of which are incorporated herein by reference.
This application also incorporates by reference the entire content of U.S. Provisional Patent Application No. 62/778,646, filed on December 12, 2018, and International Patent Application No. PCT/US2019/065718, filed on December 11, 2019, which claims priority to U.S. Provisional Patent Application No. 62/778,646, filed on December 12, 2018.
BACKGROUND OF THE INVENTION
Muscular dystrophy (MD) is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes (mutant genes) produce no functional wild-type proteins needed to form healthy muscle.
Muscular dystrophies have serious debilitating impacts on quality of life of affected patients. Duchenne type muscular dystrophy (DMD) is one of the most devastating muscle diseases affecting 1 in 5,000 newborn males. It is the most well-characterized muscular dystrophy, resulting from mutations in genes encoding members of the dystrophin-associated protein complex (DAPC). These MDs result from membrane fragility associated with the loss of sarcolemmal-cytoskeleton tethering by the DAPC.
Specifically, DMD is caused by mutations in the DMD gene, leading to reductions in DMD mRNA and the absence of dystrophin or functional dystrophin, a 427 kDa sarcolemmal protein associated with the dystrophin-associated protein complex (DAPC) (Hoffman et ah, Cell 51(6): 919-928, 1987). The DAPC is composed of multiple proteins at the muscle sarcolemma that form a structural link between the extra-cellular matrix (ECM) and the cytoskeleton via dystrophin, an actin binding protein, and alpha-dystroglycan, a laminin-binding protein. These structural links act to stabilize the muscle cell membrane during contraction, and protect against contraction-induced damage.
Loss of dystrophin as a result of DMD gene mutations disrupts the dystrophin glycoprotein complex, leading to increased muscle membrane fragility. A cascade of events
including influx of calcium into the sarcoplasm, activation of proteases and proinflammatory cytokines, and mitochondrial dysfunction results in progressive muscle degeneration. In addition, displacement of neuronal nitric oxide synthase (nNOS) contributes to tissue ischemia, increased oxidative stress, and reparative failure. Disease progression is characterized by increasing muscle necrosis, fibrosis, and fatty tissue replacement and a greater degree of fiber size variation seen in subsequent muscle biopsies.
Accumulated evidence suggests that abnormal elevation of intracellular Ca2+ (Ca2+i) is an important, early pathogenic event that initiates and perpetuates disease progression in DMD.
The normal function of sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pump accounts for > 70% of Ca2+ removal from the cytosol and proper muscle contraction. Reduction in SERCA activity therefore has been considered as a primary cause of Ca2+i overload and muscle dysfunction in DMD.
Currently there is no cure for DMD. The standard of care includes administering corticosteroids (such as prednisone or deflazacort) to stabilize muscle strength and function, prolonging independent ambulation, and delaying scoliosis and cardiomyopathy; bisphosphonates; and denosumab and recombinant parathyroid hormones.
With the advent of gene therapy, research and clinical trials for DMD treatment has focused on gene replacement or other genetic therapies aimed to at least partially restore dystrophin function. These include supplying a functional copy of the dystrophin gene, such as a dystrophin minigene, or repairing a defective dystrophin gene product by exon skipping and nonsense mutation suppression.
However, due to the broad range of effects cause by the dystrophin mutation, there is a need to treat other secondary symptoms associated with the primary dystrophin mutation.
For example, loss of dystrophin leads to the loss of the dystrophin-associated protein complex (DAPC), which in turn leads to the production of nitric oxide (NO) by nNOS, and abnormal N-nitrosylation of HDAC2. Such abnormally N-nitrosylated HDAC2 dissociates from the chromatin, and releases the inhibition of a cascade of specific microRNAs which in turn lead to a slew of downstream events such as fibrosis and increased oxidative stress.
In particular, with respect to fibrosis, with dystrophin loss, membrane fragility results in sarcolemmal tears and an influx of calcium, triggering calcium-activated proteases and
segmental fiber necrosis (Straub etal., Curr. Opin. Neurol. 10(2): 168-175, 1997). This uncontrolled cycle of muscle degeneration and regeneration ultimately exhausts the muscle stem cell population (Sacco et al, Cell 143(7): 1059-1071, 2010; Wallace et al, Annu Rev Physiol 71:37-57, 2009), resulting in progressive muscle weakness, endomysial inflammation, and fibrotic scarring.
Without membrane stabilization from dystrophin or a micro-dystrophin, DMD will manifest uncontrolled cycles of tissue injury and repair, and ultimately replace lost muscle fibers with fibrotic scar tissue through connective tissue proliferation.
Muscle biopsies taken at the earliest age of diagnosis of DMD ( e.g ., between 4-5 years old) reveal prominent connective tissue proliferation. Muscle fibrosis is deleterious in multiple ways. It reduces normal transit of endomysial nutrients through connective tissue barriers, reduces the blood flow and deprives muscle of vascular-derived nutritional constituents, and functionally contributes to early loss of ambulation through limb contractures. Over time, treatment challenges multiply as a result of marked fibrosis in muscle. This can be observed in muscle biopsies comparing connective tissue proliferation at successive time points. The process continues to exacerbate leading to loss of ambulation and accelerating out of control, especially in wheelchair-dependent patients.
Thus fibrotic infiltration is profound in DMD, and is a significant impediment to any potential therapy. In this regard, gene replacement therapy alone is usually hampered by the severity of fibrosis, already present in very young children with DMD.
Fibrosis is characterized by the excessive deposits of ECM matrix proteins, including collagen and elastin. ECM proteins are primarily produced from cytokines such as TGF that is released by activated fibroblasts responding to stress and inflammation. Although the primary pathological feature of DMD is myofiber degeneration and necrosis, fibrosis as a pathological consequence has equal repercussions. The over-production of fibrotic tissue restricts muscle regeneration and contributes to progressive muscle weakness in the DMD patient.
In one study, the presence of fibrosis on initial DMD muscle biopsies was highly correlated with poor motor outcome at a 10-year follow-up (Desguerre etal, J Neuropathol Exp Neurol 68(7): 762-767, 2009). These results point to fibrosis as a major contributor to DMD muscle dysfunction and highlight the need to develop therapies that reduce fibrotic tissue.
Most anti-fibrotic therapies that have been tested in mdx mice act to block fibrotic cytokine signaling through inhibition of the TGF pathway.
MicroRNAs (miRNAs) are single- stranded RNAs of ~22 nucleotides that mediate gene silencing at the post-transcriptional level by pairing with bases within the 3 ’ UTR of mRNA, inhibiting translation or promoting mRNA degradation. A seed sequence of 7 bp at the 5’ end of the miRNA targets the miRNA; additional recognition is provided by the remainder of the targeted sequence, as well as its secondary structure. MiRNAs play an important role in muscle disease pathology and exhibit expression profiles that are uniquely dependent on the type of muscular dystrophy in question (Eisenberg et al, Proc Natl Acad Sci U.S.A. 104(43):17016- 17021, 2007). A growing body of evidence suggests that miRNAs are involved in the fibrotic process in many organs including heart, liver, kidney, and lung (Jiang etal, Proc Natl Acad Sci U.S.A. 104(43): 17016-17021, 2007).
Recently, the down-regulation of miR-29 was shown to contribute to cardiac fibrosis (Cacchiarelli etal. , Cell Metab 12(4):341-351, 2010). Reduced expression of miR-29 was genetically linked with human DMD patient muscles (Eisenberg et al, Proc Natl Acad Sci U.S.A. 104(43): 17016-17021, 2007).
The miR-29 family consists of three family members expressed from two bicistronic miRNA clusters. MiR-29a is coexpressed with miR-29b (miR-29b-l); miR-29c is co-expressed with a second copy of miR-29b (miR-29b-2). The miR-29 family shares a conserved seed sequence, and miR-29a and miR-29b each differ by only one base from miR-29c. Furthermore, electroporation of miR-29 plasmid (a cluster of miR-29a and miR-29b-l) into mdx mouse muscle reduced the expression levels of ECM components, collagen and elastin, and strongly decreased collagen deposition in muscle sections within 25 days post-treatment (Cacchiarelli etal, Cell Metab 12(4):341-351, 2010).
Adeno-associated virus (AAV) is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length, including 145 nucleotide inverted terminal repeat (ITRs).
AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is noncytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV
infects many mammalian cells, allowing the possibility of targeting many different tissues in vivo. Moreover, AAV transduces slowly dividing and non-dividing cells, and can persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is infectious as cloned DNA in plasmids, which makes construction of recombinant genomes feasible. Furthermore, because the signals directing AAV replication, genome encapsidation and integration are contained within the ITRs of the AAV genome, some or all of the internal approximately 4.3 kb of the genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA such as a gene cassette containing a promoter, a DNA of interest and a polyadenylation signal. The rep and cap proteins may be provided in trans. Another significant feature of AAV is that it is an extremely stable and hearty virus. It easily withstands the conditions used to inactivate adenovirus (56° to 65°C for several hours), making cold preservation of AAV less critical. AAV may even be lyophilized. Finally, AAV-infected cells are not resistant to superinfection.
Multiple studies have demonstrated long-term (> 1.5 years) recombinant AAV-mediated protein expression in muscle. See, Clark et ah, Hum Gene Ther 8:659-669 (1997); Kessler el ah, Proc Nat. Acad Sc. U.S.A. 93:14082-14087 (1996); and Xiao et ah, J Virol 70: 8098-8108 (1996). See also, Chao et ah, Mol Ther 2:619-623 (2000) and Chao et ah, Mol Ther 4:217-222 (2001). Moreover, because muscle is highly vascularized, recombinant AAV transduction has resulted in the appearance of transgene products in the systemic circulation following intramuscular injection as described in Herzog etal, Proc Natl Acad Sci U.S.A. 94: 5804-5809 (1997) and Murphy etal, Proc Natl Acad Sci U.S.A. 94: 13921-13926 (1997). Moreover, Lewis et al., J Virol 76: 8769-8775 (2002) demonstrated that skeletal myofibers possess the necessary cellular factors for correct antibody glycosylation, folding, and secretion, indicating that muscle is capable of stable expression of secreted protein therapeutics.
While gene therapy using AAV vectors has fueled significant investments into the sector, significant challenges remain for commercialization. Recombinant viral vector production is seen as complex, with the production scale-up regarded as a major challenge technically, and a large barrier for commercialization.
Specifically, reported clinical doses for AAV-based viral vectors range from 1011 to 1014 genomic particles (vector genomes; vg) per patient dependent on therapeutic area. Thus, from a wider gene therapy development perspective, current scale-up approaches fall short of supplying
the required number of doses to allow later Phase ( e.g ., Phases II/III) trails to progress, thus retarding the development of gene therapy products. This is supported by the fact that the majority of clinical studies have been very small, performed on <100 patients (and in some cases <10), using adherent cell transfection processes that generate very modest amounts of product. When predicted amounts of virus required for later phase development are compared to current productivities (e.g., 5 x 1011 vg from single 10 layer cell factory), there is real concern that this approach will fall short of the material requirements for late phase and in-market needs for even ultra-orphan diseases, which have high dose and small patient cohorts, let alone more “standard” gene therapy indications.
As is stated by Clement and Grieger in a recent review article (Molecular Therapy - Methods & Clinical Development (2016) 3, 16002; doi:10.1038/mtm.2016.2): “[t]he use of rAAV in the clinical setting has underscored the urgent need for production and purification systems capable of generating very large amounts of highly pure rAAV particles. Typical FDA- approved investigational new drug includes extensive preclinical studies for toxicology, safety, dose, and bio-distribution assessments, with vector requirements often reaching the 1E15 to 1E16 vector genome range. Manufacturing such amounts, although technically feasible, still represents an incredible effort when using the current production systems.”
This problem is particularly acute for AAV vectors that are desirably delivered systematically (as opposed to locally). In a recent article, Adamson-Small et al. (Molecular Therapy - Methods & Clinical Development (2016) 3, 16031; doi:10.1038/mtm.2016.31) stated that “[cjurrent limitations in vector production and purification have hampered widespread implementation of clinical candidate vectors, particularly when systemic administration is considered. . . . This holds specifically true for the treatment of inherited genetic diseases such as muscular dystrophies, when body-wide gene transfer may be required, relying on systemic dosing often at high AAV doses.” Indeed, previous studies of rAAV in clinical trials for muscular dystrophy have delivered vector via intramuscular injection often due to the lack of large-scale manufacturing capabilities to generate the amounts needed to support systemic administration. Systematic delivery of two AAV vectors in combination therapy poses even a greater challenge in terms of producing sufficient quantities of high quality AAV vectors required for the combination therapy.
Thus, functional improvement in patients suffering from DMD and other muscular
dystrophies require both gene restoration and reduction of symptoms associated with a number of secondary cascades such as fibrosis. Alternatively or in addition, muscular dystrophies may benefit from treatments simultaneously targeting different disease-causing pathways. There is a need for methods of reducing such secondary cascade symptoms ( e.g ., fibrosis) that may be paired with gene restoration methods for more effective treatments of DMD and other muscular dystrophies. Such combination therapy must also overcome the significant clinical and commercialization challenge of producing sufficient quantities of gene therapy vectors to deliver both therapeutic components to the target tissue, particularly in the setting of systematic delivery of gene therapy vectors.
SUMMARY OF THE INVENTION
The invention described herein provides a viral vector for gene therapy, comprising a polynucleotide sequence that simultaneously encodes a first polypeptide or a first RNA (“a first transcription and/or expression unit or cassette”), and a second polypeptide or a second RNA (“a second transcription and/or expression unit or cassette”) expressed from a so-called “divergent cassette” in relation to the first transcription and/or expression cassette, which confers separate and independent control for the expression of each of first and second polypeptide and/or RNA, with minimal or no transcriptional interference between different transcription and/or expression units or casettes. In certain embodiments, the two transcription and/or expression units or cassettes are each under the control of its owe independent control elements or promoters. In certain embodiments, the two independent control elements or propmoters operate in opposite directions, such as each transcribing towards (as opposed to away from) its nearest terminal repeat sequences (such as the ITR sequences in an AAV vector).
The invention is partly based on the surprising discovery that the one or more coding sequence(s) can be inserted into certain positions, such as into a so-called “divergent cassette” (see below) situated between the control element or promoter for the gene of interest (GOI) and the nearest ITR, while both the functional protein (such as the dystrophin microgene or minigene product) and one or more coding sequences can be expressed inside the infected target cells (e.g., muscle cells) without significant reduction in expression compared to similar vector constructs encompassing only the functional protein (such as the dystrophin minigene product) or only the one or more coding sequences. In certain embodiments, the expression of the one or more
coding sequences from the divergent cassette is greatly increased compared to inserting the same coding sequences into the other parts of the viral vector, such as into the heterologous intron or 3’-UTR of the GOI.
As used herein, “transcription and/or expression unit or cassette” includes at a minimum a control element, a coding sequence, and a transcription termination sequence. The coding sequence in each transcription and/or expression unit or cassette can independently encode any of a protein, a polypeptide, an mRNA, a non-coding RNA (such as an shRNA, miRNA, siRNA, or a precursor thereof), an antisense sequence, a guide sequence for a gene editing enzyme, or a miRNA inhibitor, etc. The coding sequence is operably linked to and under the control of a control element which includes a promoter, and optionally one or more enhancers or other control elements, for initiating or affecting transcription by an RNA polymerase (including Pol II or Pol III), such that whatever that is encoded by the coding sequence can be transcribed. The coding sequence is also operably linked to a downstream transcription termination sequence (such as the T6 transcripiton termination sequence) so that transcription can be terminated as desired.
As used herein, constructs with two or more transcriptional units and/or cassettes operating in opposite / divergent / multiple directions are referred to as “divergent constructs.”
Specifically, viral vectors of the invention (such as an AAV-based viral vector or a lentivirus-based viral vector) having such arrangements of two transcription and/or expression units or cassettes, or divergent constructs in viral plasmid vector backbone, are referred to as “divergent vectors.”
For example, the vector of the invention may simultaneously encode a first therapeutic agent ( e.g ., a protein) expressed from the first transcripition cassette, and a second therapeutic agent (e.g., an RNA) expressed from the divergent cassette.
It should be understood that the reference to the first and second (divergent) expression units and/or cassettes are relative, such that any of the two GOI’s can be expressed from either expression units and/or cassettes. For example, in one embodiment, a microdystrophin coding sequence can be expressed from the first or the second (divergent) expression cassette. In another embodiment, any of the shRNA, siRNA, miRNA, etc., can also be expressed from the first or the second (divergent) expression cassette. In addition, both expression units / cassettes
ean be used to express proteins or non-protein products described herein (such as miRNA or precursors thereof).
That is, either the first or the second RNA, or both, may be a non-coding RNA that does not produce a protein or polypeptide. Such non-coding RNA can be microRNA (miR), shRNA (short hairpin RNA), piRNA, snoRNA, snRNA, exRNA, scaRNA, long ncRNAs such as Xist and HOTAIR, anti-sense RNA, or precursor thereof, preferably with therapeutic value, e.g., those associated with diseases such as cancer, autisum, Alzheimer's disease, Cartilage-hair hypoplasia, hearing loss, and Prader-Willi syndrome, particularly various types of muscular dystrophies (MDs), including DMD/BMD.
Such non-coding RNA can also be the single or multiple guide RNA(s) of a CRISPR/Cas9 protein, or a CRISPR RNA (crRNA) of a CRISPR/Casl2a(formerly Cpfl) protien.
Further, the two transcription units / cassettes may be used to express products (protein, peptide, RNA etc.) that are either biologically unrelated, or are somehow related in terms of biological function. For example, one of the coded / expressed products may replace the function of a defective gene product in a disease or condition, while the other coded / expressed product may act on a separate biological pathway and thus the two products are delivered and result in desirably additive or synergistic biological and therapeutic effects. In the context of treating muscular dystrophy, for example, one of the coded / expressed products may be a functional version of a dystrophin (such as pDys) that supplements the lost dystrophin function, while the other coded / expressed product may antagonize a side effect associated with the loss of dystrophin function, such as fibrosis.
Thus in one aspect, the invention provides a recombinant viral vector comprising: a) a first transcripiton / expression unit encoding a first functional gene or protein of interest (GOI), and b) a second transcripiton / expression unit encoding a seoend functional gene or protein of interest (GOI), wherein the first transcripiton / expression unit and the second transcripiton / expression unit are independently under the control of their own transcription control element / promoter that directs transcription in opposite / divergent directions, preferably each towards the nearest terminal repeat sequences (e.g., ITR of AAV).
In a specific embodiment, the invention provides a recombinant viral vector comprising:
a) a polynucleotide encoding a functional gene or protein of interest (GOI), such as one effective to treat a muscular dystrophy, wherein said polynucleotide comprises a 3’-UTR coding region, and is immediately 3 ’ to a heterologous intron sequence that enhances expression of the functional protein encoded by the polunucleotide; b) a first control element ( e.g ., a muscle- specific control element) operably linked to and drives the expression of the polynucleotide; and, c) one or more coding sequences (1) inserted between the first control element and the nearest viral terminal sequence (e.g., ITR in AAV) and operably linked to a second control element, and (2) optionally further inserted in the intron sequence or in the 3’-UTR coding region; wherein said one or more coding sequences independently encode: a protein, a polypeptide, an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a guide sequence for a gene editing enzyme (such as a single guide RNA (sgRNA) for CRISPR/Cas9, or acrRNA for CRISPR/Casl2a), a microRNA (miRNA), and/or a miRNA inhibitor.
In certain embodiments, the recombinant viral vector is a recombinant AAV (adeno associated viral) vector or a recombinant lentiviral vector.
In a related aspect, the invention provides a recombinant AAV (rAAV) vector comprising: a) a polynucleotide encoding a functional protein effective to treat a muscular dystrophy, wherein said polynucleotide comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the functional protein encoded by the polunucleotide; b) a muscle-specific control element operably linked to and drives the expression of the polynucleotide; and, c) one or more coding sequences inserted between the muscle-specific control element and the nearest AAV ITR and operably linked to a second control element, and (2) optionally further inserted in the intron sequence or in the 3’-UTR coding region; wherein said one or more coding sequences independently encode: an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a microRNA (miRNA), and/or a miRNA inhibitor.
In a particular embodiment, the invention described herein provides a viral vector, such as a recombinant AAV vector, that comprises: a) a dystrophin microgene or minigene encoding a functional micro-dystrophin protein (e.g., microD5), wherein said dystrophin microgene or minigene comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the dystrophin microgene or minigene; b) a muscle- specific control element operably linked to and drives the expression of the dystrophin
microgene or minigene; and, c) one or more ( e.g ., 1, 2, 3, 4, or 5) coding sequence(s) inserted between the muscle-specific control element and the nearest AAV ITR and operably linked to a second control element, and (2) optionally further inserted in the intron sequence or in the 3’- UTR coding region; wherein said one or more coding sequence(s) independently encode(s): an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a microRNA (miRNA), and/or a miRNA inhibitor.
In certain embodiments, the second control element (in the divergent cassette) is a promoter or portion of a promoter that transcribes the one or more coding sequences. For example, the second control element is a pol II promoter that transcribes the one or more coding sequences inserted between the first control element and the nearest viral terminal sequence, optionally in a direction opposite to the transcription initiated by the first control element. In other embodiments, the second control element (in the divergent cassette) is a pol III promoter.
In other embodiments, the first and seond control elements are both the same promoter. In other embodiments, the first and second control elements are different promoters.
In certain embodiments, the functional dystrophin protein is microD5, and/or the muscle- specific control element / promoter is CK promoter.
In certain embodiments, the recombinant viral vector is a recombinant AAV (adeno associated viral) vector.
In certain embodiments, the one or more coding sequences are inserted into the divergent cassette. In certain embodiments, the one or more coding sequences are further inserted into the 3’-UTR coding region, or after the polyadenylation (poly A) signal sequence (e.g., AATAAA).
In certain embodiments, expression of the functional GOI is substantially unaffected in the presence of the one or more coding sequences (e.g., as compared to otherwise identical control constructs without said one or more coding sequences).
In certain embodiments, in the recombinant AAV (rAAV) vector: a) the polynucleotide is a dystrophin minigene encoding a functional 5-spectrin-like repeat dystrophin protein (e.g., microD5; as described in US 10,479,821, incorporated herein by reference); and/or, b) the muscle-specific control element is a CK promoter operably linked to and drives the expression of the dystrophin minigene.
In certain embodiments, the one or more coding sequences comprise an exon-skipping
antisense sequence that induces skipping of an exon of a defective dystrophin, such as skipping any one of exons 45-55 of dystrophin, or exon 44, 45, 51, and/or 53 of dystrophin.
In certain embodiments, the microRNA is miR-1, miR-133a, miR-29c, miR-30c, and/or miR-206. For example, when the microRNA is miR-29c, the miR-29c optionally has a modified flanking backbone sequence that enhances the processing of the guide strand of miR-29c designed for a target sequence. The modified flanking backbone sequence can be from or based on other miR sequences, such as miR-30, -101, -155, or -451.
In certain embodiments, expression of the microRNA in a host cell is up-regulated by at least about 1.5-100 fold ( e.g ., about 2-80 fold, about 1.5-10 fold, about 15-70 fold, about 50-70 fold, about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or about 80 fold) compared to endogenous expression of the microRNA in the host cell.
In certain embodiments, the RNAi sequence is an shRNA against sarcolipin (shSLN).
In certain embodiments, the one or more coding sequences encode one or more identical or different shRNAs against sarcolipin (shSLN).
In certain embodiments, the shRNA reduces sarcolipin mRNA and/or sarcolipin protein expression by at least about 50%.
In certain embodiments, the GOI is CRISPR/Cas9, and the guide sequence is the sgRNA; or wherein the GOI is CRISPR/Casl2a, and the guide sequende is the crRNA.
In certain embodiments, the RNAi sequence (siRNA, shRNA, miRNA), the antisense sequence, said CRISPR/Cas9 sgRNA, said CRISPR/Casl2a crRNA and/or the microRNA antagonizes the function of one or more target genes, such as an inflammatory gene, an activator of NF-KB signaling pathway (e.g., TNF-a, IL-1, IL-Ib, IL-6, Receptor activator of NF-KB (RANK), and Toll-like receptors (TLRs)), NF-KB, a downstream inflammatory cytokine induced by NF-KB, a histone deacetylase (e.g., HDAC2), TGF-b, connective tissue growth factor (CTGF), collagens, elastin, a structural component of the extracellular matrix, Glucose-6- phosphate dehydrogenase (G6PD), myostatin, phosphodiesterase-5 (PED-5) or ACE, VEGF decoy-receptor type 1 (VEGFR-l or Flt-1), and hematopoietic prostaglandin D synthase (HPGDS).
In certain embodiments, in the vector, e.g., the recombinant AAV (rAAV) vector: a) the polynucleotide encodes a functional fukutin (FKTN) protein; and/or, b) the one or more coding
sequences encode an exon-skipping antisense sequence that restores correct exon 10 splicing in a defective FKTN gene in a Fukuyama congenital muscular dystrophy (FCMD) patient.
In certain embodiments, in the vector, e.g., the recombinant AAV (rAAV) vector: a) the polynucleotide encodes a functional LAMA2 protein; and/or, b) the one or more coding sequences encode an exon-skipping antisense sequence that restores expression of the C-terminal G-domain (exons 45-64), particularly G4 and G5 of a defective LAMA2 gene in a Merosin- deficient congenital muscular dystrophy type 1 A (MDC1A) patient.
In certain embodiments, in the vector, e.g., the recombinant AAV (rAAV) vector: a) the polynucleotide encodes a functional DMPK protein, or a CLCN1 gene; and/or, b) the RNAi sequence (siRNA, shRNA, miRNA), the antisense sequence, or the microRNA (miRNA) targets expanded repeats of mutant transcripts in a defective DMPK gene, or encodes an exon-skipping antisense sequence leading to the skipping of exon 7A in CLCN1 gene in a DM1 patient.
In certain embodiments, in the vector, e.g., the recombinant AAV (rAAV) vector: a) the polynucleotide encodes a functional DYSF protein; and/or, b) one or more coding sequences encode an exon-skipping antisense sequence leading to the skipping of exon 32 in a defective DYSF gene in a dysferlinopathy (LGMD2B or MM) patient.
In certain embodiments, in the vector, e.g., the recombinant AAV (rAAV) vector: a) the polynucleotide encodes a functional SGCG protein; and/or, b) one or more coding sequences encode an exon-skipping antisense sequence leading to the skipping of exons 4-7 in a defective LGMD2C gene (e.g, one with the A-521T SGCG mutation) in a LGMD2C patient.
In certain embodiments, the heterologous intron coding sequence is SEQ ID NO: 1.
In certain embodiments, the one or more coding sequences are inserted in the intron sequence.
In certain embodiments, expression of the functional protein is not negatively affected by the insertion of said one or more coding sequences.
In certain embodiments, the vector is of the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV 11, AAV 12, or AAV 13. In certain embodiments, the vector is a derivative of a known serotype. In certain embodiments, the derivative may exhibit a desired tissue specificity or tropism, a desired immunogenic profile (e.g., not subject to attack by a subject patient’s immune system), or other desirable properties
for a pharmaceutical composition or gene therapy for various indications.
In certain embodiments, the first control element (or the promoter in the divergent cassette) is a promoter or portion of a promoter that transcribes in a tissue specific manner the one or more coding GOI sequences. In certain embodiments, the tissue specific specific control element is a muscle-specific control element.
In certain embodiments, the muscle-specific control element is human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor mef, muscle creatine kinase (MCK), truncated MCK (tMCK), myosin heavy chain (MHC), C5-12, murine creatine kinase enhancer element, skeletal fast-twitch troponin c gene element, slow-twitch cardiac troponin c gene element, slow-twitch troponin i gene element, hypoxia-inducible nuclear factors, steroid-inducible element, or glucocorticoid response element (gre).
In certain embodiments, the muscle-specific control element comprises the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO: 11 of W02017/181015 (incorporated herein by reference).
Another aspect of the invention provides a composition comprising any of the vector, e.g., the recombinant viral (AAV) vector of the invention.
In certain embodiments, the composition is a pharmaceutical composition further comprising a therapeutically compatible carrier, diluent, or excipient.
In certain embodiments, the therapeutically acceptable carrier, diluent, or excipient is a sterile aqueous solution comprising 10 mM L-histidine at pH 6.0, 150 mM sodium chloride, and 1 mM magnesium chloride.
In certain embodiments, the composition is in a dosage form of about 10 mL of aqueous solution having at least 1.6 x 1013 vector genomes.
In certain embodiments, the composition has a potency of at least 2 x 1012 vector genomes per milliliter.
Another aspect of the invention provides a method of producing the subject composition, comprising producing the vector, e.g., the recombinant AAV vector in a cell and lysing the cell to obtain the vector.
In certain embodiments, the vector is an AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV 11, AAV 12, or AAV 13 vector.
Another aspect of the invention provides a method of treating a muscular dystrophy or dystrophinopathy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of any one of the recombinant vector, e.g., the recombinant AAV vector of the invention, or any one of the composition of the invention.
In certain embodiments, the recombinant vector, e.g, the recombinant AAV vector or the composition is administered by intramuscular injection, intravenous injection, parental administration or systemic administration.
In certain embodiments, the muscular dystrophy is Duchenne muscular dystrophy or Becker muscular dystrophy.
In certain embodiments, the muscular dystrophy is Duchenne muscular dystrophy,
Becker muscular dystrophy, Fukuyama congenital muscular dystrophy (FCMD), dysferlinopathy, myotonic dystrophy, and merosin-deficient congenital muscular dystrophy type 1A, facioscapulohumeral muscular dystrophy (FSHD), congenital muscular dystrophy (CMD), or limb-girdle muscular dystrophy (LGMDR5 or LGMD2C).
Another aspect of the invention provides a kit for preventing or treating DMD or related / associated diseases in a subject, the kit comprising: one or more vector, e.g., the recombinant AAV as described herein, or a composition as described herein; instructions for use (written, printed, electronic / optical storage media, or online); and/or packaging. In certain embodiments, a kit also includes a known MD (e.g., DMD) therapeutic for combination therapy.
It should be understood that any one embodiment described herein, including one described only in the example or claims, can be combined with any one or more other embodiments of the invention unless such combination is expressly disclaimed or improper.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows schematic drawings (not to scale) showing a representative and non- limiting embodiment of the subject recombinant viral (e.g., lentiviral or AAV) vector encompassing a gene of interest (GOI), such as a microdystrophin, minidystrophin or dystrophin minigene as described below (e.g., the 5-spectrin-like-repeat microD5 dystrophin protein described below, or a version of a functional DMD gene (micro dystrophin or labeled as “pDys” in the figure)) and one or more additional coding sequences for non-protein coding RNA (ncRNA) such as shRNA, between the two ITR sequences. The coding sequence for the RNAi,
miRNA, etc. can be inserted anywhere in the vector where “Transcript” is indicated, e.g., in the region between the promoter for the GOI (labeled in the figure as the exemplary muscle specific promoter CK8) and the nearest ITR sequence; in the intron before the GOI; in the 3’-UTR region; or after the polyA signal sequence. The additional ncRNA (e.g., shRNA) coding sequences can be the same or different. The so-called “fusion transcripts” have been described in more detail in International Patent Application No. PCT/US2019/065718, filed on December 11, 2019 (incorporated herein by reference). The initial transcription from the GOI promoter will result in a fusion transcript or a pre-processed mRNA encompassing the GOI and the additionally coded sequences, which, upon further processing, will be sepatrated as the GOI transcript and and the additional coded sequences. In contrast, the so-called “divergent / independent” transcripts of the invention are transcribed from its own, independent promoter, and are described in further details below.
FIG. 2 shows the relative miR-29c expression level changes (in folds over the control vector expressing pDys only) in human iPS-derived cardiomyocytes, for the various recombinant viral (e.g., AAV) vectors encoding miR-29c, either as the sole coding sequence in the viral vector (the “Solo” constructs), as part of the fusion constructs described in PCT/US2019/065718, filed on December 11, 2019 (the “Fusion” constructs), or as part of the divergent constructs of the present disclosure (the “Divergent” constructs).
FIG. 3 shows relative expression levels of miR-29c in differentiated C2C12 myotube or primary mouse cardiomyocytes for the various recombinant AAV vectors encoding miR-29c, either as the sole coding sequence in the viral vector (the “Solo” constructs), or as part of the divergent constructs of the present disclosure (the “Divergent” constructs).
FIG. 4 shows about 90% knock-down of mouse SLN luciferase construct levels measured via firefly activity normalized to control renilla construct activity via multiple shSLN-pDys divergent construct of the present disclosure. As comparison, results from using solo constructs were also shown. The last two samples are commercial negative and positive shRNA controls for mSLN knock-down.
FIG. 5 shows relative expression levels of siSLN (processed siRNA product from the transcribed shSLN) in differentiated C2C12 myotubes or mouse cardiomyocytes for the various recombinant AAV vectors encoding shSLN, either as the sole coding sequence in the viral vector (“Solo”), or as part of the divergent construct of the present disclosure (“Divergent”).
FIG. 6 shows up to -90-95% human SLN mRNA knock-down in human iPS-derived cardiomyocytes by several subject divergent constructs encoding shhSLN.
FIG. 7 shows up to -90% mouse SLN mRNA knock-down in primary mouse cardiomyocytes by several subject solo and divergent constructs encoding shmSLN.
FIG. 8 shows normalized pDys mRNA levels of several Hum-shSLN-pDys divergent constructs in human iPS-derived cardiomyocytes.
FIG. 9 is an image of denaturing agarose gel, suggesting largely intact AAV genomes in the solo, fusion, and divergent constructs with miR-29c or shSLN coding sequence.
FIG. 10 shows that the ratio of all three AAV9 capsid proteins VP1-VP3 remains the same across AAV9-based solo, fusion, and divergent vectors.
FIG. 11 shows up to 6-fold miR-29c up-regulation in left gastrocnemius (top panel), up to 5.8-fold miR-29c up-regulation in diaphragm (lower left panel), and up to 7.5-fold miR-29c up- regulation in left ventricle (lower right panel), using a miR-29c-pDys divergent construct of the invention in AAV9 vector.
FIG. 12 shows elevated plasma levels of miR-29c in mice infected by the solo or divergent vectors.
FIG. 13 shows no reduction of pDys expression at RNA (left panel) and protein (right panel) level in left gastrocnemius with miR-29c up-regulating divergent AAV9 vector.
FIG. 14 shows up to 75% mSLN mRNA down-regulation in the diaphragm (top panel), up to 95% mSLN mRNA down-regulation in the left atrium (lower left panel), and up to 80% mSLN mRNA down- regulation in the left gast (lower right panel), via AAV9-mediated expression of shSLN-pDys divergent construct relative to pDys-only AAV9.
FIG. 15 shows similar levels of pDys RNA/protein expression in diaphragm via an shmSLN-pDys divergent construct of AAV9. Similar results were also obtained for atrium (data not shown).
FIG. 16 shows similar levels of pDys protein expression and mSLN mRNA knock down in tongue, via an shmSLN-pDys divergent construct of AAV9.
FIG. 17 shows that miR-29c solo and miR-29c-pDys divergent constructs of AAV9 reduce serum CK levels. Mir-29c and pDys co-expression may cause further reductions in serum CK levels.
FIG. 18 shows serum CK levels in shmSLN solo and divergent constructs of AAV9.
FIG. 19 shows that miR-29c solo and miR-29c-pDys divergent constructs of AAV9 reduce serum TIMP1 levels.
FIG. 20 shows largely similar biodistribution of miR-29c or shSLN vectors in gastrocnemius from several miR-29c-pDys divergent vectors of AAV9, or shmSLN-pDys divergent vectors of AAV9.
FIG. 21 shows generally lower titers of AAV9 vectors in liver for miR-29c-pDys and shmSLN-pDys divergent constructs vs. the pDys solo construct.
FIG. 22 shows that plasma ALT levels were comparable in animals infected by miR-29c- expressing divergent vectors, suggesting that liver damage was not a likely casue for observed lower liver titer in certain infected animals.
FIG. 23 shows added benefit of the divergent constructs of the invention over pDys construct alone in diaphragm, based on their effects on two fibrotic marker genes.
DETAILED DESCRIPTION OF THE INVENTION
Without a parallel approach to treat a varieties of secondary cascade symptoms such as fibrosis and abnormal elevation of intracellular Ca2+, it is unlikely that the benefits of exon skipping, stop-codon read-through, or gene replacement therapies can ever be fully achieved. Even small molecules or protein replacement strategies are likely to fail without an approach to reduce symptoms of such secondary cascade events including muscle fibrosis. For example, previous work in aged mdx mice with existing fibrosis treated with AAV micro-dystrophin demonstrated that one could not achieve full functional restoration (Human molecular genetics 22:4929-4937, 2013). It is also known that progression of DMD cardiomyopathy is accompanied by scarring and fibrosis in the ventricular wall.
The present invention is partly directed to gene therapy methods to treat a patient that not only compensate defects in dystrophin and its function by providing a replacement, functional dystrophin minigene, but also directly target one or more secondary cascade genes using one or more additional coding sequences in the same gene therapy vector, thus achieving combination therapy in one compact vector for systematic delivery.
Indeed, the present invention, particularly the recombinant AAV (rAAV) vector of the
invention, is not limited to treating DMD. The invention is applicable for treating other muscular dystrophies in which a gene is defective. For example, the recombinant AAV (rAAV) vector of the invention can provide a functional protein and/or one or more coding sequences (such as non-coding RNAs, e.g., RNAi sequence, antisense RNA, miRNA) to treat the muscular dystrophy, wherein the functional protein either provides a wild-type substitute for the defective gene product in the muscular dystrophy, or provides a non-wild-type substitute that is nevertheless effective to treat the muscular dystrophy (e.g., the 5-spectrin-like microD5 dystrophin minigene product).
Thus in one aspect, the invention provides a recombinant viral vector, e.g., a recombinant lentiviral or AAV (rAAV) vector comprising: a) a polynucleotide encoding a functional gene or protein of interest (GOI), such as one effective to treat the muscular dystrophy in a patient / subject / individual in need of treatment, wherein said polynucleotide comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the functional protein encoded by the polynucleotide, wherein the corresponding wild-type of the functional protein is defective in a muscular dystrophy, or wherein the functional protein, though not wild-type, is nevertheless effective to treat the muscular dystrophy; b) a first control element (e.g., a muscle-specific control element) operably linked to and drives the expression of the polynucleotide; and, c) one or more coding sequences (1) inserted between the first control element and the nearest viral terminal sequence (e.g., ITR in AAV) and operably linked to a second control element, and (2) optionally further inserted in the intron sequence or in the 3’- UTR coding region or elsewhere in the expression cassette for the functional protein; wherein said one or more coding sequences independently encode: an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a microRNA (miRNA), and/or a miRNA inhibitor.
In certain embodiments, the recombinant viral vector is a recombinant AAV (adeno associated viral) vector.
In a related aspect, the invention described herein can also be used as a viral vector for simultaneously delivering / expressing two or more components of an enzyme-based gene editing system, e.g., such as a target sequence-specific (engineered) nuclease that can create DNA double stranded break (DSB) at a target genomic site / target genomic sequence, and a donor or template sequence that matches the (wild-type or desired) target genome sequence.
Such a system makes it possible to utilize the endogenous homologous recombination (HR)
processes within the target cell to edit out a defective / undesired target genomic sequence, and replace it with a wild-type or otherwise desired sequence at the desired target genomic location.
In certain embodiments, the recombinant viral vector is a recombinant AAV (adeno associated viral) vector.
For example, the target sequence-specific (engineered) nuclease may include meganucleases (such as those in the LAGLIDADG family) and variants thereof that recognize unique target genomic sequences; Zinc Finger Nucleases (ZFNs); Transcription Activator-Like Effector Nucleases (TALENs); and CRISPR/Cas gene editing enzymes.
In the case of CRISPR/Cas, for example, the subject vector can simultaneously deliver, other than or in addition to the donor sequence, one or more gene editing guide sequence(s) having a desired sequence(s) for targeting one or more target sequence(s), and a compatible editing enzyme that can be encoded by the viral vector as the GOI. Such a viral delivery system can be used to substitute the undesired sequence occurring in the cell, tissue, or organism for the desired sequence. One example of the CRISPR/Cas enzyme system is CRISPR/Cas9 or CRISPR/Cas 12a (formerly Cpfl), and one or more required guide sequences ( e.g ., single guide RNA or sgRNA for Cas9, or crRNA for Casl2a) to a target cell. Cas9 includes the wild-type Cas9 and functional variants thereof. Several Cas9 variants are about the same size as the micro Dystrophin gene, and can be the functional GOI encoded by the viral vector of the invention. Casl2a is even smaller than Cas9 and can also be encoded as the GOT In certain embodiments, the Cas genes encoded by the viral constructs may or may not have UTR and/or intron elements.
Thus in certain embodiments, the GOI is CRISPR/Cas9, and the guide sequence is an sgRNA (single guide RNA); or wherein the GOI is CRISPR/Casl2a, and the guide sequence is a crRNA.
In a related aspect, the invention provides a recombinant lentiviral vector for use in ex vivo or in vivo gene therapy. In ex vivo gene therapy, cultured host cells are transfected in vitro using a subject viral vector to express the gene of interest, and then transplanted into the body. In vivo gene therapy is a direct method of inserting the genetic material into the targeted tissue, and transduction takes place within the patient's own cells. Thus the lentiviral vector of the invention may comprise: a) a polynucleotide encoding a functional gene or protein (GOI) effective to treat the muscular dystrophy in a patient / subject / individual in need of treatment,
wherein said polynucleotide comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the functional protein encoded by the polynucleotide, wherein the corresponding wild-type of the functional protein is defective in a muscular dystrophy, or wherein the functional protein, though not wild-type, is nevertheless effective to treat the muscular dystrophy; b) a first control element (e.g., a muscle-specific control element) operably linked to and drives the expression of the polynucleotide; and, c) one or more coding sequences (1) inserted between the first control element and the nearest viral terminal sequence (e.g., ITR in AAV) and operably linked to a second control element, and (2) optionally further inserted in the intron sequence or in the 3’-UTR coding region or elsewherein the expression cassette; wherein said one or more coding sequences independently encode: an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a microRNA (miRNA), and/or a miRNA inhibitor.
As used herein, and depending on context, the term “fusion” may have different meanings, including fusion proteins, fusion RNA transcripts in which more than one encoded sequence may be present (such as the coding sequence for the GOI and the coding sequence for one or more RNAi agents etc inserted into / embedded in the 3-UTR region or intron sequences of the GOI, and fusion constructs in which the viral vectors contain coding sequences for the GOI and the one or more RNAi agents, etc.
Again, as used herein, and depending on context, the term “divergent” (e.g., as used in “divergent construct” or “divergent (viral) vector” etc) refers to the fact that there are at least two transcription cassettes or units in the viral construct / vector, such that one (under the control of the first control element or first promoter) is responsible for the transcription of one (first) GOI (protein, polypeptide, RNA, etc) in the first transcription cassette / unit, while the other GOI (under the control of the second control element or second promoter) is responsible for the transcription of other encoded sequences other than the first GOI, such as the ncRNA or another protein- coding sequence, wherein the other / second transcripiton unit largely operates separately and independently from the one for the first GOI transcription. The second transcrioption cassettes / units may be situated between the promoter for the first transcription unit for the first GOI, and the nearest viral vector terminal sequence (such as the nearest ITR in the AAV vector). In certain embodiments, the second transcription unit transcribes in the opposite direction compared to the transcription direction of the first transcription units.
In certain embodiments, the second control element (in the divergent cassette) is a promoter or portion of a promoter that transcribes the one or more coding sequences. For example, the second control element is a pol II promoter that transcribes the one or more coding sequences inserted between the first control element and the nearest viral terminal sequence, optionally in a direction opposite to the transcription initiated by the first control element. In other embodiments, the second control element (in the divergent cassette) is a pol III promoter.
In other embodiments, the first and seond control elements are both the same promoter. In other embodiments, the first and second control elements are different promoters.
In certain embodiments, the one or more coding sequences are further inserted in the 3’- UTR coding region, or after the polyadenylation (poly A) signal sequence ( e.g ., AATAAA).
In certain embodiments, expression of the functional GOI is up- or down-regulated due to the presence of the one or more coding sequences (e.g., as compared to otherwise identical control constructs without inserted said one or more coding sequences).
In certain embodiments, expression of the functional GOI is substantially unaffected in the presence of the one or more coding sequences (e.g., as compared to otherwise identical control constructs without inserted said one or more coding sequences).
As used herein, “muscular dystrophy (MD)” includes a group of diseases characterized by progressive weakness and loss of muscle mass, due to abnormal genes or gene mutations that interfere with the production of wild-type proteins needed to form healthy muscle. MD includes Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); a congenital muscular dystrophy (CMD), particularly one with an identified genetic mutation, such as the ones described hereinbelow, including Fukuyama congenital muscular dystrophy (FCMD) and Merosin-deficient congenital muscular dystrophy type 1 A (MDCIA); dysferlinopathy (LGMD2B and Miyoshi myopathy); myotonic dystrophy; limb-girdle muscular dystrophy (LGMD) such as LGMD2C; and Facioscapulohumeral (FSHD).
As used herein, “patient,” “subject,” and “individual” are used interchangeably to include a mammalian (e.g., human) subject to be treated, diagnosed, and/or to obtain a biological sample from in the subject methods. Typically, the subject is affected or likely to be affected with DMD and the other related diseases described herein, and in some embodiments, DMD and associated cardiomyopathy and dystrophic cardiomyopathy. In a particular embodiment, a subject is a
human child or adolescent ( e.g ., no more than 18 years old, 15 years old, 12 years old, 10 years old, 8 years old, 5 years old, 3 years old, 1 year old, 6 months old, 3 months old, 1 month old, etc.). In a particular embodiment, the child or adolescent is male. In another particular embodiment, a subject is a human adult (e.g., >18 years old), such as a male adult.
The full-length dystrophin gene is 2.6 mb and encodes 79 exons. The 11.5-kb coding sequence translates into a 427-kD protein. Dystrophin can be divided into four major domains, including the N-terminal domain, rod domain, cysteine- rich domain, and C-terminal domain.
The rod domain can be further divided into 24 spectrin-like repeats and four hinges.
A functional “dystrophin minigene” or “dystrophin microgene” has less than 24 spectrin- like repeats and one or more hinge region/s compatible with gene therapy delivery vectors (adenoviral and lentiviral) and have been described in US7001761, US6869777, US8501920, US7892824, US10479821, and US10166272 (all incorporated herein by reference).
In one embodiment, the muscular dystrophy is DMD or BMD, and in the recombinant AAV (rAAV) vector: a) the polynucleotide is a dystrophin minigene encoding a functional 5- spectrin-like repeat dystrophin protein (such as the microD5 dystrophin protein as described in US 10,479,821, incorporated herein by reference); and/or, b) the muscle-specific control element is a CK promoter operably linked to and drives the expression of the dystrophin minigene.
As used herein, “microD5,” “microdystrophin minigene encoded by SGT-001,” or “SGT- 001” for short, refers to a specific engineered 5 -repeat microdystrophin protein that contains, from N- to C-terminus, the N-terminal actin binding domain, Hinge region 1 (HI), spectrin-like repeats Rl, R16, R17, R23, and R24, Hinge region 4 (H4), and the C-terminal dystroglycan binding domain of the human full-length dystrophin protein. The protein sequence of this 5- repeat microdystrophin and the related dystrophin minigene are described in US10,479,821 & WO2016/115543 (incorporated herein by reference).
In certain embodiments, the dystrophin minigene encoding a functional dystrophin protein different from microD5 with respect to, for example, the specific spectrin-like repeats, and/or the number of spectrin-like repeats (e.g., comprising a minimum of 4, 5, or 6 spectrin-like repeats of the human dystrophin, preferably including 1, 2, or 3 most N- and/or most C-terminal repeats). One or more spectrin-like repeats of the human dystrophin may also be substituted by spectrin-like repeats from utrophin or spectrin. In certain embodiments, the dystrophin minigene
is smaller than the 5 kb packaging limit of AAV viral vectors, preferably no more than 4.9 kb,
4.8 kb, 4.6 kb, 4.5 kb, 4.4 kb, 4.3 kb, 4.2 kb, 4.1 kb, or 4 kb.
In certain embodiments, the dystrophin minigene encodes a micro-dystrophin protein that is, e.g., at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or 99% sequence identity to microD5, wherein the protein retains micro-dystrophin activity.
In certain embodiments, the micro-dystrophin is encoded by a nucleotide sequence that has at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%,
87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or 99% sequence identity to a polynucleotide sequence encoding the microD micro-dystrophin. The polynucleotide is optionally codon optimized for expression in a mammal, such as in a human.
In certain embodiments, the nucleotide sequence hybridizes under stringent conditions to the nucleic acid sequence encoding the microD5 micro-dystrophin, or compliments thereof, and encodes a functional micro-dystrophin protein.
The term “stringent” is used to refer to conditions that are commonly understood in the art as stringent. Hybridization stringency is principally determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of stringent conditions for hybridization and washing are 0.015 M sodium chloride, 0.0015 M sodium citrate at 65-68°C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at 42°C. See Sambrook el ah, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, N.Y. 1989).
More stringent conditions (such as higher temperature, lower ionic strength, higher formamide, or other denaturing agent) may also be used, however, the rate of hybridization will be affected. In instances wherein hybridization of deoxyoligonucleotides is concerned, additional exemplary stringent hybridization conditions include washing in 6* SSC 0.05% sodium pyrophosphate at 37°C (for 14-base oligoes), 48°C (for 17-base oligos), 55°C (for 20- base oligos), and 60°C (for 23-base oligos).
Other agents may be included in the hybridization and washing buffers for the purpose of
reducing non-specific and/or background hybridization. Examples are 0.1% bovine serum albumin, 0.1% polyvinyl -pyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecylsulfate, NaDodS04, (SDS), ficoll, Denhardf s solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, although other suitable agents can also be used. The concentration and types of these additives can be changed without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are usually carried out at pH 6.8-7.4, however, at typical ionic strength conditions, the rate of hybridization is nearly independent of pH. See Anderson el al. , Nucleic Acid Hybridisation: A Practical Approach, Ch. 4, IRL Press Limited (Oxford, England). Hybridization conditions can be adjusted by one skilled in the art in order to accommodate these variables and allow DNAs of different sequence relatedness to form hybrids.
Additional dystrophin minigene sequences can be found in, for example,
US2017/0368198 (incorporated herein by reference), and SEQ ID NO: 7 of WO 2017/181015 (incorporated herein by reference).
In certain embodiments, the nucleotide sequence encoding any dystrophin minigene such as microD5 can be any one based on the disclosed protein sequence. Preferably, the nucleotide sequence is codon optimized for expression in human.
The micro-dystrophin protein provides stability to the muscle membrane during muscle contraction, e.g., micro-dystrophin acts as a shock absorber during muscle contraction.
In certain embodiments, at least one of the one or more coding sequences target one of the secondary cascade genes in DMD.
For example, in certain embodiments, at least one of the one or more coding sequences encodes a microRNA, such as miR-1, miR-133a, miR-29 particularly miR29c, miR-30c, and/or miR-206. For example, miR-29c directly reduce the three primary components of connective tissue (e.g., collagen 1, collagen 3 and fibronectin) to reduce fibrosis. Optionally, in certain embodiments, said microRNA, such as miR-1, miR-133a, miR-29 particularly miR29c, miR-30c, and/or miR-206, has a modified flanking backbone sequence that enhances the processing of the guide strand designed for a target sequence. In certain embodiments, the modified flanking backbone sequence can be from or based on miR-30, -101, -155, or -451.
“Fibrosis” as used herein refers to the excessive or unregulated deposition of extracellular
matrix (ECM) components and abnormal repair processes in tissues upon injury including skeletal muscle, cardiac muscle, liver, lung, kidney, and pancreas. The ECM components that are deposited include fibronectin and collagen, e.g., collagen 1, collagen 2 or collagen 3.
As used herein, “miR-29” refers to one of miR-29a, -29b, or -29c. In certain embodiments, miR-29 refers to miR-29c.
While not wishing to be bound by any particular theory, it is believed that the expressed miR29 (such as miR-29a, miR-29b, or miR-29c) binds to the 3 ’ UTR of the collagen and fibronectin genes to down-regulate expression of these target genes.
In another embodiment, at least one of the one or more coding sequences encodes an RNAi sequence, such as an shRNA against sarcolipin (shSLN). The one or more coding sequences may encode identical or different shRNAs against sarcolipin (shSLN). In certain embodiments, the shRNA reduces sarcolipin mRNA and/or sarcolipin protein expression by at least about 50%.
As used herein, “sarcolipin (SLN),” “sarcolipin protein,” “SLN protein,” “sarcolipin polypeptide” and “SLN polypeptide” are used interchangeably to include an expression product of a SLN gene, such as the native human SLN protein having the amino acid sequence of (MGINTRELLLNLTIVLITVTLMWLLVRSYGY) (SEQ ID NO: 5), accession number NP 003054.1. The term preferably refers to the human SLN. The term may also be used to refer to a variant SLN protein that differs from SEQ ID NO: 5 by 1 amino acid, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, or 8 amino acids, optionally the differences are within residues 2-5, 10, 14, 17, 20, and 30, preferably 2-5 and 30. The term may also be used to refer to a variant SLN protein that are identical to SEQ ID NO: 5 at residues 6-29, or differ in residues 6-29 by up to 1 , 2, or 3 conservative substitutions such as L- I and/or I- V. Optionally, the variant SLN has a G30Q substitution. The variants displays a functional activity of a native SLN protein, which may include: phosphorylation, dephosphorylation, nitrosylation and/or ubiquitination of SLN, or binding to a SERCA and/or reduce the rate of calcium import by SERCA into the sarcoendoplasmic reticulum through, for example, uncoupling of Ca2+ transport from ATP hydrolysis, or its role in energy metabolism and regulation of weight gain.
As used herein, “SLN gene,” “SLN polynucleotide,” and “SLN nucleic acid” are used
interchangeably to include a native human SLN-encoding nucleic acid sequence, e.g., the native human SLN gene (RefSeq Accession: NM_003063.2), a nucleic acid having sequences from which a SLN cDNA can be transcribed; and/or allelic variants and homologs of the foregoing, such as a polynucleotide encoding any of the variant SLN described herein. The terms encompass double-stranded DNA, single-stranded DNA, and RNA.
In another embodiment, the one or more additional coding sequences of the subject vector may be targeting any other genes associated with one of the secondary cascade events resulting from the loss of dystrophin gene, such as inflammatory gene, an activator of NF-KB signaling pathway (e.g., TNF-a, IL-1, IL-Ib, IL-6, Receptor activator of NF-KB (RANK), and Toll-like receptors (TLRs)), NF-KB, a downstream inflammatory cytokine induced by NF-KB, a histone deacetylase (e.g., HDAC2), TGF-b, connective tissue growth factor (CTGF), ollagens, elastin, a structural component of the extracellular matrix, Glucose-6-phosphate dehydrogenase (G6PD), myostatin, phosphodiesterase-5 (PED-5) or ACE, VEGF decoy-receptor type 1 (VEGFR-l or Flt-1), and hematopoietic prostaglandin D synthase (HPGDS). The one or more additional coding sequences can be an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, and/or a microRNA that antagonizes the function of the above target genes.
The design of the subject recombinant vectors can simultaneously target one or more (e.g., 1, 2, 3, 4, 5) such secondary cascade genes or pathways, such as SLN, microRNA, etc.
For example, in certain embodiments, one of the additional coding sequence of the subject vector may be an RNAi sequence (siRNA, shRNA, miRNA) or an antisense sequence designed to down-regulate SLN expression, hence at least partially alleviate the secondary defect of abnormal elevation of intracellular Ca2+ in dystrophy muscle by increasing the reuptake of calcium by SERCA.
In certain alternative embodiments, instead of or in addition to targeting one of the secondary cascade genes, at least one of the one or more coding sequences may be an exon skipping antisense sequence that induces skipping of an exon of a defective endogenous dystrophin, such as any one of exons 45-55 of dystrophin, or exon 44, 45, 51, and/or 53 of dystrophin, thus further enhancing the therapeutic effect of the dystrophin minigene (e.g., microD5).
As used herein, an “exon skipping” or “splice-switching” antisense oligonucleotide
(AON) is a type of antisense sequence that is RNase-H-resistant, and acts to modulate pre- mRNA splicing and correct splicing defects in the pre-mRNA. In antisense-mediated exon skipping therapy, AONs are usually used to block specific splicing signals and induce specific skipping of certain exons. This leads to the correction of the reading frame of a mutated transcript, such that it can be translated into an internally deleted but partially functional protein.
In a specific aspect, the invention provides a recombinant AAV (rAAV) vector encoding both a dystrophin minigene coding sequence (such as microD5 / SGT-001), and one or more additional sequences for targeting one or more additional target genes involved in a secondary cascade resulting from loss of dystrophin function. Such construct comprises both a dystrophin minigene, and one or more additional coding sequences inserted between the first control element or promoter of the dystrophin minigene and the nearest viral terminal sequence (e.g., ITR in AAV) and operably linked to a second control element, and (2) optionally further inserted into heterologous intron 5’ to the dystrophin minigene or 3’-UTR region of the dystrophin minigene.
Specifically, in one aspect, the invention provides a recombinant AAV (rAAV) vector comprising: a) a dystrophin minigene encoding a functional micro-dystrophin protein, wherein said dystrophin minigene comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the dystrophin minigene; b) a muscle- specific control element operably linked to and drives the expression of the dystrophin minigene; and, c) one or more (e.g., 1, 2, 3, 4, or 5) coding sequence(s) inserted between the muscle- specific control element and the nearest AAV ITR sequence and operably linked to a second control element, and (2) optionally further inserted into the intron sequence or in the 3’-UTR coding region; wherein said one or more coding sequence(s) independently encode(s): an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a microRNA (miRNA), and/or a miRNA inhibitor.
For example, the rAAV vector may comprise a polynucleotide sequence expressing miR- 29 (e.g., miR-29c), such as a nucleotide sequence comprising the miR-29c target guide strand ( ACCGATTT C AAAT GGT GCT AGA, SEQ ID NO: 3 of W02017/181015 or , incorporated herein by reference), the miR-29c guide strand (TCTAGCACCATTTGAAATCGGTTA, SEQ ID NO: 4 of W02017/181015, incorporated herein by reference) and the natural miR-30 back bone and stem loop (GTGAAGCCACAGATG, SEQ ID NO: 5 of W02017/181015,
incorporated herein by reference).
An exemplary polynucleotide sequence comprising the miR-29c cDNA in a miR-30 backbone is set out as SEQ ID NO: 2 and FIG. 1 of W02017/181015 (incorporated herein by reference).
In certain embodiments, the microRNA-29 coding sequence encodes miR-29c.
In certain embodiments, miR-29c optionally has a modified flanking backbone sequence that enhances the processing of the guide strand of miR-29c designed for a target sequence. For example, the modified flanking backbone sequence can be from or based on that of miR-30 (miR-30E), -101, -155, or -451.
In certain embodiments, the microRNA is miR-1, miR-133a, miR-30c, and/or miR-206.
In certain embodiments, expression of said microRNA in a host cell is up-regulated by at least about 1.5-15 fold ( e.g ., about 2-10 fold, about 1.4-2.8 fold, about 2-5 fold, about 5-10 fold, about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or about 15 fold) compared to endogenous expression of said microRNA in said host cell.
In certain embodiments, the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of sarcobpin (SEN). In certain embodiments, the vector of the invention encodes an shRNA that antagonizes the function of sarcobpin (shSLN). Exemplary shSLN sequences include those disclosed in FIGs. 9 and 10 of PCT/US2019/065718, filed on December 11, 2019 (e.g., the underlined sequences in FIG. 9, and the highlighted sequences in FIG. 10). Additional exemplary shSFN sequences include SEQ ID NOs: 7-11 disclosed in WO2018/136880 (incorporated herein by reference).
The invention is also partly directed to gene therapy vectors, e.g., lentiviral or AAV expressing the one or more coding sequence(s), and the dystrophin minigene, as well as methods of delivering the same to the muscle to reduce and/or prevent a secondary cascade symptom while restoring dystrophin function.
In one embodiment, the muscular dystrophy is a congenital muscular dystrophy (CMD) associated with a known genetic defect, such as the fukutin gene or the FKRP (fukutin related protein) gene. Thus in certain embodiments, the congenital muscular dystrophy is Fukuyama congenital muscular dystrophy (FCMD).
Congenital Muscular Dystrophy (CMD) is a group of muscular dystrophies that become apparent at or near birth. In certain embodiments, the methods and rAAV of the invention can be used to treat CMD, especially CMD with known genetic defect in genes such as titin (CMD with cardiomyopathy); SEPN1 (CMD with desmin inclusions, or CMD with (early) spinal rigidity); integrin-alpha 7 (CMD with integrin alpha 7 mutations); integrin-alpha 9 (CMD with joint hyperlaxity); plectin (CMD with familial junctional epidermolysis bullosa); fukutin (Fukuyama CMD or MDDGA4); fukutin-related protein (FKRP) (CMD with muscle hypertrophy or MDCIC); FARGE (MDCID); DOK7 (CMD with myasthenic syndrome); lamin A/C (CMD with spinal rigidity and lamin A/C abnormality); SBP2 (CMD with spinal rigidity and selenoprotein deficiency); choline kinase beta (CMD with structural abnormalities of mitochondria); laminin alpha 2 (Merosin-deficient CMD or MDCl A); POMGnTl (Santavuori muscle-eye-brain disease); COFGA1, COF6A2, or COF6A3 (Ullrich CMD); B3GNT1 (Walker- Warburg syndrome: MDDGA type); POMT1 (Walker-Warburg syndrome: MDDGAl type); POMT2 (Walker-Warburg syndrome: MDDGA2 type); ISPD (MDDGA3, MDDGA4, MDDGB5, MDDGA6, and MDDGA7); GTDC2 (MDDGA8); TMEM5 (MDDGAl 0); B3GAFNT2 (MDDGAl 1); or SGK196 (MDDGAl 2).
Thus the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding any of the wild-type genes defective in the CMD (such as the ones listed herein above), or a functional equivalent thereof, to treat the CMD in a subject in need thereof. The one or more additional coding sequences may encode an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, or a microRNA (miRNA) that eliminates or modifies the mutant CMD gene, or a secondary cascade gene up-regulated due to the loss of the wild-type gene function.
For example, Fukuyama congenital muscular dystrophy (FCMD) is due to a mutant FKTN gene, and the one or more additional coding sequences may encode an exon-skipping antisense oligonucleotide to restore correct exon 10 splicing in the defective FKTN gene in the patient.
In another example, the congenital muscular dystrophy is Merosin-deficient congenital muscular dystrophy type 1A (MDCl A) caused by mutations in the 65-exon FAMA2 gene.
Thus the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding a functional FAMA2 protein. The one or more additional coding sequences may encode an exon-skipping antisense sequence leading to the restored expression of the C-terminal
G-domain (exons 45-64), particularly G4 and G5 of LAMA2 that are most important for mediating interaction with a-dystroglycan. For example, exon 4 of the mutant LAMA2 gene may be skipped to treat MDC1 A.
In one embodiment, the muscular dystrophy is myotonic dystrophy (DM), such as DM1 or DM2.
Thus the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding a functional Dystrophia Myotonica Protein Kinase (DMPK) protein defective in DM1, or a functional CCHC-type zinc finger, nucleic acid binding protein gene (CNBP) protein in DM2. The one or more additional coding sequences may encode an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, or a microRNA (miRNA) that can be used to target expanded repeats of mutant transcripts in the DMPK gene or the CNBP gene for RNase- mediated degradation. The one or more additional coding sequences may also encode an exon skipping antisense sequence leading to the skipping of exon 7A in CLCN1 gene in a DM1 patient.
In one embodiment, the muscular dystrophy is Dysferlinopathy caused by mutations in the dysferlin (DYSF) gene, including limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM).
Thus the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding a functional DYSF protein defective in LGMD2B or MM. The one or more additional coding sequences may encode an exon-skipping antisense sequence leading to the skipping of exon 32 in a defective DYSF gene in a dysferlinopathy patient.
In one embodiment, the muscular dystrophy is limb-girdle muscular dystrophy (LGMD) caused by mutations in any of the four sarcoglycans genes, namely a (LGMD2D), b (LGMD2E), g (LGMD2C) and d (LGMD2F) gene, particularly the g sarcoglycan (LGMD2C) encoded by the SGCG gene.
Thus the lentiviral or rAAV vector of the invention may comprise a polynucleotide encoding a functional sarcoglycan protein defective in a LGMD, such as the SGCG gene defective in LGMD2C. The one or more additional coding sequences may encode an exon skipping antisense sequence leading to the skipping of exons 4-7 in a defective LGMD2C gene, such as one with the A-521T SGCG mutation.
In one embodiment, the muscular dystrophy is Facioscapulohumeral muscular dystrophy (FSHD) caused by mutations in the DUX4 gene.
Thus the one or more additional coding sequences may encode an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, or a microRNA (miRNA) that reduces the expression of DUX4 or a downstream target such as PITX1.
In certain embodiments, the one or more additional coding sequences encode an exon skipping antisense sequence that targets 3’-UTR of DUX4 to reduce its expression. This is because the DUX4 coding sequence is entirely located in the gene first exon, and exon skipping that targets elements in the mRNA 3 ’ UTR can either disrupt the permissive polyadenylation or interfere with intron 1 or 2 splicing, hence destroying a functional DUX4 mRNA.
Facioscapulohumeral muscular dystrophy (FSHD) is an inherited autosomal dominant disorder characterized clinically by progressive muscle degeneration. It is the third most common muscular dystrophy after Duchenne muscular dystrophy (DMD) and myotonic dystrophy. FSHD is genetically characterized by a pathogenic contraction of a subset of macrosatellite repeats on chromosome 4, leading to aberrant expression of the double homeobox protein 4 (DUX4) gene.
There are two types of FSHD: FSHDl and FSHD2. FSHDl is the most common form that occurs in over 95% of all FSHD patients. Genetic analysis links FSHD 1 to the genetic contraction of macrosatellite D4Z4 repeat array on chromosome 4. FSHD2, on the other hand, has a normal number of D4Z4 repeats but instead involves a heterozygous mutation in the SMCHD1 gene on chromosome 18p, a chromatin modifier. Patients with FSHDl and FSHD2 share similar clinical presentations.
Current drug therapy does not cure FSHD, but focus on the management of FSHD symptoms, including myostatin inhibitor luspatercept and anti-inflammatory biologies (ATYR1940). The basis for anti-inflammatory biologies is to suppress inflammation commonly seen in muscle pathology of FSHD patients in order to slow phenotype progression. Thus the subject one or more coding sequences may encode an RNAi reagent or antisense RNA against myostatin or an inflammatory pathway gene. Meanwhile, the RNAi reagent such as small interfering RNA (siRNA) and small hairpin RNA (shRNA), or microRNA (miRNA), or antisense oligonucleotides, can be used to knockdown expression of the myopathic DUX4 gene
and its downstream molecules including paired-like homeodomain transcription factor 1 (PITX1). Indeed, in vitro studies have demonstrated success in the suppression of DUX4 mRNA expression by administering antisense oligoes into primary skeletal muscle cells of FSHD patients, and by using miRNA against DUX4 delivered to a DUX4 mouse model using AAV vector. In addition, success in the suppression of PITX1 expression has already been demonstrated systemically in vivo.
In certain embodiments, the one or more additional coding sequences can encode the same sequence ( e.g ., siRNA, shRNA, miRNA, or antisense), and thus the copy number of the additional coding sequence may be regulated or fine tuned for dosing consideration.
In certain embodiments, the one or more additional coding sequences can encode different sequences, either targeting different targets, or targeting the same target. For example, in certain embodiments, one additional coding sequence is an antisense against a target, while another additional coding sequence is an shRNA against the same target. Alternatively, two additional coding sequences are both shRNAs but they target different regions of the same target.
In certain embodiments, expression of the functional protein, such as the dystrophin minigene product, is not negatively affected by the insertion of the one or more coding sequence(s).
By early 1990s, it has been found that many intronless transgenes, while express perfectly in tissue culture cells in vitro , fail to express the same transgene in vivo (e.g., in transgenic mice harboring the transgene), while inserting certain heterologous intron sequences between the promoter and the (intronless) coding sequence of the transgene greatly enhances transgene expression in vivo.
In particular, Palmiter etal. (Proc. Natl. Acad. Sci. U.S.A. 88:478-482, 1991, incorporated herein by reference) showed that several heterologous introns inserted between the metallothionein promoter and the growth hormone transgene improves transgene expression, and provided addition of certain heterologous introns as a general strategy for improving transgene expression. These include heterologous introns selected from: the natural first intron of rGH, intron A of the rat insulin II (rlns-II) gene, intron B of the IibO gene, and the SV40 small t intron.
A similar finding was confirmed by Choi etal. (Mol. Cell. Biol. 11 (6): 3070-3074, 1991, incorporated herein by reference), who reported that in transgenic mice carrying the human
histone H4 promoter linked to the bacterial gene for chloramphenicol acetyltransferase (CAT), the presence of a 230-bp heterologous hybrid intron in the transcription unit greatly enhanced CAT activity (by 5- to 300-fold, compared to an analogous transgene precisely deleted for the intervening sequences). This hybrid intron, consisting of an adenovirus splice donor and an immunoglobulin G splice acceptor, stimulated expression in a broad range of tissues in the animal. Since the hybrid intron stimulated the expression of tissue plasminogen activator and factor VIII in tissue culture, Choi concluded that the enhancement seen in mice is unlikely to be specific to CAT and instead is generally applicable to the expression of any cDNAs in transgenic mice.
Thus in certain embodiment, the heterologous intron in the subject lentiviral or rAAV vector is selected from the group consisting of: the natural first intron of rGH, intron A of the rat insulin II (rlns-II) gene, intron B of the IibO gene, the SV40 small t intron, and the hybrid intron of Choi.
In certain embodiments, the heterologous intron sequence is SEQ ID NO: 1:
GTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAG AGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCT CCACAG.
In certain embodiments, in addition to being inserted into the divergent cassette (e.g., between the GOI promoter and the nearest AAV ITR), the one or more additional coding sequences are all inserted into the heterologous intron sequence (SEQ ID NO: 1), or all inserted into the 3’-UTR region, or are inserted into both regions. For example, the microRNA-29c coding sequence can be inserted into the intron coding sequence as in SEQ ID NO: 2 GTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGATCTC TTACACAGGCTGACCGATTTCTCCTGGTGTTCAGAGTCTGTTTTTGTCTAGCACCATTTGAAAT CGGTTATGATGTAGGGGGAAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGAC ATCCACTTTGCCTTTCTCTCCACAG.
The miR-29c sequence in SEQ ID NO: 2 is
ATCTCTTACACAGGCTGACCGATTTCTCCTGGTGTTCAGAGTCTGTTTTTGTCTAGCACCATTT GAAATCGGTTATGATGTAGGGGGA (SEQ ID NO: 3).
In certain embodiments, the lentiviral or rAAV further comprises two lentiviral or AAV
LTR/ITR sequences flanking the polynucleotide (such as the dystrophin minigene) and the additional coding sequence(s).
In certain embodiments, the GOI encoded by the lentiviral or rAAV vectors of the invention may be operably linked to a muscle-specific control element. For example, the muscle-specific control element can be: human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor MEF, muscle creatine kinase (MCK), tMCK (truncated MCK), myosin heavy chain (MHC), C5-12 (synthetic promoter), murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, slow-twitch troponin I gene element, hypozia-inducible nuclear factors, steroid-inducible element, or glucocorticoid response element (GRE).
In certain embodiments, muscle-specific control element is 5’ to the heterologous intron sequence, which is 5’ to the dystrophin minigene, which comprises a 3’-UTR region including a translation stop codon (such as TAG), a polyA adenylation signal (such as AATAAA), and an mRNA cleavage site (such as CA).
In certain embodiments, the muscle-specific control element comprises the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO: 11 of W02017/181015.
SEQ ID NO: 10 of W02017/181015:
CAGCCACTAT GGGTCTAGGC TGCCCATGTA AGGAGGCAAG GCCTGGGGAC ACCCGAGATG 60
CCTGGTTATA ATTAACCCAG ACATGTGGCT GCTCCCCCCC CCCAACACCT GCTGCCTGAG 120
CCTCACCCCC ACCCCGGTGC CTGGGTCTTA GGCTCTGTAC ACCATGGAGG AGAAGCTCGC 180
TCTAAAAATA ACCCTGTCCC TGGTGG 206
SEQ ID NO: 11 of W02017/181015:
GCTGTGGGGG ACTGAGGGCA GGCTGTAACA GGCTTGGGGG CCAGGGCTTA TACGTGCCTG 60
GGACTCCCAA AGTATTACTG TTCCATGTTC CCGGCGAAGG GCCAGCTGTC CCCCGCCAGC 120
TAGACTCAGC ACTTAGTTTA GGAACCAGTG AGCAAGTCAG CCCTTGGGGC AGCCCATACA 180
AGGCCATGGG GCTGGGCAAG CTGCACGCCT GGGTCCGGGG TGGGCACGGT GCCCGGGCAA 240
CGAGCTGAAA GCTCATCTGC TCTCAGGGGC CCCTCCCTGG GGACAGCCCC TCCTGGCTAG 300
TCACACCCTG TAGGCTCCTC TATATAACCC AGGGGCACAG GGGCTGCCCC CGGGTCAC 358
In certain embodiments, the rAAV vectors of the invention can be operably linked to the muscle-specific control element comprising the MCK enhancer nucleotide sequence (see SEQ ID NO: 10 of W02017/181015, incorporated herein by reference) and/or the MCK promoter
sequence (see SEQ ID NO: 11 of W02017/181015, incorporated herein by reference).
In certain embodiments, the rAAV further comprises a promoter operably linked to and is capable of driving the transcription of the dystrophin minigene and the additional coding sequence.
An exemplary promoter is the CMV promoter.
In certain embodiments, the rAAV further comprises a poly-A adenylation sequence for inserting a polyA sequence into a transcribed mRNA.
In certain embodiments, the rAAV vectors of the invention are of the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV 12 or AAV13.
Another aspect of the invention provides a method of producing a viral vector, e.g., rAAV vector of the invention, comprising culturing a cell that has been transfected with any viral vector, e.g., rAAV vector of the invention and recovering the virus, e.g, rAAV particles from the supernatant of the transfected cells.
Another aspect of the invention provides viral particles comprising any of the viral vector, e.g., recombinant AAV vectors of the invention.
Another aspect of the invention provides methods of producing a functional protein either defective in a muscular dystrophy, or effective to treat the muscular dystrophy (such as a micro dystrophin protein), and one or more additional coding sequence(s), comprising infecting a host cell with a subject recombinant AAV vector co-expressing the functional protein (e.g., micro dystrophin) of the invention and the coding sequence product (e.g., RNAi, siRNA, shRNA, miRNA, antisense, microRNA or inhibitor thereof) in the host cell.
Another aspect of the invention provides methods of treating a muscular dystrophy (such as DMD or BMD) or dystrophinopathy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a viral vector, e.g., recombinant AAV vector of the invention, or a composition of the invention.
The invention contemplates administering any of the viral vector, e.g., AAV vectors of the invention to patients diagnosed with dystrophinopathy or muscular dystrophy, such as DMD or BMD or any other MD, particularly defective dystrophin-associated muscular dystrophy, preferably before one or more secondary cascade symptoms such as fibrosis is observed in the
subject, or before the muscle force has been reduced in the subject, or before the muscle mass has been reduced in the subject.
The invention also contemplates administering any of the viral vector, e.g., rAAV of the invention to a subject suffering from dystrophinopathy or muscular dystrophy, such as DMD or BMD or any other MD, particularly dystrophin-associated muscular dystrophy, who already has developed one or more secondary cascade symptoms such as fibrosis, in order to prevent or slow down further disease progression in these subjects.
Another aspect of the invention provides recombinant viral vector, e.g., AAV vectors comprising a nucleotide sequence encoding a functional protein either defective in a muscular dystrophy, or effective to treat the muscular dystrophy (e.g, a micro-dystrophin protein) and the one or more additional coding sequences.
In certain embodiments, the invention provides for a rAAV comprising a nucleotide sequence having at least 85%, 90%, 95%, 97%, or 99% identity to the nucleotide sequence that encodes a functional micro-dystrophin protein such as microD5.
The viral vector, e.g., rAAV vector may comprise a muscle-specific promoter, such as the MCK promoter, a heterologous intron sequence effective to enhance the expression of the dystrophin gene, the coding sequence for the micro-dystrophin gene, polyA adenylation signal sequence, the ITR/LTR repeats flanking these sequences. The viral vector, e.g., rAAV vector may optionally further comprises ampicillin resistance and plasmid backbone sequences or pBR322 origin or replication for amplification in a bacteria host.
In one aspect, the recombinant AAV vectors of the invention are AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV 11 , AAV 12 or AAV 13.
In any of the methods of the invention, the rAAV vector can be administered by intramuscular injection or intravenous injection.
In any of the methods of the invention, the viral vector, e.g., rAAV vector or composition is administered systemically. For examples, the viral vector, e.g., rAAV vector or composition is parentally administration by injection, infusion or implantation.
Another aspect of the invention provides a composition, such as a pharmaceutical composition, comprising any of the viral vector, e.g., rAAV vectors of the invention.
In certain embodiments, the composition is a pharmaceutical composition, which may
further comprise a therapeutically compatible carrier or excipient.
In another embodiment, the invention provides for composition comprising any of the viral vector, e.g., rAAV vectors co-expressing the subject functional protein (e.g., micro dystrophin) and said one or more additional coding sequences for treating a subject suffering from dystrophinopathy or a muscular dystrophy, such as DMD or Becker Muscular dystrophy.
The compositions (e.g., pharmaceutical compositions) of the invention can be formulated for intramuscular injection or intravenous injection. The composition of the invention can also be formulated for systemic administration, such as parentally administration by injection, infusion or implantation. In addition, any of the compositions are formulated for administration to a subject suffering from dystrophinopathy or a muscular dystrophy, such as DMD, Becker muscular dystrophy or any other dystrophin associated muscular dystrophy.
In a further embodiment, the invention provides for use of any of the viral vector, e.g., rAAV vectors of the invention co-expressing a subject functional protein (e.g., a micro dystrophin) and said one or more additional coding sequences for preparation of a medicament for reducing the subject suffering from dystrophinopathy or muscular dystrophy, such as DMD, Becker muscular dystrophy or any other dystrophin associated muscular dystrophy.
The invention contemplates use of the any of the viral vector, e.g., AAV vectors of the invention for the preparation of a medicament for administration to a patient diagnosed with DMD before one or more secondary cascade symptoms such as fibrosis is observed in the subject.
The invention also contemplates use of any of the viral vector, e.g., AAV vectors of the invention for the preparation of a medicament for administering any of the viral vector, e.g., rAAV of the invention to a subject suffering from muscular dystrophy who already has developed a secondary cascade symptom such as fibrosis, in order to prevent or delay disease progression in these subjects.
The invention also provides for use of the viral vector, e.g., rAAV vectors of the invention co-expressing a subject functional protein such as a micro-dystrophin, and said one or more additional coding sequences for the preparation of a medicament for treatment of a muscular dystrophy, such as DMD / BMD.
In any of the uses of the invention, the medicament can be formulated for intramuscular
injection. In addition, any of the medicaments may be prepared for administration to a subject suffering from muscular dystrophy such as DMD or any other dystrophin associated muscular dystrophy.
The present invention also provides for gene therapy vectors, e.g., rAAV vectors that co express a subject functional protein (e.g., a micro-dystrophin) and said one or more additional coding sequences in a muscular dystrophy patient.
It should be understand that any one embodiment of the invention described herein can be combined with any one or more additional embodiments of the invention, including those embodiments described only in the examples or only described in one of the sections above or below, or one aspect of the invention.
AAV
As used herein, the term “AAV” is a standard abbreviation for adeno-associated virus. Adeno-associated virus is a single-stranded DNA parvovirus that grows only in cells in which certain functions are provided by a co-infecting helper virus. There are at least thirteen serotypes of AAV that have been characterized. General information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228, and Berns, 1990, Virology, pp. 1743- 1764, Raven Press, (New York) (incorporated herein by reference).
However, it is fully expected that these same principles will be applicable to additional AAV serotypes since it is well known that the various serotypes are quite closely related, both structurally and functionally, even at the genetic level. See, for example, Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, J. R. Pattison, ed.; and Rose, Comprehensive Virology 3: 1-61 (1974). For example, all AAV serotypes apparently exhibit very similar replication properties mediated by homologous rep genes; and all bear three related capsid proteins such as those expressed in AAV2. The degree of relatedness is further suggested by heteroduplex analysis which reveals extensive cross-hybridization between serotypes along the length of the genome; and the presence of analogous self-annealing segments at the termini that correspond to “inverted terminal repeat sequences” (ITRs). The similar infectivity patterns also suggest that the replication functions in each serotype are under similar regulatory control.
An “AAV vector” as used herein refers to a vector comprising one or more polynucleotides of interest (or transgenes) that are flanked by AAV terminal repeat sequences
(ITRs). Such AAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been transfected with a vector encoding and expressing rep and cap gene products.
An “AAV virion” or “AAV viral particle” or “AAV vector particle” refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. If the particle comprises a heterologous polynucleotide (i.e., a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell), it is typically referred to as an “AAV vector particle” or simply an “AAV vector.” Thus, production of AAV vector particle necessarily includes production of AAV vector, as such a vector is contained within an AAV vector particle.
Recombinant AAV genomes of the invention comprise nucleic acid molecule of the invention and one or more AAV ITRs flanking a nucleic acid molecule.
There are multiple serotypes of AAV, and the nucleotide sequences of the genomes of the AAV serotypes are known. For example, the nucleotide sequence of the AAV serotype 2 (AAV2) genome is presented in Srivastava etal, J Virol 45:555-564 (1983) as corrected by Ruffing etal, J Gen Virol 75:3385-3392 (1994). Both incorporated herein by reference. As other examples, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077 (incorporated herein by reference); the complete genome of AAV-3 is provided in GenBank Accession No. NC 001829 (incorporated herein by reference); the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829 (incorporated herein by reference); the AAV-5 genome is provided in GenBank Accession No. AF085716 (incorporated herein by reference); the complete genome of AAV-6 is provided in GenBank Accession No. NC_001862 (incorporated herein by reference); at least portions of AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 (incorporated herein by reference) and AX753249 (incorporated herein by reference), respectively (see also U.S. Patent Nos. 7,282,199 and 7,790,449 relating to AAV-8); the AAV-9 genome is provided in Gao et ah, J. Virol 78:6381-6388 (2004), incorporated herein by reference; the AAV-10 genome is provided in Mol. Ther. 13(l):67-76 (2006), incorporated herein by reference; and the AAV-11 genome is provided in Virology 330(2):375-383 (2004), incorporated herein by reference. The AAVrh74 serotype is described in Rodino-Klapac et ah, J. Trans. Med. 5:45 (2007), incorporated herein by reference.
AAV DNA in the rAAV genomes may be from any AAV serotype for which a
recombinant virus can be derived including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV- 9, AAV-10, AAV-11, AAV-12, AAV-13, RhlO, Rh74, and AAV-2i8.
Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692 which is incorporated by reference herein in its entirety.
Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014). The nucleotide sequences of the genomes of various AAV serotypes are known in the art.
In certain embodiments, to promote skeletal muscle specific expression, AAV1, AAV6, AAV8 or AAVrh.74 may be used.
In certain embodiments, the AAV serotype of the subject AAV vector is AAV9.
( V.s-acting sequences directing viral DNA replication (rep), encapsidation/packaging and host cell chromosome integration are contained within the ITRs. Three AAV promoters (named p5, pi 9, and p40 for their relative map locations) drive the expression of the two AAV internal open reading frames encoding rep and cap genes.
The two rep promoters (p5 and pi 9), coupled with the differential splicing of the single AAV intron (e.g., at AAV2 nucleotides 2107 and 2227), result in the production of four rep proteins (rep 78, rep 68, rep 52, and rep 40) from the rep gene. Rep proteins possess multiple enzymatic properties that are ultimately responsible for replicating the viral genome.
The cap gene is expressed from the p40 promoter and it encodes the three capsid proteins VP1, VP2, and VP3. Alternative splicing and non-consensus translational start sites are responsible for the production of the three related capsid proteins.
A single consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, Current Topics in Microbiology and Immunology 158:97-129 (1992).
DNA plasmids of the invention comprise rAAV genomes of the invention. The DNA plasmids are transferred to cells permissible for infection with a helper virus of AAV (e.g., adenovirus, El-deleted adenovirus or herpes virus) for assembly of the rAAV genome into infectious viral particles. Techniques to produce rAAV particles, in which an AAV genome to be packaged, rep and cap genes, and helper virus functions are provided to a cell, are standard in
the art. Production of rAAV requires that the following components are present within a single cell (denoted herein as a packaging cell): a rAAV genome, AAV rep and cap genes separate from (i.e., not in) the rAAV genome, and helper virus functions. The AAV rep and cap genes may be from any AAV serotype for which recombinant virus can be derived and may be from a different AAV serotype than the rAAV genome ITRs, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV- 7, AAVrh.74, AAV-8, AAV-9, AAV- 10, AAV-11, AAV- 12 and AAV-13.
A method of generating a packaging cell is to create a cell line that stably expresses all the necessary components for AAV particle production. For example, a plasmid (or multiple plasmids) comprising a rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell. AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al, Proc. Natl. Acad. Sci. U.S.A. 79:2077-2081, 1982), addition of synthetic linkers containing restriction endonuclease cleavage sites (Laughlin etal, Gene 23:65-73, 1983) or by direct, blunt-end ligation (Senapathy & Carter, J. Biol. Chem. 259:4661-4666, 1984). The packaging cell line is then infected with a helper virus such as adenovirus. The advantages of this method are that the cells are selectable and are suitable for large-scale production of rAAV.
Other examples of suitable methods employ adenovirus or baculovirus rather than plasmids to introduce rAAV genomes and/or rep and cap genes into packaging cells.
General principles of rAAV production are reviewed in, for example, Carter, Current Opinions in Biotechnology 1533-1539, 1992; and Muzyczka, Curr. Topics in Microbial and Immunol. 158:97-129, 1992). Various approaches are described in Ratschin etal., Mol. Cell. Biol. 4:2072, 1984; Hermonat etal., Proc. Natl. Acad. Sci. U.S.A. 81:6466, 1984; Tratschin e/ al., Mol. Cell. Biol. 5:3251, 1985; McLaughlin etal., J. Virol. 62: 1963, 1988; and Lebkowski et al, Mol. Cell. Biol. 7:349, 1988; Samulski etal, J. Virol. 63:3822-3828, 1989; U.S. Patent No. 5,173,414; WO 95/13365, and corresponding U.S. Patent No. 5,658,776; W095/13392; WO 96/17947; PCT/US98/18600; WO 97/09441 (PCT/US96/14423); WO 97/08298 (PCT/US96/13872); WO 97/21825 (PCT/US96/20777); WO 97/06243 (PCT/FR96/01064); WO 99/11764; Perrin etal, Vaccine 13:1244-1250, 1995; Paul etal, Human Gene Therapy 4:609- 615, 1993; Clark etal, Gene Therapy 3:1124-1132, 1996; U.S. Patent. No. 5,786,211; U.S.
Patent No. 5,871,982; and U.S. Patent. No. 6,258,595. The foregoing documents are hereby incorporated by reference in their entirety herein, with particular emphasis on those sections of the documents relating to rAAV production.
In certain embodiments, the AAV vectors of the invention are produced according to the method described in Adamson-Small et al. (Molecular Therapy - Methods & Clinical Development (2016) 3, 16031; doi:10.1038/mtm.2016.31, incorporated herein by reference), a scalable method for the production of high-titer and high quality adeno-associated type 9 vectors using the HSV platform. It is a complete herpes simplex virus (HSV)-based production and purification process capable of generating greater than 1 xlO14 rAAV9 vector genomes per 10- layer CellSTACK of HEK 293 producer cells, or greater than 1 105 vector genome per cell, in a final, fully purified product. This represents a 5- to 10-fold increase over transfection-based methods. In addition, rAAV vectors produced by this method demonstrated improved biological characteristics when compared to transfection-based production, including increased infectivity as shown by higher transducing unit-to-vector genome ratios and decreased total capsid protein amounts, shown by lower empty-to-full ratios. This method can also be readily adapted to large- scale good laboratory practice (GLP) and good manufacturing practice (GMP) production of rAAV9 vectors to enable preclinical and clinical studies and provide a platform to build on toward late-phases and commercial production. Although AAV9 was used in the study, this method is likely extendable to other serotypes and should bridge the gap between preclinical research, early phase clinical studies, and large-scale, worldwide development of gene therapy based-drugs for genetic diseases and disorders.
The invention thus provides packaging cells that produce infectious rAAV. In one embodiment, packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line). In another embodiment, packaging cells are cells that are not transformed cancer cells, such as low passage 293 cells (human fetal kidney cells transformed with El of adenovirus), MRC-5 cells (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).
Recombinant AAV (i.e., infectious encapsidated rAAV particles) of the invention comprise a rAAV genome. In exemplary embodiments, the genomes of both rAAV lack AAV rep and cap DNA, that is, there is no AAV rep or cap DNA between the ITRs of the genomes. Examples of rAAV that may be constructed to comprise the nucleic acid molecules of the
invention are set out in International Patent Application No. PCT/US2012/047999 (WO 2013/016352) incorporated by reference herein in its entirety.
The rAAV may be purified by methods standard in the art such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper virus are known in the art and include methods disclosed in, for example, Clark etal, Hum.
Gene Ther. 10(6):1031-1039, 1999; Schenpp and Clark, Methods Mol. Med. 69:427-443, 2002; U.S. Patent No. 6,566,118 and WO 98/09657.
Additional Coding Sequences
In addition to the coding sequence for a dystrophin protein, such as microD5, the recombinant vector of the invention also comprises one or more additional coding sequences for targeting gene(s) in one of the secondary complications / secondary cascades associated with or resulting from loss of dystrophin.
In certain embodiments, the vector of the invention encodes an exon-skipping antisense sequence that can correct specific dystrophin gene mutations.
For example, the exon-skipping antisense sequence induces skipping of specific exons during pre-messenger RNA (pre-mRNA) splicing of a defective dystrophin gene in the subject, resulting in restoration of the reading frame and partial production of an internally truncated protein, similar to the dystrophin protein expression seen in Becker muscular dystrophy.
In certain embodiments, the exon-skipping antisense sequence skips or splices out a frame-disrupting exon (mutated exon) and/or a neighboring exon to restore the correct transcriptional reading frame, and to produce a shorter but functional dystrophin protein.
In certain embodiments, the exon-skipping antisense sequence induces single exon skipping. In certain embodiments, the exon-skipping antisense sequence induces multiple exon skipping, such as skipping of one or more of, or all of exons 45-55 (i.e., native exons 44 is joined directly to exon 56). For example, 11 antisense sequences may be used together to skip all 11 exons including exons 45-55. A cocktail of 10 AONs was used in the mdx52 mouse model (with deletion of exon 52) to induce skipping of exon 45-51 and 53-55, thus restoring functional dystrophin expression.
In certain embodiments, the exon-skipping antisense sequence induces skipping of exon
51 in a dystrophin pre-mRNA. Successful skipping of exon 51 can in theory treat about 14% of all DMD patients.
In certain embodiments, the exon-skipping antisense sequence targets an exonic splice enhancer (ESE) site in exon 51 of dystrophin gene, thus causing a skip of exon 51 and producing a truncated but partially functional dystrophin protein.
In certain embodiments, the exon-skipping antisense sequence induces skipping of one or more of exons 44, 45, and 53.
In certain embodiments, the exon-skipping antisense sequence targets the same target sequence as that of casimersen (exon 45), NS-065/NCNP-01 or golodirsen (exon 53), or eteplirsen or Exondys 51 (exon 51).
In certain embodiments, the exon-skipping antisense sequence targets a cryptic splicing donor and/or acceptor site in the mutated FCMD/FKTN gene in a Fukuyama congenital muscular dystrophy (FCMD) patient to restore correct exon 10 splicing.
Fukuyama congenital muscular dystrophy (FCMD) is a rare autosomal recessive disease and the second prevalent form of childhood muscular dystrophy in Japan. The gene responsible for FCMD (FCMD, also known as FKTN) encodes the protein fukutin, which is a putative glycosyltransferase and glycosylates a-dystroglycan, a member of the dystrophin-associated glycoprotein complex (DAGC). The pathogenesis of FCMD is caused by an ancestral insertion of SINE-VNTR-Alu(SVA) retrotransposon into the 3 ’ -untranslated region (UTR) of the fukutin gene, leading to the activation of a new, cryptic splice donor in exon 10, and a new, cryptic splice acceptor in the SVA insertion site, thus inducing aberrant mRNA splicing between the cryptic donor and acceptor sites. The result is a premature truncation of exon 10 of FCMD. In FCMD patient cells and model mice in vivo, it has been shown that a cocktail of three vivo- PMOs targeting the cryptic splice modulating regions prevented pathogenic SVA exon trapping and restored normal FKTN protein levels and O-glycosylation of a-dystroglycan.
In certain embodiments, the antisense sequence targets a pathological expansion of 3- or 4-nucleotide repeats, such as a CTC triplet repeat in the 3 ’-UTR region of the DMPK gene in DM1 patients, or a CCTG repeat in the first intron of the CNBP gene in DM2 patients.
Myotonic dystrophy (DM) is the most common form of muscular dystrophy in adulthood. It is an autosomal dominant disease that can be categorized into myotonic dystrophy type 1
(DM1) and myotonic dystrophy type 2 (DM2). DM1 is caused by a pathological expansion of CTC triplet in 3’-UTR region of the Dystrophia Myotonica Protein Kinase (DMPK) gene, while DM2 is caused by a pathological expansion of CCTG tract in the first intron of the CCHC-type zinc finger, nucleic acid binding protein gene (CNBP). RNA gain-of-function toxicity, arising from transcribed RNA aggregates with expanded repeats, leads to aberrant splicing (spliceopathy). Aggregates of toxic RNA disrupt the function of alternative splicing regulators such as Muscleblind-like (MBNL) protein and CUG-binding protein 1 (CUGBP1), by sequestering and depleting the former within the nuclear RNA foci, and increasing the expression and phosphorylation of the latter in DM1. Alterations in the function of MBNL and CUGBP1 proteins lead to aberrant splicing in pre-mRNAs of target genes, namely insulin receptor (INSR), the muscle chloride channel (CLCN1), bridging integrator-1 (BIN1), and dystrophin (DMD), which are respectively associated with insulin resistance, myotonia, muscle weakness, and dystrophic muscle processes (all typical symptoms of myotonic dystrophy).
Thus an expanded CUG repeat in the DMPK gene sequesters MBNLl protein and causes aberrant splicing in several downstream genes, thereby causing DM1 phenotype. Meanwhile, antisense oligonucleotides can be used to target such expanded repeats of mutant transcripts for RNase- mediated degradation, thereby restoring splicing of downstream genes. A 2’-0- methoxyethyl gapmer AON has been used to target the degradation of expanded CUG by RNase H in mutant RNA transcripts, resulting in a reduction of mutant mRNA transcripts and restored protein expression.
In certain embodiments, the exon-skipping antisense sequence leads to skipping of exon 7A in CLCN 1 gene in a DM1 patient.
DM1 can also be treated by correcting aberrant splicing of chloride channel 1 (CLCN1), as this gene causes myotonia in DM1 patients. Using PMOs (phosphorodiamidate morpholino oligomer) with bubble liposomes through ultrasound exposure to enhance delivery of PMOs into muscles of DM1 mice (HSALR), skipping of exon 7A of CLCN1 was achieved in vivo, resulting in ameliorated myotonia and Clcnl protein expression in skeletal muscles.
In certain embodiments, the exon-skipping antisense sequence targets exons 17, 32, 35, 36, and/or 42 of the DYSF gene, preferably exon 32 and/or 36, for exon skipping in a dysferlinopathy (e.g., LGMD2B or MM) patient with a DYSF mutation.
Dysferlinopathy is an umbrella term that encompasses muscular dystrophies caused by mutations in the dysferlin (DYSF) gene. Dysferlin gene encodes a sarcolemmal protein required for repairing muscle membrane damage. It consists of calcium-dependent C2 lipid binding domains and a vital transmembrane domain. There are two common dysferlinopathies - limb- girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM), both have clinically distinct phenotypes and an autosomal recessive inheritance. LGMD2B is characterized by proximal muscle weakness, while MM is characterized by distal muscle weakness. Initial clinical phenotypes of LGMD2B and MM are distinct. However, as the disease progresses, the clinical presentations for both conditions overlap, becoming more similar, and patients experience muscle weakness in both proximal and distal limbs. Dysferlin-deficient muscle fibers have a defect in membrane repair.
Dysferlinopathies can be treated by exon skipping using antisense oligonucleotides, partly due to the observed mild phenotype in a patient with only 10% wild- type level expression of a truncated mutant DYSF protein. Specifically, in an LGMD2B case of a compound heterozygous female patient, the patient harbored one null allele and a DYSF branch point mutation on the other allele in intron 31. A natural in-frame skipping of exon 32 resulted in a truncated dysferlin protein expressed at about 10% that of the wild type levels, which was sufficient to partially complement the null mutation. The patient exhibited mild symptoms, and was ambulant at age 70. Recently, it has been shown that exon 32 skipping in patient cells resulted in quasi-dysferlin expression levels, which rescued membrane repair in treated cells that were subject to hypo-osmotic pressure and sarcolemmal localized laser injury in vitro.
In certain embodiments, the exon-skipping antisense sequence targets exon 4 of the LAMA2 gene, for exon skipping in a merosin-deficient congenital muscular dystrophy type 1 A (MDCIA) patient with a LAMA2 mutation. In certain embodiments, exon skipping results in restored expression of the C-terminal G-domain (exons 45-64), particularly G4 and G5 that are most important for mediating interaction with a-dystroglycan.
Merosin-deficient congenital muscular dystrophy type 1A (MDCIA) is caused by mutations in the 65 -exon LAMA2 gene that results in a complete or partial deficiency in laminin-a2 chain expression. Laminin-a2 chain, together with betal (bΐ), and gammal (gΐ) chains, are parts of the heterotrimeric laminin isoform known as Laminin-211 or merosin, which is expressed particularly in the basement membranes of skeletal muscles, including the
neuromuscular junction and Schwann cells (peripheral nerves). Laminin-a2 interacts with the dystrophin-dystroglycan complex (DGC), mediating cell signaling, adhesion, and tissue integrity in skeletal muscles and peripheral nerves. Although not always the case, the partial expression of laminin-a2 causes milder MDC1A, while complete absence of laminin-a2 causes severe MDC1A. The C-terminal G-domain (exons 45-64), particularly G4 and G5, are most important for mediating interaction with a-dystroglycan. Mutations eliminating G4 and G5 is associated with severe phenotypes even in the presence of partial truncated laminin-a2 expression.
Exon-skipping has been explored for treating MDCl A, in that PMO-mediated exon 4 skipping corrected the open reading frame, resulting in the recovery of a truncated laminin-a2 chain and a slightly extended patient life span.
In certain embodiments, the exon-skipping antisense sequence induces skipping of exons 4-7 of the most common A-521T mutation in the LGMD2C / SGCG gene, and restoration of the reading frame to generate an internally truncated SGCG protein, for treating a limb-girdle muscular dystrophy type 2C patient with a A-521T SGCG mutation. In certain embodiments, exon skipping results in restored expression of the internally truncated SGCG protein that retains the intracellular, transmembrane, and extreme carboxy -terminus of the wild-type SGCG protein.
Dystrophin-associated protein (DAP) is a complex in the muscle cell membrane, the transmembrane components of which link the cytoskeleton to the extracellular matrix in adult muscle fibers, and are essential for the preservation of the integrity of the muscle cell membrane. The sarcoglycan subcomplex within the DGC is composed of 4 single-pass transmembrane subunits: a-, b-, g-, and d-sarcoglycan. The a to d-sarcoglycans gene, namely a (LGMD2D), b (LGMD2E), g (LGMD2C) and d (LGMD2F), are expressed predominantly (b) or exclusively (a, g and d) in striated muscle. A mutation in any of the four sarcoglycan genes may lead to a secondary deficiency of the other sarcoglycan proteins, presumably due to destabilization of the sarcoglycan complex, leading to sarcoglycanopathies - autosomal recessive limb girdle muscular dystrophies (LGMDs). The disease-causing mutations in the a to d genes cause disruptions within the dystrophin-associated protein (DAP) complex in the muscle cell membrane.
In human, g sarcoglycan (LGMD2C) is a protein encoded by the SGCG gene. Severe childhood autosomal recessive muscular dystrophy (SCARMD) is a progressive muscle-wasting disorder that segregates with microsatellite markers at the g-sarcoglycan gene. Mutations in the g-sarcoglycan gene were first described in the Maghreb countries of North Africa, where g-
sarcoglycanopathy has a higher than usual incidence. One of the most common mutation in LGMD 2C patients, D-521T, is a deletion of a thymine from a string of 5 thymines at nucleotide bases 521-525 in exon 6 of the g-sarcoglycan gene. This mutation shifts the reading frame and results in the absence of g-sarcoglycan protein and secondary reduction of b- and d-sarcoglycans, thus causing a severe phenotype. The mutation occurs both in the Maghreb population and in other countries.
Exon-skipping has been explored for treating LGMD2C with the D-521T mutation, in that the resulting internally truncated SGCG protein provided functional and pathological benefits to correct the loss of g-sarcoglycan in a Drosophila model, in heterologous cell expression studies, and in transgenic mice lacking g-sarcoglycan. A cellular model of human muscle disease was also generated to show that multiple exon skipping could be induced in RNA that encodes a mutant human g-sarcoglycan.
In certain embodiments, the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of sarcolipin (SLN). In certain embodiments, the vector of the invention encodes an shRNA that antagonizes the function of sarcolipin (shSLN).
Exemplary shSLN sequences include those disclosed in FIGs. 9 and 10 of PCT/US2019/065718, filed on December 11, 2019 ( e.g ., the underlined sequences in FIG. 9, and the highlighted sequences in FIG. 10). Additional exemplary shSFN sequences include SEQ ID NOs: 7-11 disclosed in WO2018/136880 (incorporated herein by reference).
Further shSFN sequences can be designed based on any art recognized methods, using the human SEN mRNA sequence shown below.
1 AGACAGCCTG GGAGGGGAGA AGGAGTTGGA GCTCAAGTTG GAGACAGCGA GGAGAAACCT
61 GCCATAGCCA GGGTGTGTCT TTGATCCTCT TCAGGAGGTG AGGAGAAGCC AGAGGTCCTT
121 GGTGTGCCCT CAGAAATCTG CCTGCAGTTC TCACCAAGCC GCTGTGAAAA TGGGGATAAA
181 CACCCGGGAG CTGTTTCTCA ACTTCACTAT TGTCTTGATT ACGGTTATTC TTATGTGGCT
241 CCTTGTGAGG TCCTATCAGT ACTGAGAGGC CATGCCATGG TCCTGGGATT GACTGAGATG
301 CTCCGGAGCT GCCTGCTCTA TGCCCTGAGA CCCCACTGCT GTCATTGTCA CAGGATGCCA
361 TTCTCCATCC GAGGGCACCT GTGACCTGCA CTCACAATAT CTGCTATGCT GTAGTGCTAG
421 GATTGATTAT GTGTTCTCCA AAGATGCTGC TCCCAAGGGC TGCCAAGTGT TTGCCAGGGA
481 ACGGTAGATT TATTCCCCAA CTCTTAACTG AAAATGTGTT AGACAAGCCA CAAAGTTAAA
541 ATTAAACTGG ATT CAT GAT G AT G TAG GATT GTTACAAGCC CCTGATCTGT CTCACCACAC
601 ATCCCTTCAA CCCACACGGT CTGCAACCAA ACTCTAATTC AACCTGCCAG AAGGAATGTT
661 AGAGGAAGTC TTTGTCAGCC CTTATAGCTA TCATGTGAAT AAAGTTAAGT CAACTTCAAA
721 AA ( SEQ I D NO : 4 )
In certain embodiments, the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of one or more target genes, such as an inflammatory gene.
The IKB kinase / nuclear factor-kappa B (NF-kB) signaling is persistently elevated in immune cells and regenerative muscle fibers in both animal models and patients with DMD. In addition, activators of NF-KB such as TNF-a and IL-1 and IL-6 are upregulated in DMD muscles. Thus, inhibiting the NF-KB signaling cascade components, such as NF-KB itself, its upstream activators and the downstream inflammatory cytokines, are beneficial for treating the subject patients in conjunction with replacing / repairing a defective dystrophin gene.
Thus in certain embodiments, the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of one or more inflammatory genes, such as NF-KB, TNF-a, IL-1 (IL-1 b), IL-6, Receptor activator of NF- KB (RANK), and Toll-like receptors (TLRs).
In certain embodiments, the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of a histone deacetylase, such as HDAC2. In DMD, the absence of dystrophin at the sarcolemma delocalizes and downregulates nitric oxide synthase (nNOS), which alters S-nitrosylation of HDAC2 and its chromatin association. In the dystrophin-deficient mdx mice, which are defective for the NO pathway, the activity of HDAC2 resulted to be specifically increased. In contrast, rescue of nNOS expression in mdx animals ameliorated the dystrophic phenotype. In addition, deacetylase inhibitors conferred a strong morphofunctional benefit to dystrophic muscle fibers. Indeed, givinostat, a histone deacetylase inhibitor, is under evaluation as potential disease-modifying treatment for DMD. Data indicates that, in both murine and human dystrophic cells, the absence of dystrophin correlates with HDAC2 binding to a specific subset of miRNAs (see below), while upon dystrophin rescue HDAC2 is released from these promoters.
In certain embodiments, the vector of the invention encodes an antisense sequence, an RNAi sequence (siRNA, shRNA, miRNA etc.), or a microRNA, that antagonizes the function of
TGF-b, or connective tissue growth factor (CTGF). Elevated levels of TGF-b in muscular dystrophies stimulate fibrosis and impair muscle regeneration by blocking the activation of satellite cells. Anti-fibrotic agents have been tested in murine models of muscular dystrophy, including losartan, an angiotensin II-type 1 receptor blocker that reduces the expression of TGF- b. FIT-100 (halofuginone) has also been shown to prevent fibrosis via the TGF^/Smad3 pathway in muscular dystrophies. Meanwhile, FG-3019, a fully human monoclonal antibody that interferes with the action of connective tissue growth factor, a central mediator in the pathogenesis of fibrosis, has been evaluated in an open-label phase 2 trial in patients with idiopathic pulmonary fibrosis (IPF).
In certain embodiments, the vector of the invention encodes a microRNA (miR), such as miR-1, miR-29c, miR-30c, miR-133, and/or miR-206. The differential HDAC2 nitrosylation state in Duchenne versus wild-type conditions deregulates the expression of a specific subset of microRNA genes. Several circuitries controlled by the identified microRNAs, such as the one linking miR-1 to the G6PD enzyme and the redox state of cell, or miR-29 to extracellular proteins and the fibrotic process, explain some of the DMD pathogenetic traits. The muscle- specific (myomiR) miR-1 and miR-133, and the ubiquitous miR-29c and miR-30c, downregulated in mdx, recovered toward wildtype levels in exon-skipping-treated animals. According to the mdx model, when dystrophin synthesis was restored via exon skipping, the levels of miR-1, miR-133a, miR-29c, miR-30c, and miR-206 increased, while miR-23a expression did not change.
In certain embodiments, the vector of the invention encodes a microRNA inhibitor, which inhibits the function of a microRNA upregulated in DMD or its related diseases. For example, the inflammatory miR-223 expression level is upregulated in mdx mice muscles, and is downregulated in exon-skipping-treated mice. Its decrease is consistent with the observed amelioration of the inflammatory state of the muscle, due to dystrophin rescue by exon-skipping.
The mdx animals undergo extensive fibrotic degeneration, and miR-29 has been shown to target mRNAs of crucial factors involved in fibrotic degeneration, such as collagens, elastin, and structural components of the extracellular matrix. In mdx mice, miR-29 is poorly expressed, and the mRNAs for collagen (COL1A1) and elastin (ELN) were upregulated. Thus expression of miR-29c alleviates fibrotic degeneration in DMD patients, partly through downregulating collagen and elastin expression, and pathological extracellular matrix modification associated
with collagen and elastin expression.
In certain embodiments, the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of G6PD (Glucose- e-phosphate dehydrogenase). One important issue in dystrophic muscles is their susceptibility and response to oxidative stress suggested to be involved in disease progression. G6PD is a cytosolic enzyme in the pentose phosphate pathway that supplies reducing energy to cells by maintaining the level of NADPH, which in turn ensures high ratio between reduced and oxidized glutathione (GSH/GSSG), GSH being the major antioxidant molecule that protects cells against oxidative damage. G6PD mRNA is deregulated in mdx muscles. It contains in its 3’-UTR region three putative binding sites for the miR-1 family, and miR-1 and miR-206 are able to repress G6PD expression. Indeed, there is an inverse correlation between G6PD and miR-1 expression: in vitro differentiation of C2 myoblasts showed that the increase in miR-1 levels correlated with decrease of G6PD protein, mRNA levels, and GSH/GSSG ratio. In mdx mice, where miR-1 is downregulated, G6PD was detected at higher levels than in WT muscles, whereas in exon-skipping -treated mdx, in which miR-1 resumes, the amount of G6PD was reduced. Notably, in mdx mice, increase in G6PD levels was accompanied by a decrease in GSH/GSSG ratio.
In certain embodiments, the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of myostatin. Myostatin is a negative regulator of muscle mass. Inhibition or blockade of endogenous myostatin compensates for the severe muscle wasting common in many types of muscular dystrophies including DMD. A myostatin blocking antibody, MYO-029, is in clinical trial for adult subjects with BMD and other dystrophies. Other clinical trials using myostatin inhibitors such as follistatin and PF-06252616 (NCT02310764) and BMS-986089 have also been conducted.
In certain embodiments, the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of phosphodiesterase-5 (PED-5) or ACE, or VEGF decoy-receptor type 1 (VEGFR-l or Flt-1).
Loss of dystrophin leads to displacement of neuronal nitric oxide synthase and reduction of muscle-derived nitric oxide to the microvasculature, resulting in functional muscle ischemia and further muscle injury. Thus several inhibitors of phosphodiesterase-5 or ACE, or VEGF decoy-
receptor type 1 (VEGFR-1 or Flt-1), have been tested as part of the strategies to increase blood flow to muscles, include pharmaceutical inhibition of either phosphodiesterase-5 or ACE.
In certain embodiments, the vector of the invention encodes an antisense sequence, or an RNAi sequence (siRNA, shRNA, miRNA etc.), that antagonizes the function of hematopoietic prostaglandin D synthase (HPGDS). Prostaglandin D2 (PGD2) is produced by various inflammatory cells, and hematopoietic PGD synthase (HPGDS) is shown to be expressed in necrotic muscle of DMD patients. The administration of an HPGDS inhibitor decreased the urinary excretion of tetranor-PGDM, a urinary metabolite of PGD2, and suppressed myonecrosis in a mdx mouse model of DMD. TAS-205, a novel HPGDS inhibitor, has been evaluated for DMD treatment in clinical trial.
RNAi and Antisense Design
In RNA interference (RNAi), short RNA molecules are created that are complimentary and bind to endogenous target mRNA. Such binding leads to functional inactivation of the target mRNA, including degradation of the target mRNA.
The RNAi pathway is found in many eukaryotes, including plants and animals, and is initiated in the cytoplasm by the enzyme Dicer, which cleaves long double-stranded RNA (dsRNA) or small hairpin RNAs (shRNA) molecules into short double-stranded fragments of ~21 nucleotide siRNAs. Each siRNA is then unwound into two single-stranded RNAs (ssRNAs), the passenger strand and the guide strand. The passenger strand is degraded and the guide strand is incorporated into the RNA-induced silencing complex (RISC). The most well- studied outcome is post-transcriptional gene silencing, which occurs when the guide strand pairs with a complementary sequence in an mRNA molecule and induces cleavage by Argonaute 2 (Ago2), the catalytic component of the RISC. In some organisms, this process spreads systemically, despite the initially limited molar concentrations of siRNA.
Other than the siRNA and shRNA, another type of small RNA molecules that are central to RNA interference is microRNA (miRNA).
MicroRNAs are genomically encoded non-coding RNAs that help regulate gene expression, particularly during development. Mature miRNAs are structurally similar to siRNAs, but they must first undergo extensive post-transcriptional modification before reaching maturity. An miRNA is expressed from a much longer RNA-coding gene as a primary transcript
known as a pri-miRNA, which is then processed in the cell nucleus to a 70-nucleotide stem-loop structure called pre-miRNA, by the microprocessor complex consisting of an RNase III enzyme Drosha and a dsRNA-binding protein DGCR8. Upon transporting this pre-miRNA into the cytosol, its dsRNA portion is bound and cleaved by Dicer to produce the mature miRNA molecule, which two strands can be separated into a passenger strand and a guide strand. The miRNA guide strand, like the siRNA guide strand, can be integrated into the same RISC complex.
Thus, the two dsRNA pathways, miRNA and siRNA/shRNA, both require processing of a precursor molecule (pri-miRNA, pre-miRNA, and dsRNA or shRNA) with a backbone sequence in order to generate the mature functional guide strand for miRNA or siRNA, and both pathways eventually converge at the RISC complex.
After integration into the RISC, siRNAs base-pair to their target mRNA and cleave it, thereby preventing it from being used as a translation template. Differently from siRNA, however, a miRNA-loaded RISC complex scans cytoplasmic mRNAs for potential complementarity. Instead of destructive cleavage (by Ago2), miRNAs target the 3’-UTR regions of mRNAs where they typically bind with imperfect complementarity, thus blocking the access of ribosomes for translation. siRNAs differ from miRNAs in that miRNAs, especially those in animals, typically have incomplete base pairing to a target and inhibit the translation of many different mRNAs with similar sequences. In contrast, siRNAs typically base-pair perfectly and induce mRNA cleavage only in a single, specific target.
Historically, siRNA and shRNA have been used in RNAi applications. siRNA is typically a double-stranded RNA molecules, 20-25 nucleotides in length. siRNA inhibits the target mRNA transiently until they are also degraded within the cell. shRNA is typically ~80 base pairs in length, that include a region of internal hybridization that creates a hairpin structure. As described previously, shRNA molecules are processed within the cell to form siRNA, which in turn knock down gene expression. One benefit of shRNA is that they can be incorporated into plasmid vectors and integrated into genomic DNA for longer-term or stable expression, and thus longer knockdown of the target mRNA. shRNAs design is commercially available. For example, Cellecta offers RNAi screening
service against any target gene ( e.g ., all 19,276 protein-encoding human genes) using the Human Genome-Wide shRNA Library or Mouse DECIPHER shRNA Library (which targets about 10,000 mouse genes). ThermoFisher Scientific provides Silencer Select siRNA (classic 21- mers) from Ambion, which, according to the manufacturer, incorporates the latest improvements in siRNA design, off-target effect prediction algorithms, and chemistry.
ThermoFisher Scientific also provides Ambion® Pre-miR™ miRNA Precursor Molecules that are small, chemically modified double-stranded RNA molecules designed to mimic endogenous mature miRNAs. Use of such Pre-miR miRNA Precursors enable miRNA functional analysis by up-regulation of miRNA activity, and can be used in miRNA target site identification and validation, screening for miRNAs that regulate the expression of a target gene, and screening for miRNAs that affect a function of the target gene (such as SLN) or a cellular process.
ThermoFisher Scientific further provides Ambion® Anti-miR™ miRNA Inhibitors, which are chemically modified, single stranded nucleic acids designed to specifically bind to and inhibit endogenous microRNA (miRNA) molecules.
Antisense sequence design is also commercially available from a number of commercial and public sources, such as IDT (Integrated DNA Technologies) and GenLink. Design considerations may include oligo length, secondary / tertiary structure in the target mRNA, protein-binding sites on target mRNA, presence of CG motifs in either the target mRNA or the antisense oligo, formation of tetraplexes in antisense oligo, and the presence of antisense activity-increasing or -decreasing motifs.
Exon skipping antisense oligo design is known in the art. See, for example, Camilla Bernardini (ed.), Duchenne Muscular Dystrophy: Methods and Protocols, Methods in Molecular Biology, vol. 1687, DOI 10.1007/978-l-4939-7374-3_10, Chapter 10 by Shimo etai, published by Springer Science+Business Media LLC, 2018), which discuss in detail the design of effective exon-skipping oligonucleotides, taking into consideration factors such as the selection of target sites, the length of the oligoes, the oligo chemistry, and the melting temperature versus the RNA strand, etc. Also discussed is the use of a cocktail of antisense oligoes to skip multiples exons. The specific genes and muscular dystrophies covered include: DMD (Duchenne muscular dystrophy), LAMA2 (merosine-deficient CMD, DYSF (dysferlinopathy, FKTN (Fukuyama CMD), DMPK (myotonic dystrophy, and SGCG (LGMD2C). The entire content is incorporated
herein by reference.
For example, protein / gene sequences and mutations thereof in the affected disease genes are publically available from NCBI and the Leiden muscular dystrophy pages online. Potential target sites for efficient exon skipping can be obtained by using the human splicing finder website at www dot umd dot be slash HSF. Secondary structure of the target mRNA can be evaluated using, e.g., the mfod web server at the Albany dot edu website. The length of the oligoes normally can be 8-30 mer. Oligo GC content calculation is available at OligoCalc website at the Northwestern University server. Search for any off-target sequences can be done using the GGGenome website. Melting temperature of the oligoes can be estimated by LNA oligo prediction tool or OligoAnalyzer 3.1 software at sg dot idtdna dot com.
Enhanced Guide Strand Generation for RNAi (miR, siRNA, & shRNA)
In certain embodiments, the coding sequence encodes an RNAi reagent, such as miR, siRNA, or shRNA.
In certain embodiments, for miR and/or shRNA / siRNA design, the wild-type backbone sequence from which a mature miR or a mature siRNA is generated can be modified to enhance guide strand generation and minimize / eliminate passenger strand production. Since both strands of a mature miR / siRNA / shRNA (after cleavage) can in theory be incorporated into the RISC complex and become guide strand for RNAi, it is advantageous to selectively enhance the utilization of the designed guide strand and minimize the utilization of the largely complementary passenger strand in the RISK complex, in order to reduce or minimize, e.g., off- target effect (e.g., due to the cleavage of unintended target sequences when the passenger strand is loaded into the RISC.
One approach that can be used to achieve this goal (enhance leading strand generation and minimize / eliminate passenger strand production) is through using a hybrid construct in which the designed mature miR / siRNA / shRNA sequences comprising the desired guide strand are embedded inside the backbone sequences of other miR sequences which favor the generation of the guide strand and disfavor the production of the passenger strand.
This principle is illustrated in the design of a few modified miR-29c constructs and shSLN constructs, though the same principle that can be readily adopted for other RNAi reagents targeting any other sequences.
For all designs illustrated below, the adopted design strategy includes engineering flanking backbone sequences, loop sequences, and passenger strand nucleotide sequences, in order to preserve the 2D and 3D structure of the natural backbone sequence. In this context, for miRNA/shRNA designs, 2D/3D structure of the natural backbone sequence refers largely to the distances between stem loop and the flanking backbone polynucleotide sequences, the structure of the central stem, the location and/or sizes of the bulges, the presence and localization of any internal loops and mismatches within the stem, etc. Certain exemplary 2D structure maps for selected miR-30E, miR-101, and miR-451 backbone sequence-based miR-29c hybrid constructs are provided below as illustration.
A. hybrid miR-29c with miR-30 backbone sequence (29c-M30E)
Fellmann et al. (Cell Rep. 5(6): 1704-1713, 2013, incorporated herein by reference) describe a systematic approach to optimize the experimental miR-30 backbone, by identifying a conserved element 3’ of the basal stem as critically required for optimal processing of so-called “shRNAmir” - a synthetic shRNA embedded into endogenous microRNA contexts. The resulting optimized backbone, termed “miR-E,” strongly increased mature shRNA levels and knockdown efficacy. This approach can easily convert existing miR and shRNA reagents to miR-E for generating more effective miR and shRNA.
Applying this technology, 29c-M30E hybrid sequences were generated based on the desired mature miR-29c sequence, and the engineered / optimized miR-30 backbone sequence described in Fellmann et al. This 29c-M30E sequence (see FIG. 29 of PCT/US2019/065718, filed on December 11, 2019 for its predicted 2D structure) has been incorporated into the following subject viral vectors used in the examples below: pDys-29c-M30E-i2, EF1 A-29c- M30E, U6-29c-M30E. The following 5’->3’ sequence of 29c-M30E is a continuous sequence artificially separated to different lines to illustrate the different segments of the continuous sequence.
TCGACTTCTTAACCCAACAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG TAACCGATTTCAAATGGTGCTA TAGTGAAGCCACAGATGTA TAGCACCATTTGAAATCGGTTA TGCCTACTGCCTCGGACTTCAAGGGGCTAGAATTCGA
Specifically, in the continuous sequence above, the middle line represents the passenger strand sequence, the double underlined loop sequence, and the mature miR-29c guide sequence. Note that the passenger and guide sequences can be reverse complement of each other and can
snap back and form a stem-loop structure with the intervening loop sequence. However, it should be noted that perfect reverse complement sequences are not necessary. There can be internal bulges, etc., and therefore the two strands are not necessarily 100% complementary to each other in some cases (see the guide and passenger strands in the last sequence of this subsection). The top line and the bottom line represent the M30E flanking backbone sequence optimized to ensure enhanced production of the guide sequence and to minimize the production of the passenger strand.
In a similar design, an siRNA targeting human SLN is embedded in the same M30E backbone sequence in miR-30E-hSLN-cl (compare the top and bottom rows of the sequences immediately above and below this paragraph, and the double underlined loop sequence). But the guide and passenger strands are different. This so-called cl-M30E sequence has been incorporated into the following subject viral vectors used in the examples below: cl-M30E-i2, cl-M30E-3UTR, and cl-M30E-pa.
TCGACTTCTTAACCCAACAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG AACTTCACTATTGTCTTGATTAC TAGTGAAGCCACAGATGTA GT AAT C AAGAC AAT AGT GAAGT T TGCCTACTGCCTCGGACTTCAAGGGGCTAGAATTCGA
A similarly designed second siRNA also targeting human SLN is embedded in the same M30E backbone sequence in miR-30E-hSLN-c2 (compare the top and bottom rows of the sequences immediately above and below this paragraph, and the double underlined loop sequence). But the guide and passenger strands are different. This so-called c2-M30E sequence has been incorporated into the following subject viral vectors used in the examples below: c2- M30E-12, C2-M30E-3UTR, and c2-M30E-pa.
TCGACTTCTTAACCCAACAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG AACACCCGGGAGCTGTTTCTCAA TAGTGAAGCCACAGATGTA TTGAGAAACAGCTCCCGGGTGTT TGCCTACTGCCTCGGACTTCAAGGGGCTAGAATTCGA
The sequence of a modified miR-29c using the natural miR-30 backbone sequence (“M30N”) is also provided below as a comparison. Note the guide strand in this case is 5’ to the loop sequence. This M3 ON backbone sequence similarly enhanced the production of the guide strand, though to a lesser extent than the M30E backbone sequence in the experimental system tested (data not shown).
GGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTGACAGTGAGCGAC
TAGCACCATTTGAAATCGGTTA CTGTGAAGCCACAGATGGG TAACCGATTAAATGGTGCTA
GCTGCCTACTGCCTCGGACTTCAAGGGGCTACTTTAGGA
B. hybrid miR-29c with miR-101 backbone sequence (29c-101)
A different miR-29c hybrid (29c-101, see FIG. 30 of PCT/US2019/065718, filed on December 11, 2019 for its predicted 2D structure) using the miR-101 backbone sequence is illustrated below using the same naming convention herein. Here, the top row and the last two rows represent the backbone sequences of miR-101, while the 2nd row is the mature miR-29c with the passenger strand, loop sequence, and guide strand. This 29c-101 sequence has been incorporated into the following subject viral vectors used in the examples below: pDys-29c-101- i2, pDys-29c-3UTR-101.
CCACCAGAAAGGAT GCCGTT GACCGACACAGT GACT GACAGGCT GCCCTGGCG AACCGATTTCAAATGGTGCATACC GTCTATTCTAAAGG TAGCACCATTTGAAATCGGTTA GGATGGCAGCCATCTTACCTTCCATCAGAGGAGCCTCACCGTACCCAGGAAGAAAGAAGGTGAAAGAGGA ATGTGAAACAGGTGGCTGGGA
C. hybrid miR-29c with miR-155 backbone sequence (29c-155)
A different miR-29c hybrid (29c-155) using the miR-155 backbone sequence is illustrated below using the same naming convention herein. Here, the top row and the bottom row represent the flanking backbone sequences of miR-155, while the 2nd row is the mature miR-29c with the guide strand, loop sequence, and passenger strand. This 29c-155 sequence has been incorporated into the following subject viral vector used in the examples below: EF1 A- 29c- 155
CCTGGAGGCTTGCTGAAGGCTGTATGCTG
TAGCACCATTTGAAATCGGTTA TTTTGGCCTCTGACTGA TGACCGCTGGAATGGTGCTA CAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCC
Another miR-29c hybrid (29c-19nt) also using the miR-155 backbone sequence is illustrated below using the same naming convention herein. Here, the top row and the bottom row represent the flanking backbone sequences of miR-155 (identical to that in the sequence immediately above), while the 2nd row is the mature miR-29c with the guide strand, loop sequence, and passenger strand. Note the loop sequence here is 19 nt, instead of the 17 nt loop in the sequence above. This 29c-19nt sequence has been incorporated into the following subject viral vector used in the examples below: EFlA-29c-19nt, 29c-19nt-pDys-pA, 29c-19nt-pDys-
3UTR.
CCTGGAGGCTTGCTGAAGGCTGTATGCTG
TAGCACCATTTGAAATCGGTTA GTTTTGGCCACTGACTGAC TAACCGATCAAATGGTGCTA CAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCC
D. hybrid shSLN with miR-155 backbone sequence (shmSLN-v2 & cl/c2-ml55)
A shSLN in the miR-155 backbone sequence is illustrated below using the same naming convention herein. Here, the top row and the bottom row represent the flanking backbone sequences of miR-155, while the 2nd row is the mature shRNA targeting mouse SLN (shmSLN) with the guide strand, loop sequence (19 nt), and passenger strand. This shmSLN-v2 sequence has been incorporated into the following subject viral vector used in the examples below: EF1 A- mSLN, Fusion-vl, pDys-shmSFN-vl .
CCTGGAGGCTTGCTGAAGGCTGTATGCTG
GT GAT GAGGAC AAC T GT GAAG GTTTTGGCCACTGACTGAC CTTCACAGGTCCTCATCAC CAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCC
A shSFN in the miR-155 backbone sequence is illustrated below using the same naming convention herein. Here, the top row and the bottom row represent the flanking backbone sequences of miR-155, while the 2nd row is another mature shRNA targeting mouse SFN (shmSFN) with the guide strand, loop sequence (19 nt), and passenger strand. Compared to the similar / related shmSFN sequence above, the presence of the extra dinucleotide base pairs TT:AA (or strictly speaking, UU at the 3’ end of the siRNA) have been associated with increased potency of the produced guide strand siRNA. This shmSFN-v2 sequence has been incorporated into the following subject viral vector used in the examples below: EF1 A-mSFN-v2, Fusion-v2, pDys-shmSLN-v2.
CCTGGAGGCTTGCTGAAGGCTGTATGCTG
GT GAT GAGGAC AAC T GT GAAGT T GTTTTGGCCACTGACTGAC AACTTCACTTGTCCTCATCAC CAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCC
Another shSFN in the miR-155 backbone sequence is illustrated below using the same naming convention herein. Here, the top row and the bottom row represent the flanking backbone sequences of miR-155, while the 2nd row is the mature shRNA targeting human SFN with the guide strand, loop sequence (19 nt), and passenger strand. This cl -ml 55 sequence has been incorporated into the following subject viral vector used in the examples below: cl-ml55-
pa, cl-ml55-i2, cl-ml55-3UTR
CCTGGAGGCTTGCTGAAGGCTGTATGCTG
GTAATCAAGACAATAGTGAAGTT GTTTTGGCCACTGACTGAC AACTTCACTTGTCTTGATTAC CAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCC
Another shSLN in the miR-155 backbone sequence is illustrated below using the same naming convention herein. Here, the top row and the bottom row represent the flanking backbone sequences of miR-155, while the 2nd row is the mature shRNA targeting human SLN with a different guide strand, loop sequence (19 nt), and passenger strand. This c2-ml55 sequence has been incorporated into the following subject viral vector used in the examples below: c2-ml55-pa, c2-ml55-i2, c2-ml55-3UTR.
CCTGGAGGCTTGCTGAAGGCTGTATGCTG
TTGAGAAACAGCTCCCGGGTGTT GTTTTGGCCACTGACTGAC AACACCCGGGAGCTGTTTCTCAA CAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCC
E. hybrid miR-29c with miR-451 backbone sequence (29c-451)
A miR-29c hybrid (29c-451, see FIG. 31 of PCT/US2019/065718, filed on December 11, 2019 for its predicted 2D structure) using the miR-451 backbone sequence is illustrated below using the same naming convention herein. Here, the top 2 rows and the bottom 2 rows represent the flanking backbone sequences of miR-451, and the 3rd row is the mature miR-29c with the guide strand, loop sequence, and passenger strand.
GGACAGGAGAGATGCTGCAAGCCCAAGAAGCTCTCTGCTCAGCCTGTCACAACCTACTGACTGCCAGGGC ACT T GGGAAT GGCAAGG
TAGCACCATTTGAAATCGGTTA CGATTTCAAATGGTGCTG TCTTGCTATACCCAGA
AAACGTGCCAGGAAGAGAACTCAGGACCCTGAAGCAGACTACTGGAAGGGAGACTCCAGCTCAAACAAGG
CA
F. U6 Driven miR-29c and shSLN
The experimental section below also describes the use of certain “solo” viral vector constructs that express only miR-29c or only shSLN. Such solo expression cassettes are driven by the strong Pol III U6 promoter. Such sequences do not belong to modified miR-29c or modified shSLN sequences, since the strong U6 promoter directly generates the pre-miRNA or shSLN without any flanking nucleotide sequences. For comparison purpose, however, such sequences are also listed here using the same nomenclature.
A miR-29c driven by the U6 promoter is illustrated below (U6-29c-vl). Here, the 2nd row is the mature miR-29c with the passenger strand, loop sequence, and guide strand. This has been used in the pGFP-U6-shAAV-GFP vector to generate a “solo” control vector. The nucleotides in the first row of the continuous sequence below are the first 5 nucleotides after the transcription start site in the U6 promoter, and the T6 transcription termination sequence preceeds the sequence used for cloning in the last row of the continuous sequence below.
GATCG
TAACCGATTTCAAATGGTGCTA GCCCTGACCCAGC TAGCACCATTTGAAATCGGTTA TTTTTTGAAGCT
A shSLN driven by the U6 promoter is illustrated below (U6-shmSLN-vl). Here, the 2nd row is the mature shSLN with the passenger strand, loop sequence, and guide strand. This has been used in the U6-shmSLN-vl vector in the examples.
GATCG
ACTTCACAGTTGTCCTCATCAC TCGA GTGATGAGGACAACTGTGAAG CTTTTTTGAAGCT
A shSLN driven by the U6 promoter is illustrated below (U6-mSLN-v4). Here, the 2nd row is the mature shSLN with the passenger strand, loop sequence, and guide strand. This has been used in the U6-mSLN-v4 vector in the examples.
GATCG
ACTTCACAGTTGTCCTCATCAC TCAAGAG GTGATGAGGACAACTGTGAAG TTTTTTGAAGCT
G. Divergent Constructs
Several miR29c coding sequences, and SLN-targeting shRNA coding sequences, as expressed from the divergent expression cassette within the subject viral vectors, are described herein below.
In general, all sequences below are directly inserted downstream of the U6 promoter transcription start site, and the TTTTTT stretch is the T6 transcription stop site. For all designs below, design strategy included engineering flanking sequences, loop and passenger strand nucleotide sequences to preserve the natural backbone 2D and 3D structures. For miRNA/shRNA designs, 2D/3D structures - defined largely by distances between stem loop and
flanking nucleotide sequences, the central stem structure, the locations and sizes of the bulges, internal loops, and mismatches within the stem - are all important considerations.
> Divergent_29c_vl
TAACCGATTTCAAATGGTGCTA GCCCTGACCCAGC TAGCACCATTTGAAATCGGTTA
A miR-29c driven by the U6 promoter in the divergent expression cassette. Here, from 5’ to 3’, the mature miR-29c with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> Divergent_29c_v2
TAACCGATTTCAAATGGTGCTA TCAAGAG TAGCACCATTTGAAATCGGTTA
A miR-29c driven by the U6 promoter in the divergent expression cassette. Here, from 5’ to 3’, the mature miR-29c with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> Divergent_29c_v3
TAACCGATTTCAAATGGTGCTA CTTCCTGTCAGA TAGCACCATTTGAAATCGGTTA
A miR-29c driven by the U6 promoter in the divergent expression cassette. Here, from 5’ to 3’, the mature miR-29c with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> Divergent_29c_v4
TAACCGATTTCAAATGGTGCTA TTCAAGAGA TAGCACCATTTGAAATCGGTTA T T T T T T
A miR-29c driven by the U6 promoter in the divergent expression cassette. Here, from 5’ to 3’, the mature miR-29c with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> Divergent_29c_v5 (mir-155 backbone-based design)
CCTGGAGGCTTGCTGAAGGCTGTATGCTG
TAGCACCATTTGAAATCGGTTA GTTTTGGCCACTGACTGAC TAACCGATCAAATGGTGCTA CAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCC TTTTTT
A miR-29c driven by the U6 promoter in the divergent expression cassette. Here, the miR-29c uses the miR-155 backbone sequences, with the top row and the bottom row sequences represent the flanking backbone sequences of miR-155, while the 2nd row sequence, from 5’ to 3’, includes the mature miR-29c with the guide strand sequence, loop sequence (double underlined), and the passenger strand sequence.
> Divergent mSLN shvl
ACTTCACAGTTGTCCTCATCAC TCGA GTGATGAGGACAACTGTGAAG CTTTTTT
An shRNA targeting mSLN driven by the U6 promoter in the divergent expression cassette. Here, from 5’ to 3’, the mature shmSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> Divergent_mSLN_shv2
ACTTCACAGTTGTCCTCATCAC TCGA GTGATGAGGACAACTGTGAAG TTTTTT
An shRNA targeting mSLN driven by the U6 promoter in the divergent expression cassette. Here, from 5’ to 3’, the mature shmSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> Divergent_mSLN_shv3
ACTTCACAGTTGTCCTCATCAC GCCCTGACCCAGC GTGATGAGGACAACTGTGAAG TTTTTT
An shRNA targeting mSLN driven by the U6 promoter in the divergent expression cassette. Here, from 5’ to 3’, the mature shmSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> Divergent_mSLN_shv4
ACTTCACAGTTGTCCTCATCAC TCAAGAG GTGATGAGGACAACTGTGAAG TTTTTT
An shRNA targeting mSLN driven by the U6 promoter in the divergent expression cassette. Here, from 5’ to 3’, the mature shmSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
The following sequences have been used either in solo constructs encoding only shRNA
targeting human SLN (shhSLN) i.e., not in the divergent cassette), or in combination (“combo”) constructs encoding both a GOI (e.g., a pDys coding sequence) and an shRNA targeting human SLN in the divergent expression cassette. See FIG. 6.
> U6-hSLN-cl-vl
CTTCACTATTGTCTTGATTAC TCGA GTAATCAAGACAATAGTGAAG TTTTTT
An shRNA targeting hSLN driven by the U6 promoter. Here, from 5’ to 3’, the mature shhSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> U6-hSLN-cl-v2
CTTCACTATTGTCTTGATTAC GCCCTGACCCAGC GTAATCAAGACAATAGTGAAG TTTTTT
An shRNA targeting hSLN driven by the U6 promoter. Here, from 5’ to 3’, the mature shhSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> U6-hSLN-c2-vl
CACCCGGGAGCTGTTTCTCAA TCGA TTGAGAAACAGCTCCCGGGTG TTTTTT
An shRNA targeting hSLN driven by the U6 promoter. Here, from 5’ to 3’, the mature shhSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> U6-hSLN-c2-v2
CACCCGGGAGCTGTTTCTCAA GCCCTGACCCAGC TTGAGAAACAGCTCCCGGGTG TTTTTT
An shRNA targeting hSLN driven by the U6 promoter. Here, from 5’ to 3’, the mature shhSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> U6-hSLN-c3-vl
TGTGGCTCCTTGTGAGGTCCT TCGA AGGACCTCACAAGGAGCCACA TTTTTT
An shRNA targeting hSLN driven by the U6 promoter. Here, from 5’ to 3’, the mature shhSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
> U6-hSLN-c3-v2
TGTGGCTCCTTGTGAGGTCCT GCCCTGACCCAGC AGGACCTCACAAGGAGCCACA TTTTTT
An shRNA targeting hSLN driven by the U6 promoter. Here, from 5’ to 3’, the mature shhSLN with the passenger strand sequence, loop sequence (double underlined), and the guide strand sequence are depicted just 5’ to the T6 transcription stop site.
Composition and Pharmaceutical Composition
In another embodiment, the invention contemplates compositions comprising rAAV of the present invention. Compositions of the invention comprise rAAV and a pharmaceutically acceptable carrier. The compositions may also comprise other ingredients such as diluents and adjuvants. Acceptable carriers, diluents and adjuvants are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counter ions such as sodium; and/or nonionic surfactants such as Tween, pluronics or polyethylene glycol (PEG).
Dosing and Administration
Titers of rAAV to be administered in methods of the invention will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art. Titers of rAAV may range from about 1 x 106, about 1 x 107, about 1 x 108, about 1 x 109, about 1 x 1010, about lxlO11, about 1 xlO12, aboutlxlO13, to about lxlO14 or more DNase resistant particles (DRP) per ml. Dosages may also be expressed in units of viral genomes (vg).
Methods of transducing a target cell with rAAV, in vivo or in vitro , are contemplated by the invention. The in vivo methods comprise the step of administering an effective dose, or effective multiple doses, of a composition comprising a rAAV of the invention to an animal (including a human being) in need thereof. If the dose is administered prior to development of a disorder/disease, the administration is prophylactic. If the dose is administered after the
development of a disorder/disease, the administration is therapeutic. In embodiments of the invention, an effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with the disorder/disease state being treated, that slows or prevents progression to a disorder/disease state, that slows or prevents progression of a disorder/disease state, that diminishes the extent of disease, that results in remission (partial or total) of disease, and/or that prolongs survival. An example of a disease contemplated for prevention or treatment with methods of the invention is PMD or other disease characterized by defects in myelin production, degeneration, regeneration, or function.
For administration, effective amounts and therapeutically effective amounts (also referred to herein as doses) may be initially estimated based on results from in vitro assays and/or animal model studies. For example, a dose may be formulated in animal models to achieve a circulating concentration range that includes the IC50 as determined in cell culture. Such information may be used to more accurately determine useful doses in subjects of interest.
Administration of an effective dose of the compositions may be by routes standard in the art including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal. Route(s) of administration and serotype(s) of AAV components of the rAAV (in particular, the AAV ITRs and capsid protein) of the invention may be chosen and/or matched by those skilled in the art taking into account the infection and/or disease state being treated and the target cells/tissue(s) that are to express the one or more coding sequences and/or micro-dystrophin.
Specifically, the formulations described herein may be administered by, without limitation, injection, infusion, perfusion, inhalation, lavage, and/or ingestion. Routes of administration may include, but are not limited to, intravenous, intradermal, intraarterial, intraperitoneal, intralesional, intracranial, intraarticular, intraprostatic, intrapleural, intratracheal, intranasal, intravitreal, intravaginal, intrarectal, topically, intratumoral, intramuscular, intravesicular, intrapericardial, intraumbilical, intraocularal, mucosal, oral, subcutaneous, and/or subconjunctival.
The invention provides for local administration or systemic administration of an effective dose of rAAV and compositions of the invention including combination therapy of the invention. For example, systemic administration is administration into the circulatory system so that the entire body is affected. Systemic administration includes enteral administration such as
absorption through the gastrointestinal tract and parental administration through injection, infusion or implantation.
In particular, actual administration of rAAV of the present invention may be accomplished by using any physical method that will transport the rAAV recombinant vector into the target tissue of an animal, such as the skeletal muscles. Administration according to the invention includes, but is not limited to, injection into muscle, the bloodstream and/or directly into the liver. Simply re-suspending a rAAV in phosphate buffered saline has been demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known restrictions on the carriers or other components that can be co-administered with the rAAV (although compositions that degrade DNA should be avoided in the normal manner with rAAV). Capsid proteins of a rAAV may be modified so that the rAAV is targeted to a particular target tissue of interest such as muscle. See, for example, WO 02/053703, the disclosure of which is incorporated by reference herein.
Pharmaceutical compositions can be prepared as injectable formulations or as topical formulations to be delivered to the muscles by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the invention. The rAAV can be used with any pharmaceutically acceptable carrier for ease of administration and handling.
The dose of rAAV to be administered in methods disclosed herein will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art.
The actual dose amount administered to a particular subject may also be determined by a physician, a veterinarian, or a researcher, taking into account parameters such as, but not limited to, physical and physiological factors including body weight, severity of condition, type of disease, previous or concurrent therapeutic interventions, idiopathy of the subject, and/or route of administration.
Titers of each rAAV administered may range from about 1 x 106, about 1 x 107, about lxlO8, about lxlO9, about lxlO10, about lxlO11, about l xlO12, aboutlxlO13, about lxlO14, or to about lxlO15 or more DNase resistant particles (DRP) per ml. Dosages may also be expressed in
units of viral genomes (vg) (i.e., Ixl07 vg, lxl08 vg, lxl09 vg, l xl010 vg, l xlOn vg, l xl012 vg, 1 xlO13 vg, 1 xlO14 vg, 1 xlO15 vg, respectively). Dosages may also be expressed in units of viral genomes (vg) per kilogram (kg) of bodyweight (i.e., lxlO10 vg/kg, lxlO11 vg/kg, lxlO12 vg/kg,
1 x 1013 vg/kg, l xlO14 vg/kg, lxlO15 vg/kg respectively). Methods for titering AAV are described in Clark etal., Hum. Gene Ther. 10:1031-1039, 1999.
Exemplary doses may range from about l xlO10 to about l xlO15 vector genomes (vg)/kilogram of body weight. In some embodiments, doses may comprise l xlO10 vg/kg of body weight, l xlO11 vg/kg of body weight, lxlO12 vg/kg of body weight, l xlO13 vg/kg of body weight, l xlO14 vg/kg of body weight, or 1 x 1015 vg/kg of body weight. Doses may comprise lxlO10 vg/kg/day, l xlO11 vg/kg/day, l xlO12 vg/kg/day, l xlO13 vg/kg/day, lxlO14 vg/kg/day, or lxlO15 vg/kg/day. Doses may range from 0.1 mg/kg/day to 5 mg/kg/day or from 0.5 mg/kg/day to 1 mg/kg/day or from 0.1 mg/kg/day to 5 pg/kg/day or from 0.5 mg/kg/day to 1 pg/kg/day. In other non-limiting examples, a dose may comprise 1 pg/kg/day, 5 pg/kg/day, 10 pg/kg/day, 50 pg/kg/day, 100 pg/kg/day, 200 pg/kg/day, 350 pg/kg/day, 500 pg/kg/day, 1 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day, 50 mg/kg/day, 100 mg/kg/day, 200 mg/kg/day, 350 mg/kg/day, 500 mg/kg/day, or 1000 mg/kg/day. Therapeutically effective amounts may be achieved by administering single or multiple doses during the course of a treatment regimen (i.e., days, weeks, months, etc.).
In some embodiments, the pharmaceutical composition is in a dosage form of 10 mL of aqueous solution having at least 1.6xl013 vector genomes. In some embodiments, the dosage has a potency of at least 2xl012 vector genomes per milliliter. In some embodiments, the dosage comprises a sterile aqueous solution comprising 10 mM L- histidine at pH 6.0, 150 mM sodium chloride, and 1 mM magnesium chloride. In some embodiments, the pharmaceutical composition is in a dosage form of 10 mL of a sterile aqueous solution comprising 10 mM L- histidine at pH 6.0, 150 mM sodium chloride, and 1 mM magnesium chloride; and having at least 1.6x1013 vector genomes.
In some embodiments, the pharmaceutical composition may be a dosage comprising between l xlO10 and l xlO15 vector genomes in 10 mL aqueous solution; between l xlO11 and lxlO14 vector genomes in 10 mL aqueous solution; between l xlO12 and 2xl013 vector genomes in 10 mL aqueous solution; or greater than or equal to about 1.6x1013 vector genomes in 10 mL aqueous solution. In some embodiments the aqueous solution is a sterile aqueous solution
comprises about 10 mM L-histidine pH 6.0, with 150 mM sodium chloride, and 1 mM magnesium chloride. In some embodiments, the dosage has a potency of greater than about lxlO11 vector genomes per milliliter (vg/mL), greater than about V I 012 vg/mL, greater than about 2/ 1012 vg/mL, greater than about 3/ 1012 vg/mL, or greater than about 4/ 1012 vg/mL.
In some embodiments, at least one AAV vector is provided as part of a pharmaceutical composition. The pharmaceutical composition may comprise, for example, at least 0.1% w/v of the AAV vector. In some other embodiments, the pharmaceutical composition may comprise between 2% to 75% of compound per weight of the pharmaceutical composition, or between 25% to 60% of compound per weight of the pharmaceutical composition.
In some embodiments, the dosage is in a kit. The kit may further include directions for use of the dosage.
For purposes of intramuscular injection, solutions in an adjuvant such as sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions. Such aqueous solutions can be buffered, if desired, and the liquid diluent first rendered isotonic with saline or glucose. Solutions of rAAV as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxpropylcellulose. A dispersion of rAAV can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.
In some embodiments, for injection, formulations may be made as aqueous solutions, such as in buffers including, but not limited to, Hanks' solution, Ringer's solution, and/or physiological saline. The solutions may contain formulatory agents such as suspending, stabilizing, and/or dispersing agents. Alternatively, the formulation may be in lyophilized and/or powder form for constitution with a suitable vehicle control (e.g., sterile pyrogen-free water) before use.
Any formulation disclosed herein may advantageously comprise any other pharmaceutically acceptable carrier or carriers which comprise those that do not produce significantly adverse, allergic, or other untoward reactions that may outweigh the benefit of
administration, whether for research, prophylactic, and/or therapeutic treatments. Exemplary pharmaceutically acceptable carriers and formulations are disclosed in Remington's Pharmaceutical Sciences, 18th Ed., Mack Printing Company, 1990, which is incorporated by reference herein for its teachings regarding the same. Moreover, formulations may be prepared to meet sterility, pyrogenicity, general safety, and purity standards as required by the United States FDA’s Division of Biological Standards and Quality Control and/or other relevant U.S. and foreign regulatory agencies.
Exemplary, generally used pharmaceutically acceptable carriers may comprise, but are not limited to, bulking agents or fillers, solvents or co-solvents, dispersion media, coatings, surfactants, antioxidants ( e.g ., ascorbic acid, methionine, and vitamin E), preservatives, isotonic agents, absorption delaying agents, salts, stabilizers, buffering agents, chelating agents (e.g., EDTA), gels, binders, disintegration agents, and/or lubricants.
Exemplary buffering agents may comprise, but are not limited to, citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers, and/or trimethylamine salts.
Exemplary preservatives may comprise, but are not limited to, phenol, benzyl alcohol, meta-cresol, methylparaben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkyl parabens (such as methyl or propyl paraben), catechol, resorcinol, cyclohexanol, and/or 3-pentanol.
Exemplary isotonic agents may comprise polyhydric sugar alcohols comprising, but not limited to, trihydric or higher sugar alcohols, (e.g., glycerin, erythritol, arabitol, xylitol, sorbitol, and/or mannitol).
Exemplary stabilizers may comprise, but are not limited to, organic sugars, polyhydric sugar alcohols, polyethylene glycol, sulfur- containing reducing agents, amino acids, low molecular weight polypeptides, proteins, immunoglobulins, hydrophilic polymers, and/or polysaccharides.
Formulations may also be depot preparations. In some embodiments, such long-acting formulations may be administered by, without limitation, implantation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, compounds may be formulated with suitable polymeric and/or hydrophobic materials (e.g., as an emulsion in an
acceptable oil) or ion exchange resins, or as sparingly soluble derivatives ( e.g ., as a sparingly soluble salt).
Additionally, in various embodiments, the AAV vectors may be delivered using sustained-release systems, such as semipermeable matrices of solid polymers comprising the AAV vector. Various sustained-release materials have been established and are well known by those of ordinary skill in the art. Sustained-release capsules may, depending on their chemical nature, release the vector following administration for a few weeks up to over 100 days.
The pharmaceutical carriers, diluents or excipients suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating actions of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating rAAV in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique that yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile- filtered solution thereof.
Transduction with rAAV may also be carried out in vitro. In one embodiment, desired
target muscle cells are removed from the subject, transduced with rAAV and reintroduced into the subject. Alternatively, syngeneic or xenogeneic muscle cells can be used where those cells will not generate an inappropriate immune response in the subject.
Suitable methods for the transduction and reintroduction of transduced cells into a subject are known in the art. In one embodiment, cells can be transduced in vitro by combining rAAV with muscle cells, e.g., in appropriate media, and screening for those cells harboring the DNA of interest using conventional techniques such as Southern blots and/or PCR, or by using selectable markers. Transduced cells can then be formulated into pharmaceutical compositions, and the composition introduced into the subject by various techniques, such as by intramuscular, intravenous, subcutaneous and intraperitoneal injection, or by injection into smooth and cardiac muscle, using e.g., a catheter.
Transduction of cells with rAAV of the invention results in sustained co-expression of said one or more additional coding sequences and micro-dystrophin. The present invention thus provides methods of administering/delivering rAAV which co-expresses said one or more additional coding sequences and micro-dystrophin to an animal, preferably a human being.
These methods include transducing tissues (including, but not limited to, tissues such as muscle, organs such as liver and brain, and glands such as salivary glands) with one or more rAAV of the present invention. Transduction may be carried out with gene cassettes comprising tissue specific control elements. For example, one embodiment of the invention provides methods of transducing muscle cells and muscle tissues directed by muscle specific control elements, including, but not limited to, those derived from the actin and myosin gene families, such as from the myoD gene family (See Weintraub et al., Science 251 :761-766, 1991), the myocyte- specific enhancer binding factor MEF-2 (Cserjesi and Olson, Mol Cell Biol 11 : 4854-4862,
1991), control elements derived from the human skeletal actin gene (Muscat et al., Mol Cell Biol 7:4089-4099, 1987), the cardiac actin gene, muscle creatine kinase sequence elements (Johnson et al., Mol Cell Biol 9:3393-3399, 1989), and the murine creatine kinase enhancer (mCK) element, control elements derived from the skeletal fast-twitch troponin C gene, slow-twitch cardiac troponin C gene and the slow-twitch troponin I gene: hypoxia-inducible nuclear factors (Semenza et al., Proc Natl Acad Sci U.S.A. 88:5680-5684, 1991), steroid-inducible elements and promoters including the glucocorticoid response element (GRE) (See Mader and White, Proc. Natl. Acad. Sci. U.S.A. 90:5603-5607, 1993), and other control elements.
Muscle tissue is an attractive target for in vivo DNA delivery, because it is not a vital organ and is easy to access. The invention contemplates sustained co-expression of miRNAs and micro-dystrophin from transduced myofibers.
As used herein, “muscle cell” or “muscle tissue” is meant a cell or group of cells derived from muscle of any kind (for example, skeletal muscle and smooth muscle, e.g., from the digestive tract, urinary bladder, blood vessels or cardiac tissue). Such muscle cells may be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes and cardiomy oblasts.
The term “transduction” is used to refer to the administration/delivery of the one or more additional coding sequences and the coding region of the micro-dystrophin to a recipient cell either in vivo or in vitro, via a replication-deficient rAAV of the invention resulting in co expression of the one or more additional coding sequences and micro-dystrophin by the recipient cell.
Thus, the invention provides methods of administering an effective dose (or doses, administered essentially simultaneously or doses given at intervals) of rAAV that encode said one or more additional coding sequences and micro-dystrophin to a patient in need thereof.
1 1 V Production
Genes encoding the necessary replication (rep) and structural (cap) proteins of AAV vectors have been deleted from AAV vectors to allow insertion of the sequences to be delivered between the remaining terminal repeat sequences. Thus for growth of AAV vectors, not only is a helper virus required, but the genes encoding the rep and cap proteins need to be delivered to infected cells. Alternatively, the genes encoding the rep and cap proteins need to be present in the cells used for production.
AAV vectors suitable for the methods of the invention can be produced using any of the art-recognized methods. In a recent review, Penaud-Budloo et al. (Molecular Therapy: Methods & Clinical Development Vol. 8, pages 166-180, 2018) provided a review of the most commonly used upstream methods to produce rAAVs. Each methods described therein are incorporated herein by reference.
Transient Transfection of Packaging Cell Line (HEK293)
In particular, in certain embodiments, the AAV vector is produced using transient transfection of a packaging cell line such as HEK293 cells. This is the most established AAV production method comprising plasmid transfection of human embryonic HEK293 cells. Typically, HEK293 cells are simultaneously transfected by a vector plasmid (containing the gene of interest, such as the subject polynucleotide encoding both the dystrophin minigene and the one or more additional coding sequences), and one or two helper plasmids, using calcium phosphate or polyethylenimine (PEI), a cationic polymer.
The helper plasmid(s) allow the expression of the four Rep proteins, the three AAV structural proteins VP1, VP2, and VP3, the AAP, and the adenoviral auxiliary functions E2A,
E4, and VARNA. The additional adenoviral E1A/E1B co-factors necessary for rAAV replication are ex-pressed in HEK293 producer cells. Rep-cap and adenoviral helper sequences are either cloned on two separate plasmids or combined on one plasmid, hence both a triple plasmid system and a two plasmid system for transfection are possible. The triple plasmid protocol lends versatility with a cap gene that can easily be switched from one serotype to another.
The plasmids are usually produced by conventional techniques in E. coli using bacterial origin and anti-biotic-resistance gene or by minicircle technology.
Transient transfection in adherent HEK293 cells has been used for large-scale manufacturing of rAAV vectors. Recently, HEK293 cells have also been adapted to suspension conditions to be economically viable in the long term.
HEK293 lines are usually propagated in DMEM completed with L-glutamine, 5%-10% of fetal bovine serum (FBS), and 1% penicillin-streptomycin, except for suspension HEK293 cells that are maintained in serum-free suspension FI 7, Expi293, or other manufacturer-specific media. For adherent cells, the percentage of FBS can be reduced during AAV production in order to limit contamination by animal-derived components.
Generally, the rAAV vectors are recovered 48-72 hr after plasmid transfection from the cell pellet and/or supernatant, depending on the serotype.
Infection of Insect Cells with Recombinant Baculovirus
The baculovirus- Sf9 platform has been established as a GMP-compatible and scalable alternative AAV production method in mammalian cells. It can generate up to 2x105 vector
genomes (vg) per cell in crude harvests.
Current protocol involves infection of the Sf9 insect cells with two recombinant baculoviruses a baculovirus expression vector (BEV) allowing the synthesis of Rep78/52 and Caps, and a recombinant baculovirus carrying the gene of interest flanked by the AAV ITRs. Several serum-free media are adapted for Sf9 cell growth in suspension.
The dual-baculovirus-Sf9 production system has many advantages over other production platforms regarding these safety issues: (1) the use of serum-free media; (2) despite the discovery of adventitious virus transcripts in Sf cell lines, most of the viruses infecting insects do not replicate actively in mammalian cells; and (3) no helper virus is required for rAAV production in insect cells besides baculovirus.
In certain embodiments, stable Sf9 insect cell lines expressing Rep and Cap proteins are used, thus requiring the infection of only one recombinant baculovirus for the production of infectious rAAV vectors at high yield.
Infection of Mammalian Cells with rHSV Vectors
HSV is a helper virus for replication of AAV in permissive cells. Thus, the HSV can serve both as a helper and as a shuttle to deliver the necessary AAV functions that support AAV genome replication and packaging to the producing cells.
AAV production based on co-infection with rHSV can efficiently generate a large amount of rAAV. In addition to high overall yields (up to 1.5 xlO5 vg/cell), the method is further advantageous in that it creates rAAV stocks with apparently increased quality as measured by an improved viral potency.
In this method, cells, typically the hamster BHK21 cell line or the HEK293 and derivatives, are infected with two rHSVs, one carrying the gene of interest bracketed by AAV ITR (rHSV- AAV), and the second with the AAV rep and cap ORFs of the desired serotype (rHSVrepcap). After 2-3 days, the cells and/or the media are collected, and rAAV is purified over multiple purification steps to remove cellular impurities, HSV-derived contaminants, and unpackaged AAV DNA.
Thus in some embodiments, HSV serves as a helper virus for AAV infection. In some embodiments, AAV growth is accomplished using non-replicating mutants of HSV with ICP27 deleted.
Certain methods for producing recombinant AAV viral particles in a mammalian cell have been known in the art and improved over the past decade. For example, U.S. Application Publication No. 20070202587 describes recombinant AAV production in mammalian cells based on co-infection of the cells with two or more replication-defective recombinant HSV vectors.
U.S. Application Publication No. 20110229971 and Thomas etal. (Hum. Gene Ther. 20(8):861- 870, 2009) describes a scalable recombinant AAV production method using recombinant HSV type 1 coinfection of suspension-adapted mammalian cells. Adamson-Small et al. (Hum. Gene Ther. Methods 28(1): 1-14, 2017) describes an improved AAV production method in a serum- free suspension manufacturing platform using the HSV system.
Mammalian Stable Cell Lines rAAV vectors can also be efficiently and scalably produced using stable mammalian producer cells stably expressing rep and cap genes. Such cells can be infected by wild-type Ad5 helper virus (which is genetically stable and can be easily produced at high titers) to induce high- level expression of rep and cap. Infectious rAAV vectors can be generated upon infection of these packaging cells lines with wild-type Ad type 5, and providing the rAAV genome by either plasmid transfection or after infection with a recombinant Ad/AAV hybrid virus.
Alternatively, Ad can be replaced by HSV-1 as the helper virus.
Suitable stable mammalian producer cells may include HeLa-derived producer cell lines, A549 cells, or HEK293 cells. A preferred HeLa cell line is HeLaS3 cells, a suspension adapted HeLa subclone.
The methods herein described can be used to manufacture the subject AAV vectors in animal components-free medium, preferably at 250-L scale, or 2,000-L commercial scale.
EXAMPLES
Example 1 In vitro Expression of Coding Sequences From Divergent Constructs
The divergent viral vectors of the invention are capable of expressing not only the functional gene or protein of interest (GOI) but also one or more coding sequences for certain RNAi, antisense, sgRNA, miRNA or inhibitors thereof. A representative, non-limiting configuration of the recombinant viral vector of the invention is illustrated in FIG. 1. For example, the recombinant viral vector of the invention may be a divergent AAV vector, such as
AAV9 vector, designed to express a version of a functional dystrophin gene, such as any one of the pDys gene described herein above. The same divergent vector also expresses one or more additional coding sequence(s) from an independent / divergent transcription unit situated between the GOI promoter and the nearest ITR sequence (see FIG. 1). That is, at least one of such one or more additional coding sequence(s) is/are transcribed from an independent / divergent promoter different from the GOI promoter (such as the muscle specific CK8 promoter). The direction of transcription in the divergent transcription unit can be opposite to that of the GOI promoter. The design of the subject divergent vector permits independent and separate control of the GOI transcripiton unit and the divergent transcription unit, thus providing more flexibility and control in expression of the separate transcription units.
In case that the additional coding sequence encodes an miRNA, such as miR-29c, the backbone sequence of the miR-29c coding sequence can be modified such that the surrounding sequences for the mature miR-29c sequence are obtained from other miRNA, such as that for miR-30, -101, -155, or -451 (see above). It has been found that replacing the native surrounding sequences of miR-29c by those from miR-30, -101, -155, or -451 can enhance the production of the one strand (i.e., the guide strand) of miR-29c designed to target the miR-29c target sequence (i.e., reduce the production of its complement passenger strand that is not useful for targeting the miR-29c target sequence).
As controls, several so-called miR-29c “solo” expression constructs were generated on the same vector background. These miR-29c solo expressing constructs do not express pDys gene, but may instead express a reporter gene such as EGFP or GFP.
For example, one such solo vector may express the miR-29c coding sequence inserted into the intron sequence upstream of an EGFP coding sequence, all from an EF1 A promoter.
The backbone sequences of the miR-29c coding sequence may be modified by that of miR-30, - 101, -155, or -451.
Another such solo vector may express an shRNA, such as shSLN that targets / down- regulates the expression of SLN. Expression of the shRNA may be driven by the U6 promoter that can be used by RNA Pol III, which produces strong transcription of short RNA transcripts. The shRNA coding sequence can be inserted into the intron in the U6 transcription cassette, before a coding sequence for GFP.
As a comparison, several so-called “fusion” vectors as described in International Patent Application No. PCT/US2019/065718, filed on December 11, 2019 were also included in this experiment.
Specifically, several representative divergent, fusion, or solo vectors were used to transfect human iPS -derived cardiomyocytes in vitro , and the expression of miR-29c in the infected cardiomyocytes were determined, and the results were shown in FIG. 2.
Specifically, the five solo constructs, five fusion constructs, three divergent constructs, and a couple of control pDys expressing constructs were transfected to human iPS-derived cardiomyocytes according to standard procedure. Mature miR-29c levels were measured via Taqman stem-loop QPCR. The five solo constructs tested include U6- or EF1 A- driven miR-29c expression cassettes designed in miR-30 (EFlA-29c-M30E and U6-29c-M30E) and miR-155 (EF1 A-29c-19nt and EF1 A-29c-l 55) backbones. The five fusion constructs tested include miR- 29c expression cassettes designed in miR-101 (pDys-29c-101-i2 & pDys-29c-3UTR- 101 ), miR- 30 (pDys-29c-M30E-i2), and miR-155 (29c- 19nt-pDys-3UTR & 29c-19nt-pDys-pa) backbones, inserted into intronic (i2), 3’UTR (3UTR) and after pA (pa) site locations relative to the pDys expression cassette. The three divergent constructs (Divergent-29c-vl, -v2, and -v5) all expressed miR-29c from the divergent expression cassette driven by a Pol III (U6) promoter.
It is apparent that the fusion constructs generally over-expressed miR-29c in the infected human iPS-derived cardiomyocytes by a factor of 2 to 11 fold, compared to a control in which a similar construct was used to express only pDys (and thus only background level of endogenous miR-29c expression was present).
Specific fusion constructs used to generate the data in FIG. 2 include:
29c-19nt-pDys-3UTR: a modified miR29c in miR-155 backbone, inserted into the 3’- UTR region of the pDys expression cassette (before the polyA adenylation signal sequence).
29c-19nt-pDys-pA: the same modified miR29c coding sequence in miR-155 backbone, inserted after the polyA adenylation signal sequence of the pDys expression cassette. pDys-29c-M30E-i2: a modified miR29c coding sequence in miR-30E backbone, inserted into the intron region of the pDys expression cassette. pDys-29c-101-i2: a modified miR29c coding sequence in miR-101 backbone, inserted into the intron region of the pDys expression cassette.
pDys-29c-3UTR- 101 : a modified miR29c coding sequence in miR-101 backbone, inserted into the 3’-UTR region of the pDys expression cassette.
Meanwhile, the solo constructs expressing miR-29c generally over-expressed miR-29c in the infected human iPS-derived cardiomyocytes by a factor of 6-73 fold, compared to the same control vector that expresses only pDys.
Specific solo constructs used to generate the data in FIG. 2 include:
EF1 A-29c-M30E: a modified miR29c coding sequence in the miR-30E backbone, driven by the EF1 A promoter.
U6-29c-M30E: a modified miR29c coding sequence in miR-30E backbone, driven by the Pol III U6 promoter.
U6-29c-vl: a miR29c coding sequence driven by the Pol III U6 promoter.
EFlA-29c-19nt: a modified miR29c coding sequence in miR-155 backbone, driven by the EF1A promoter.
EFlA-29c-155: another modified miR29c coding sequence in miR-155 backbone, driven by the EF1 A promoter.
The three divergent constructs all expressed high to very high levels of miR-29c transcripts, with the v2 construct approaching that of the highest fusion construct pDys-29c- M30E-i2, while the vl and v5 divergent constructs both approaching the highest solo constructs (50-70-fold). See FIG. 2.
Similar trends indicating (preferential) production of miR-29c from these constructs were also obtained when these constructs were evaluated in other in vitro cell systems, including the Mouly human healthy primary myoblasts, the mouse C2C12 immortalized myoblast line, and mouse fibroblast NIH3T3 cells, all without changes in pDys expression from the same vector (data not shown). Thus, insertion of the miR-29c expression cassette into the subject divergent vectors which also contain a pDys expression cassette does not cause significant reductions (if any) in pDys mRNA production.
A few selected divergent recombinant viral vectors in AAV9 viral particles (Divergent- 29c-vl, -v2, and -v5) were also used to infect differentiated C2C12 myotube and primary mouse cardiomyocytes, and expression of miR-29c was confirmed in these cells as well. See FIG. 3, with results being expressed as relative miR-29c expression after normalization against controls
expressing only pDys.
In this experiment, pDys production appeared largely unaffected relative to control group. In addition, miR-29c passenger strand levels did not show increased levels.
Meanwhile, expression of shmSLN from the subject divergent constructs, and the resulting -90% down-regulation of mouse SLN-firefly construct levels in mouse C2C12 cells transfected by such divergent constructs, were shown in FIG. 4.
The various constructs used in FIG. 4 are described below. pDys: control AAV9 vector encoding only the pDys (GOI).
EF1 A-mSLN: a solo construct expressing only shRNA targeting mouse SLN (mSLN). Transcription of the shRNA coding sequence is driven by the EF1 A promoter.
EF1 A-mSLN (V2): another solo construct expressing only shRNA targeting mouse SLN. Transcription of the shRNA coding sequence is driven by the EF1 A promoter. mSLN-shRNA control: a commercial positive control shRNA targeting mouse SLN. scramble: a commercial negative control shRNA with scambled sequence of the positive control shRNA.
The four divergent constructs (Divergent Vl to _V4) were described above.
In contrast to the fusion constructs that achieved about 50% mSLN expression knock down (data not shown), the subject divergent constructs consistently achieved >90% mSLN knock down in a dual luciferase based assay, with the results being expressed as the ratio of RLU (relative luciferase unit) from the firefly luciferase to RLU from the renilla liciferase. The results in FIG. 4 shows that all four tested divergent constructs (Divergent- VI, -V2, -V3 and 4) expressing shRNA targeting mSLN each knocked down mSLN expression by >90%, compared to a control construct expressing only pDys but no shRNA against mSLN (pDys) (with a normalized ratio of 1.0). In comparison, the EFIA-mSLN and EFlA-mSLNV2 fusion constructs knocked down mSLN by about 50% to 30%, respectively, in similar dual luciferase-based assays. The mSLN-shRNA positive control similarly knocked down about 80-90% mSLN expression, while the scambled control had no effect. See FIG. 4.
FIG. 5 shows relative expression levels of siSLN (processed siRNA product from the transcribed shSLN) in differentiated C2C12 myotubes or mouse primary cardiomyocytes for the various recombinant AAV9 vectors encoding shmSLN, either as the sole coding sequence in the
viral vector (“Solo”), or as part of the divergent construct of the present disclosure (“Divergent”). siRNA production was quantified via a custom Taqman stem-loop QPCR system. The relative siSLN expression levels of the solo and divergent constructs were normalized against the level in the pDys control group, although apparent high fold changes may not be informative due to the near absent or very minimal siSLN-like RNA production in the control group. Nevertheless, it is apparent that, in both cell types tested, the solo construct expressed about 1000-fold higher level of siSLN from the strong U6 Pol III promoter, as compared to the control group. Meanwhile, the tested divergent construct reached similarly high (if not higher) level of siSLN compared the solo constructs.
All the divergent AAV constructs have AAV yields that are largely comparable to that of the solo constructs expressing only pDys.
Numerous additional solo and divergent constructs expressing shRNA targeting human SLN were also tested in human iPS-derived cardiomyocytes. These include 6 solo constructs and 6 divergent constructs targeting human SLN. The results of these experiments were summarized in FIG. 6.
Specifically, several negative controls ( e.g ., multiple pDys and GFP plasmids) and positive controls were used in the experiments in FIG. 6. The negative controls include: two constructs (pDysl and pDys2) expressing pDys alone (which had no effect on the expression level of SLN mRNA); a construct expressing GFP under the muscle-specific promoter CK8 (CK8-GFP) (which GFP also had no effect on SLN mRNA expression); and “sigma scramble” - a construct expressing a scrambled sequence of a hSLN-targeting shSLN (which expectedly had no effect on SLN mRNA expression). The positive control is “sigma shrna,” which is a commercially available shRNA plasmid from Sigma that encodes an hSLN-targeting shSLN that down-regulates about 80% of the hSLN mRNA.
Six solo constructs, each expressing a version of the shRNA targeting hSLN, and each under the transcriptional control of the strong Pol III U6 promoter, were tested and were shown to generally down-regulate about 80-90% of hSLN mRNA expression.
Up to 90-95% hSLN mRNA expression down-down were also observed across 6 solo constructs, and 4 divergent constructs of the invention. For example, the combo-cl-vl construct is a divergent construct that co-expresses pDys and shRNA targeting hSLN. Up to 90% of the
hSLN mRNA was knocked down upon infecting the human iPS-derived cardiomyocytes with this construct. The same was also observed for three other combo constructs, combo-cl-v2, combo-c2-vl, and combo-c2-v2.
Similar results were also obtained in primary mouse cardiomyocytes, with up to 90% mSLN mRNA expression knock down using the solo or divergent AAV9 constructs of the invention expressing shRNA targeting mSLN. See FIG. 7.
Although the divergent constructs greatly affected hSLN mRNA expression, they did not appear to have negative impact on the expression of the pDys from the same vector. As shown in FIG. 8, 6 solo and 6 divergent constructs targeting human SLN were transfected to human iPS-derived cardiomyocytes. Most divergent constructs showed largely similar (>50%) pDys mRNA expression as that of the control pDys-only constructs.
Denaturing agarose gel analysis of selected solo, fusion, and divergent constructs also confirmed that the AAV9 genomes of these miR-29c or shSLN constructs were largely intact.
See FIG. 9. Furthermore, the ratio of all three AAV9 capsid proteins VP1-VP3 remiains the same across all AAV9-based solo, fusion, and divergent vectors in FIG. 9. See FIG. 10.
These results demonstrate that AAV9 viral vectors produced from the subject divergent vectors, like the fusion vectors, have genome integrity.
Example 2 In vivo Expression of Coding Sequences From Divergent Constructs
This experiment demonstrates that the subject divergent constructs, like the fusion constructs, can be used to simultaneously express pDys and one or more additional coding sequence(s) that affect a separate pathway (e.g., down-regulation of SLN, and/or up-regulation of miR-29c) to achieve better-than-solo if not synergistic therapeutic efficacy.
In this set of experiments, several fusion and divergent constructs of AAV9 encoding a pDys gene as well as a second coding sequence - either miR-29c or shmSLN targeting mouse SLN were used. These fusion and divergent constructs were injected into 6- weeks-old male mdx mice via tail vein, at a dose of about 5E13 vg/kg (except for one group, U6-29c-vl, at 1 El 4 vg/kg). Expression of pDys, miR-29c, and SLN mRNA were then monitored over a period of 28 days post injection. The detailed experimental set-ups are summarized below:
In the miR-29c experimental group, it was found that the two tested fusion constructs, one in M30E backbone and inserted into the intron of the pDys expression cassette, and one in miR-101 backbone and inserted into the 3’-UTR region of the pDys expression cassette, led to 1.4-2.8-fold miR-29c up-regulation in left gastrocnemius (see FIG. 20 A of PCT/US2019/065718), diaphragm (see FIG. 20B of PCT/US2019/065718), and left ventricle (see FIG. 20C of PCT/US2019/065718). The miR-29c-pDys fusion AAV9 constructs were administered at 5E13 vg/kg dose. The solo U6 promoter-driven miR-29c construct in AAV9 produced 2-11 fold up-regulation at 5E13 vg/kg dose, and 6-16-fold at 1E14 vg/kg dose.
Meanwhile, miR-29c up-regulation by the fusion AAV9 constructs did not result in reduction of pDys production in gastrocnemius (see FIG. 21 of PCT/US2019/065718), diaphragm (data not shown) and left ventricle (data not shown). The fusion AAV9 constructs
showed similar pDys expression, at both RNA and protein levels, as that of the control pDys- only AAV9 constructs. Solo constructs expressing only miR-29c do not produce pDys, therefore showed absent pDys levels.
Similarly, it was found that the three tested divergent constructs (Divergent-29c-vl, -v2, and -v5) led to 2-6-fold miR-29c up-regulation in left gastrocnemius (FIG. 11, top panel), up to 5.8-fold miR-29c up-regulation in diaphragm (FIG. 11, lower left panel), and up to 7.5-fold miR- 29c up-regulation in left ventricle (FIG. 11, lower right panel).
Interestingly, increased level of miR-29c expression can also be detected in the plasma (FIG. 12), suggesting that serum/plasma level of miR-29c may be used as a biomarker to track miR-29c expression level. miR-29c up-regulation by the divergent AAV9 constructs also did not result in reduction of pDys production in the left gastrocnemius (FIG. 13, left panel for RNA, right panel for protein), diaphragm (data not shown) and left ventricle (data not shown). The divergent AAV9 constructs showed similar pDys expression, at both RNA and protein levels, as that of the control pDys-only AAV9 constructs. Solo constructs expressing only miR-29c do not produce pDys, therefore showed negligible pDys levels.
In the shmSLN experimental group, it was found that the tested shmSLN fusion AAV9 construct led to up to 50% mSLN mRNA down-regulation in the diaphragm, left gast, and atrium (see FIG. 22 of PCT/US2019/065718), as well as in tongue (data not shown). Similarly, mSLN mRNA down-regulation by the fusion AAV9 construct did not result in reduction of pDys production, at both RNA and protein levels, in gastrocnemius (see FIG. 23 of PCT/US2019/065718), diaphragm (data not shown), and left ventricle (data not shown), as compared to that of the control AAV9 expressing only pDys. Solo construct expressing only shmSLN did not produce pDys, thus showing absent pDys levels. Diaphragm results are shown. Similar results in tongue and atrium.
Similarly, it was found that the two tested shmSLN divergent AAV9 constructs (Divergent-shmSLN-vl and -v2) led to up to 75% mSLN mRNA down-regulation in the diaphragm (FIG. 14, top panel), up to 95% mSLN mRNA down-regulation in the left atrium (FIG. 14, lower left panel), and up to 80% mSLN mRNA down-regulation in the left gast (FIG. 14, lower right panel), as well as in tongue (see FIG. 16). siRNA productions were separately
confirmed in these experiments. mSLN mRNA down- regulation by one divergent AAV9 construct also did not result in reduction of pDys production, at both RNA and protein levels, in diaphragm (FIG. 15, left panel for RNA, right panel for protein), tongue (FIG. 16, left panel), and atrium (data not shown), as compared to that of the control AAV9 expressing only pDys, except that the Divergent- shmSLN-v2 construct reduced pDys expression in the left gastrocnemius by 60-70%. Solo construct expressing only shmSLN did not produce pDys, thus showing absent pDys levels.
These data show that the subject divergent constructs can simultaneously express both the pDys gene and at least one additional coding sequence such as miR-29c or shRNA against SLN, thus achieving better therapeutic outcome compared to viral vectors expressing only one coding sequence such as pDys.
Example 3 Coding Sequences Expressed In vivo from the Divergent Constructs are Biologically Active
This experiment demonstrates that the coding sequences expressed from the divergent constructs of the invention are biologically active.
Dystrophin provides structural stability to the muscle cell membrane, and increased permeability of the sarcolemma leads to the release of creatine kinase (CK) from muscle fibers. Thus, increased creatine kinase (CK) levels are a hallmark of muscle damage. In DMD patients, CK levels are significantly increased above the normal range ( e.g ., 10-100 times the normal level since birth). Likewise, serum CK levels are considered as a general measure of muscle health in the mdx mouse model.
The data in this experiment shows that miR-29c solo (administered at the high dose of 1E14 vg/kg) and miR-29c-pDys divergent (administered at 5E13 vg/kg dose) constructs of AAV9 both reduced serum CK levels in the mdx mouse model, to the similar extent compared to the pDys control, therefore suggesting a therapeutic benefit of expressing miR-29c in DMD patients.
Specifically, in the in vivo experiments of Example 2, serum CK levels were also determined for the various groups of mice. FIG. 17 shows that expression of pDys alone caused significant drop in serum CK level. Co-expressing pDys and miR-29c, with all three tested divergent constructs, also led to similarly significant drop in serum CK levels. Interestingly,
expressing miR-29c alone also led to significant decrease of serum CK level, especially when a higher viral dose (of miR-29c-expressing solo constructs) was used.
In FIG. 18, expression of shmSLN from either the solo or divergent constructs did not appear to reduce serum CK level.
On the other hand, tissue inhibitors of metalloproteinase- 1 (ΉMR-l) has been proposed as a serum biomarker for monitoring disease progression and/or treatment effects in Duchenne muscular dystrophy (DMD) patients, since serum levels of TIMP-1 were significantly higher in DMD patients compared to healthy controls. Similarly, ΉMR1 is also a serum marker for muscle health in the mdx mouse model.
Thus in the in vivo experiments of Example 2, serum TIMP1 levels were also determined for the various groups of mdx mice. It was shown in FIG. 25, left panel of PCT/US2019/065718 that expression of pDys alone caused significant drop in serum TIMP1 level. Co-expressing pDys and miR-29c, with both tested fusion constructs, also led to similarly significant drop in serum ΉMR1 levels. Meanwhile, expressing miR-29c alone did not lead to decrease of serum TIMP1 level, even when a higher viral dose (of miR-29c-expressing solo constructs) was used.
Likewise, FIG. 25 of PCT/US2019/065718, right panel, shows that expression of pDys alone caused significant drop in serum TIMP1 level. Co-expressing pDys and shRNA against mSLN with the tested fusion construct also led to similarly significant drop in serum ΉMR1 levels. Meanwhile, expressing shRNA against mSLN alone did not lead to decrease of serum TIMP1 level.
Here, similar results were obtained from the divergent constructs. In FIG. 19, left panel, expression of pDys alone caused significant drop in serum ΉMR1 level. Co-expressing pDys and miR-29c, with all three tested divergent constructs, also led to similarly significant drop in serum ΉMR1 levels. Meanwhile, expressing miR-29c alone did not lead to decrease of serum TIMP1 level, even when a higher viral dose (of miR-29c-expressing solo constructs) was used.
Likewise, in FIG. 19, right panel, expression of pDys alone caused significant drop in serum TIMP1 level. Co-expressing pDys and shRNA against mSLN with the tested divergent construct also led to similarly significant drop in serum TIMP1 levels. Meanwhile, expressing shRNA against mSLN alone in the solo construct did not lead to decrease of serum ΉMR1 level.
Example 4 The Divergent Constructs Show Comparable Biodistribution Compared to
Control Constructs in Gastrocnemius
In the in vivo experiments in Example 2, biodistribution of the divergent viral vectors was compared to that of the solo viral vector expressing only pDys. It was found that biodistribution for most viral vectors used were largely similar in gastrocnemius, regardless of whether the divergent construct expresses miR-29c or shmSLN. See FIG. 20. One of the divergent vector encoding shmSLN, however, appeared to be lower compared to that of the pDys solo construct.
Example 5 Two Divergent Constructs Showed Reduced Biodistribution in the Liver
In the in vivo experiments in Example 2, liver levels of the divergent viral vectors were compared to that of the solo viral vector expressing only pDys. It was found that viral titers of most viral vectors used were somewhat lower in liver, regardless of whether the divergent construct expresses miR-29c or shSLN. See FIG. 21. The only exception seems to be the DIV- 29c-v5 vector expresing miR-29c, which apparently had the same (if not higher) viral titer compared to that of the pDys solo construct.
In order to determine whether liver damage was the cause for the apparent lower titer in the liver, plasma ALT levels were assessed for the verious groups infected by the divergent vectors. The results in FIG. 22 showed that liver damage is unlikely to be the cause of lower titer in liver, because the two divergent constructs having lower viral titers in the liver, DIV-29c- vl and -v2, both had plasma ALT levels comparable, if not lower than that of the PBS control.
Example 6 Enhanced Therapeutic Efficacy Using The Divergent Constructs Compared to pDys Single Therapy
In order to determine whether co-expressing pDys and miR-29c leads to better therapeutic efficacy and/or less complication such as fibrosis, the expression levels of two fibrotic marker genes, Col3al and Fnl, were examined in mice administered with the various divergent, solo, or control constructs in Example 2. Col3Al expression and FN1 expression have been used as markers of fibrotic activity.
In the diaphragm, solo AAV9 vectors expressing only pDys or miR-29c resulted in about 35-50% decreased expression of the fibrosis marker gene Col3Al. Higher dose of the solo miR- 29c construct (at 1E14 vg/kg) reduced Col3Al expression further to about 1/3 of the control level (FIG. 23, upper left panel). One of the divergent construct, DIV-29c-vl dramatically
reduced Col3Al level by over 90%, which was unexpected given the level of reduction by pDys and miR-29c alone. The other divergent vector, DIV-29c-v5, reduced Col3Al expression to the same extent of the miR-29c solo construct U6-29c-vl.
Expression of the other fibrosis gene Fnl was also reduced, though to a lesser extent. While the pDys alone construct did not seem to significantly reduce Fnl expression in the diaphragm, the miR-29c solo construct did moderately reduce Fnl expression by about 25% at the normal dose of 5E13 vg/kg, and by more than 50% at the high dose of 1E14 vg/kg. Both divergent vectors reduced Fnl expression at a level between the normal and high titer miR-29c.
In left gastrocnemius, however, expression level of Col3Al was reduced by pDys by more than 50%, but was apparently increased by miR-29c by about 50% at normal titer, and 100% at high titer. Both divergent vectors reduced Col3Al expression in the left gast to about just under 50%.
Similar results were observed for Fnl expression in left gastrocnemius. While pDys reduced Fnl expression and miR-29c increased Fnl expression there, both divergent vectors unexectedly reduced Fnl expression to the same extent (if not better) than pDys alone.
It should be noted, however, that at this age of mdx mice (i.e., 10 weeks), fibrosis is typically only manifesting in diaphragm. Gastrocnemius is largely “normal” from fibrosis perspective.
These results show added benefit of the divergent constructs of the invention over pDys construct alone in diaphragm and possibly also in left gast, based on their effects on these two fibrotic marker genes.
Example 7 Delivery of Enzyme-based Gene Editing: CRISPR/Cas and sgRNA/crRNA
The subject viral vectors, e.g., rAAV viral vectors can be used to deliver CRISPR/Cas9 or CRISPR/Cas 12a (or other engineered or modified Cas enzymes or homologous thereof) into a target cell, together with one or more sgRNA (for Cas9), or one or more crRNA (for Cas 12a), for simultaneous knock down of target genes in the target cell. The target cell tropism can be controlled in part by the tropism of the viral particles in which the CRISPR/Cas and sgRNA/crRNA-encoding sequences resides.
For example, for AAV-mediated delivery, the GOI in the subject viral vector can be the
coding sequence for CRISPR/Cas9 or CRISPR/Casl2a. The one or more sgRNA or crRNA that can be loaded onto Cas9 or Cast 2a, respectively, can be expressed from the divergent expression cassette, the intron, the 3’-UTR, and/or elsewhere in the expression cassette of Cas9 / Casl2a.
Upon infecting the target cell with the subject viral vectors, e.g., AAV vectors, Cas proteins and sgRNA/crRNA are co-expressed inside the target cell to mediate gene editing.
Claims
1. A recombinant viral vector comprising: a) a polynucleotide encoding a gene or protein of interest (GOI), such as one effective to treat a muscular dystrophy, wherein said polynucleotide comprises a 3’-UTR coding region, and is immediately 3’ to a heterologous intron sequence that enhances expression of the functional protein encoded by the polunucleotide; b) a first control element operably linked to and drives the expression of the polynucleotide; and, c) one or more coding sequences (1) inserted between the first control element and the nearest viral terminal sequence (e.g., ITR in AAV) and operably linked to a second control element, and (2) optionally further inserted in the intron sequence or in the 3’-UTR coding region; wherein said one or more coding sequences independently encode: a protein, a polypeptide, an RNAi sequence (siRNA, shRNA, miRNA), an antisense sequence, a guide sequence for a gene editing enzyme, a microRNA (miRNA), and/or a miRNA inhibitor.
2. The recombinant viral vector of claim 1 , wherein the first control element is a muscle specific control element.
3. The recombinant viral vector of claim 1 or 2, wherein the second control element is a pol II or Pol III promoter that transcribes said one or more coding sequences inserted between the first control element and the nearest viral terminal sequence.
4. The recombinant viral vector of any one of claims 1-3, wherein the second control element directs transcription in a direction opposite to the transcription initiated by the first control element.
5. The recombinant viral vector of any one of claims 1-4, wherein the recombinant viral vector is a recombinant AAV (adeno associated viral) vector.
6. The recombinant viral vector of any one of claims 1-5, wherein: said one or more coding sequences are further inserted in the 3’-UTR coding region, or after the polyadenylation (poly A) signal sequence (e.g., AATAAA).
7. The recombinant viral vector of any one of claims 1 -6, wherein expression of the functional GOI is substantially unaffected in the presence of the one or more coding sequences ( e.g ., as compared to otherwise identical control constructs without said one or more coding sequences).
8. The recombinant viral vector of any one of claims 1-7, wherein: a) the polynucleotide is a dystrophin microgene or minigene encoding a functional dystrophin protein; and/or, b) the control element is a muscle-specific promoter operably linked to and drives the expression of the dystrophin minigene.
9. The recombinant viral vector of claim 8, wherein the functional dystrophin protein is microD5, and/or the muscle-specific promoter is CK promoter.
10. The recombinant viral vector of any one of claims 1-9, wherein said one or more coding sequences comprise an exon-skipping antisense sequence that induces skipping of an exon of a defective dystrophin, such as any one of exons 45-55 of dystrophin, or exon 44, 45, 51, and/or 53 of dystrophin.
11. The recombinant viral vector of any one of claims 1-10, wherein said microRNA is miR- 1, miR-133a, miR-29c, miR-30c, and/or miR-206.
12. The recombinant viral vector of claim 11, wherein said microRNA is miR-29c, optionally having a modified flanking backbone sequence that enhances the processing of the guide strand of miR-29c designed for a target sequence.
13. The recombinant viral vector of claim 12, wherein said modified flanking backbone sequence is from or based on miR-30, -101, -155, or -451.
14. The recombinant viral vector of any one of claims 11-13, wherein expression of said microRNA in a host cell is up-regulated by at least about 1.5-100 fold (e.g., about 2-80 fold, about 1.5-10 fold, about 15-70 fold, about 50-70 fold, about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or about 80 fold) compared to endogenous expression of said microRNA in said host cell.
15. The recombinant viral vector of any one of claims 1-14, wherein said RNAi sequence is an shRNA against sarcolipin (shSLN).
16. The recombinant viral vector of any one of claims 1-15, wherein said one or more coding sequences encode one or more identical or different shRNAs against sarcolipin (shSLN).
17. The recombinant viral vector of claim 15 or 16, wherein said shRNA reduces sarcolipin mRNA and/or sarcolipin protein expression by at least about 50%.
18. The recombinant viral vector of any one of claims 1-17, wherein said GOI is CRISPR/Cas9, and said guide sequence is an sgRNA (single guide RNA); or wherein said GOI is CRISPR/Casl2a, and said guide sequende is a crRNA.
19. The recombinant viral vector of any one of claims 1-18, wherein said RNAi sequence (siRNA, shRNA, miRNA), said antisense sequence, said CRISPR/Cas9 sgRNA, said CRISPR/Casl2a crRNA and/or said microRNA antagonizes the function of one or more target genes, such as an inflammatory gene, an activator of NF-KB signaling pathway
( e.g ., TNF-a, IL-1, IL-Ib, IL-6, Receptor activator of NF-KB (RANK), and Toll-like receptors (TLRs)), NF-KB, a downstream inflammatory cytokine induced by NF-KB, a histone deacetylase (e.g., HDAC2), TGF-b, connective tissue growth factor (CTGF), ollagens, elastin, a structural component of the extracellular matrix, Glucose-6-phosphate dehydrogenase (G6PD), myostatin, phosphodiesterase-5 (PED-5) or ACE, VEGF decoy- receptor type 1 (VEGFR-l or Flt-1), and hematopoietic prostaglandin D synthase (HPGDS).
20. The recombinant viral vector of claim 1, wherein: a) the polynucleotide encodes a functional fukutin (FKTN) protein; and/or, b) the one or more coding sequences encode an exon-skipping antisense sequence that restores correct exon 10 splicing in a defective FKTN gene in a Fukuyama congenital muscular dystrophy (FCMD) patient.
21. The recombinant viral vector of claim 1, wherein: a) the polynucleotide encodes a functional LAMA2 protein; and/or, b) the one or more coding sequences encode an exon-skipping antisense sequence that restores expression of the C-terminal G-domain (exons 45-64), particularly G4 and G5 of a defective LAMA2 gene in a Merosin-deficient congenital muscular dystrophy type 1A (MDC1A) patient.
22. The recombinant viral vector of claim 1, wherein: a) the polynucleotide encodes a functional DMPK protein, or a CLCN 1 gene; and/or, b) the RNAi sequence (siRNA, shRNA, miRNA), the antisense sequence, or the microRNA (miRNA) targets expanded repeats of mutant transcripts in a defective DMPK gene, or encodes an exon-skipping antisense sequence leading to the skipping of exon 7A in CLCN1 gene in a DM1 patient.
23. The recombinant viral vector of claim 1, wherein: a) the polynucleotide encodes a functional DYSF protein; and/or, b) one or more coding sequences encode an exon-skipping antisense sequence leading to the skipping of exon 32 in a defective DYSF gene in a dysferlinopathy (LGMD2B or MM) patient.
24. The recombinant viral vector of claim 1, wherein: a) the polynucleotide encodes a functional SGCG protein; and/or, b) one or more coding sequences encode an exon-skipping antisense sequence leading to the skipping of exons 4-7 in a defective LGMD2C gene ( e.g ., one with the A-521T SGCG mutation) in a LGMD2C patient.
25. The recombinant viral vector of any one of claims 1-24, wherein the heterologous intron sequence is SEQ ID NO: 1.
26. The recombinant viral vector of any one of claims 1-25, wherein said one or more coding sequences are inserted in the intron sequence.
27. The recombinant viral vector of any one of claims 1-26, wherein expression of the functional protein is not negatively affected by the insertion of said one or more coding sequences.
28. The recombinant viral vector of any one of claims 1-27, wherein the vector is a recombinant AAV vector of the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV 11, AAV 12, or AAV 13.
29. The recombinant viral vector of any one of claims 1-28, wherein the first control element is human skeletal actin gene element, cardiac actin gene element, myocyte-specific
enhancer binding factor mef, muscle creatine kinase (MCK), truncated MCK (tMCK), myosin heavy chain (MHC), C5-12, murine creatine kinase enhancer element, skeletal fast-twitch troponin c gene element, slow-twitch cardiac troponin c gene element, slow- twitch troponin i gene element, hypoxia-inducible nuclear factors, steroid-inducible element, or glucocorticoid response element (gre).
30. The recombinant viral vector of any one of claims 1-29, wherein the first control element comprises the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO: 11 of W02017/181015.
31. A composition comprising the recombinant viral vector of any one of claims 1 -30.
32. The composition of claim 31, which is a pharmaceutical composition further comprising a therapeutically compatible carrier, diluent, or excipient.
33. The composition of claim 32, wherein the therapeutically acceptable carrier, diluent, or excipient is a sterile aqueous solution comprising 10 mM L-histidine at pH 6.0, 150 mM sodium chloride, and 1 mM magnesium chloride.
34. The composition of claim 32 or 33, in a dosage form of about 10 mL of aqueous solution having at least 1.6 x 1013 vector genomes.
35. The composition of any one of claims 32-34, having a potency of at least 2 x 1012 vector genomes per milliliter.
36. A method of producing the composition of any one of claims 31-35, comprising producing the recombinant viral vector ( e.g ., the recombinant AAV vector) in a cell and lysing the cell to obtain the vector.
37. The method of claim 36, wherein the vector is a recombinant AAV vector of the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV 11, AAV 12, or AAV 13.
38. A method of treating a muscular dystrophy or dystrophinopathy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the recombinant viral vector (e.g., the recombinant AAV vector) of any one of claims 1-30, or the composition of any one of claims 31-35.
39. The method of claim 38, wherein the recombinant AAV vector or the composition is administered by intramuscular injection, intravenous injection, parental administration or systemic administration.
40. The method of claim 38 or 39, wherein the muscular dystrophy is Duchenne muscular dystrophy, Becker muscular dystrophy, Fukuyama congenital muscular dystrophy (FCMD), dysferlinopathy, myotonic dystrophy, and merosin-deficient congenital muscular dystrophy type 1A, facioscapulohumeral muscular dystrophy (FSHD), congenital muscular dystrophy (CMD), or limb-girdle muscular dystrophy (LGMDR5 or LGMD2C).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062959256P | 2020-01-10 | 2020-01-10 | |
US62/959,256 | 2020-01-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021142435A1 true WO2021142435A1 (en) | 2021-07-15 |
WO2021142435A8 WO2021142435A8 (en) | 2022-03-24 |
Family
ID=76787556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/012942 WO2021142435A1 (en) | 2020-01-10 | 2021-01-11 | Combination therapy for treating muscular dystrophy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021142435A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11535868B2 (en) | 2020-04-29 | 2022-12-27 | Bristol-Myers Squibb Company | Miniaturized dystrophins having spectrin fusion domains and uses thereof |
EP4087617A4 (en) * | 2020-01-10 | 2024-05-01 | Solid Biosciences Inc | Viral vector for combination therapy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8426374B1 (en) * | 2006-05-04 | 2013-04-23 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Method for modifying myostatin expression |
US20140248665A1 (en) * | 2012-12-31 | 2014-09-04 | Boehringer Ingelheim International Gmbh | Novel intron sequences |
US20190060489A1 (en) * | 2016-04-15 | 2019-02-28 | Research At Nationwide Children's Hospital | Adeno-associated virus vector delivery of microrna-29 and micro-dystrophin to treat muscular dystrophy |
US20190328804A1 (en) * | 2012-09-28 | 2019-10-31 | The University Of North Carolina At Chapel Hill | AAV Vectors Targeted to Oligodendrocytes |
-
2021
- 2021-01-11 WO PCT/US2021/012942 patent/WO2021142435A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8426374B1 (en) * | 2006-05-04 | 2013-04-23 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Method for modifying myostatin expression |
US20190328804A1 (en) * | 2012-09-28 | 2019-10-31 | The University Of North Carolina At Chapel Hill | AAV Vectors Targeted to Oligodendrocytes |
US20140248665A1 (en) * | 2012-12-31 | 2014-09-04 | Boehringer Ingelheim International Gmbh | Novel intron sequences |
US20190060489A1 (en) * | 2016-04-15 | 2019-02-28 | Research At Nationwide Children's Hospital | Adeno-associated virus vector delivery of microrna-29 and micro-dystrophin to treat muscular dystrophy |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4087617A4 (en) * | 2020-01-10 | 2024-05-01 | Solid Biosciences Inc | Viral vector for combination therapy |
US11535868B2 (en) | 2020-04-29 | 2022-12-27 | Bristol-Myers Squibb Company | Miniaturized dystrophins having spectrin fusion domains and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2021142435A8 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220031865A1 (en) | Combination therapy for treating muscular dystrophy | |
US20230001015A1 (en) | Adeno-Associated Virus Vector Delivery of Microrna-29 to Treat Muscular Dystrophy | |
US20230183740A1 (en) | Viral vector for combination therapy | |
US11939579B2 (en) | Modified U6 promoter system for tissue specific expression | |
WO2021142435A1 (en) | Combination therapy for treating muscular dystrophy | |
AU2017250790B2 (en) | Adeno-associated virus vector delivery of microrna-29 and micro-dystrophin to treat muscular dystrophy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21738927 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21738927 Country of ref document: EP Kind code of ref document: A1 |